Guillermo Garcia-Manero - Leukemia - Faculty

'	Guillermo Garcia-Manero

Present Title & Affiliation

Primary Appointment

Associate Professor, Department of Leukemia, Division of Cancer Medicine, University of Texas M.D. Anderson Cancer Center, Houston, TX

Education & Training

Degree-Granting Education
1991	University of Zaragoza, Spain, MD, Medical Doctor
1985	Colegio "Luis Vives", Palma de Mallorca, Spain, Bachillerato, Pre-Med
Postgraduate Training
1996-1999	Clinical Fellowship, Hematology and Medical Oncology, Thomas Jefferson University Hospital, Philadelphia, PA
1993-1996	Clinical Residency, Thomas Jefferson University Hospital, Philadelphia, PA

Board Certifications

1999	Medical Oncology
1999	Hematology Eligible
1996	Internal Medicine

Experience/Service

Administrative Appointments/Responsibilities

Chief, Section of Myelodysplastic Syndromes, Department of Leukemia, Division of Cancer Medicine, University of Texas M. D. Anderson Cancer Center, Houston, TX, 1/2006-present

Honors and Awards

2008-2011	Faculty Scholar Award, The University of Texas M. D. Anderson Cancer Center
2007	Faculty Educator of the Month, The University of Texas M. D. Anderson Cancer Center
2002	Physician-Scientist Program, University of Texas MD Anderson Cancer Center
2001	Career Development Award, American Society of Clinical Oncology
1998	Oncology Research Competition, Delaware Valley Hematology Oncology Association
1994	Research Award for Clinical Trainees Program, National Institutes of Health
1991	Fellowship, European Society of Human Genetics
1991	Research Student Award, University of Zaragoza
1990	Research Student Award, University of Zaragoza

Professional Memberships

American Association for the Advancement of Science
Member, 1993-present

American Association of Cancer Research
Chair, Scientific Review Committee, 1/2009-present
Member, 2001-present

American Society of Clinical Oncology
Member, 1998-present

American Society of Hematology
Member, 1997-present

Jefferson Medical College Alumni Association
Member, 2000-present

London Goodenough Trust, London, United Kingdom
Life Member, 1990-present

NCI Leukemia Steering Committee
Member, 6/2009-present

Peruvian Society of Oncology
Honorary Member, 10/2003-present

The Myelodysplastic Syndromes Foundation
Member, 2007-present

Selected Publications

Peer-Reviewed Original Research Articles
1.	Kuang SQ, Zweidler-Mckay PA, Fang ZH, Tong WG, Wei Y, Gonzales-Cervantes EA, Garcia-Manero G. Differential DNA Methylation and Epigenetic Inactivation of Notch-Hes Pathway Genes in Human B cell Acute Lymphoblastic Leukemias. Blood. In Press.
2.	Hoshino K, Quintás-Cardama A, Radich J, Dai H, Yang H, Garcia-Manero G. Downregulation of JUNB mRNA expression in advanced phase chronic myelogenous leukemia. Leuk Res 33(10):1361-6, 10/2009. e-Pub 5/2009. PMID: 19409613.
3.	Choi SH, Worswick S, Byun HM, Shear T, Soussa JC, Wolff EM, Douer D, Garcia-Manero G, Liang G, Yang AS. Changes in DNA methylation of tandem DNA repeats are different from interspersed repeats in cancer. Int J Cancer 125(3):723-729, 8/2009. e-Pub 2/2009. PMID: 19437537.
4.	Steensma DP, Baer MR, Slack JL, Buckstein R, Godley LA, Garcia-Manero G, Albitar M, Larsen JS, Arora S, Cullen MT, Kantarjian H. Multicenter Study of Decitabine Administered Daily for 5 Days Every 4 Weeks to Adults With Myelodysplastic Syndromes: The Alternative Dosing for Outpatient Treatment (ADOPT) Trial. J Clin Oncol 27(23):3842-8, 8/2009. e-Pub 6/2009. PMID: 19528372.
5.	Tong WG, Wei Y, Stevenson W, Kuang SQ, Fang Z, Zhang M, Arts J, Garcia-Manero G. Preclinical antileukemia activity of JNJ-26481585, a potent second-generation histone deacetylase inhibitor. Leukemia Research. e-Pub 8/2009.
6.	Alvarado Y, Kantarjian H, O'Brien S, Faderl S, Borthakur G, Burger J, Wierda W, Garcia-Manero G, Shan J, Cortes J. Significance of suboptimal response to imatinib, as defined by the European LeukemiaNet, in the long-term outcome of patients with early chronic myeloid leukemia in chronic phase. Cancer 115(16):3709-3718, 8/2009. e-Pub 6/2009. PMID: 19517462.
7.	Konoplev S, Huang X, Drabkin HA, Koeppen H, Jones D, Kantarjian HM, Garcia-Manero G, Chen W, Medeiros LJ, Bueso-Ramos CE. Cytoplasmic localization of nucleophosmin in bone marrow blasts of acute myeloid leukemia patients is not completely concordant with NPM1 mutation and is not predictive of prognosis. Cancer, 7/2009. e-Pub 7/2009. PMID: 19637342.
8.	Abdel-Wahab O, Mullally A, Hedvat C, Garcia-Manero G, Patel J, Wadleigh M, Malinge S, Yao J, Kilpivaara O, Bhat R, Huberman K, Thomas S, Dolgalev I, Heguy A, Paietta E, Le Beau MM, Beran M, Tallman MS, Ebert BL, Kantarjian HM, Stone RM, Gilliland DG, Crispino JD, Levine RL. Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies. Blood 114(1):144-7, 7/2009. e-Pub 5/2009. PMID: 19420352.
9.	Garg r, Faderly S, Garcia-Manero G, Cortes J, Koller C, Huang X, York S, Pierce S, Brandt M, Beran M, Borthakur G, Kantarjian H, Ravandi F.. Phase II study of rabbit anti-thymocyte globulin, cyclosporine and granulocyte colony-stimulating factor in patients with aplastic anemia and myelodysplastic syndrome. Leukemia 23(7):1297-1302, 7/2009. e-Pub 2/2009. PMID: 19242494.
10.	Lakshmikuttyamma A, Takahashi N, Pastural E, Torlakovic E, Amin HM, Garcia-Manero G, Voralia M, Czader M, Decoteau JF, Geyer CR. RIZ1 is potential CML tumor suppressor that is down-regulated during disease progression. J Hematol Oncol 2(1). e-Pub 7/2009. PMID: 19602237.
11.	De Padua Silva L, de Lima M, Kantarjian H, Faderl S, Kebriaei P, Giralt S, Davisson J, Garcia-Manero G, Champlin R, Issa JP, Ravandi F. Feasibility of allo-SCT after hypomethylating therapy with decitabine for myelodysplastic syndrome. Bone Marrow Transplant 43(11):839-843, 6/2009. e-Pub 1/2009. PMID: 19151791.
12.	Jain N, Cortes J, Quintás-Cardama A, Manshouri T, Luthra R, Garcia-Manero G, Kantarjian H, Verstovsek S. Imatinib has limited therapeutic activity for hypereosinophilic syndrome patients with unknown or negative PDGFRalpha mutation status. Leuk Res 33(6):837-9, 6/2009. e-Pub 11/2008. PMID: 19013640.
13.	Shi P, Chandra J, Sun X, Gergely M, Cortes JE, Garcia-Manero G, Arlinghaus RB, Lai R, Amin HM. Inhibition of IGF-IR tyrosine kinase induces apoptosis and cell cycle arrest in imatinib-resistant chronic myeloid leukemia cells. J Cell Mol Med. e-Pub 6/2009. PMID: 19508387.
14.	Fava C, Kantarjian HM, Jabbour E, O'Brien S, Jain N, Rios MB, Garcia-Manero G, Ravandi F, Verstovsek S, Borthakur G, Shan J, Cortes J. Failure to achieve a complete hematologic response at the time of achievement of a major cytogenetic response with second generation tyrosine kinase inhibitors is associated with a poor prognosis among patients with chronic myeloid leukemia in accelerated or blast phase. Blood 113(21):5058-5063, 5/2009. e-Pub 3/2009. PMID: 19282457.
15.	Jabbour E, Giralt S, Kantarjian H, Garcia-Manero G, Jagasia M, Kebriaei P, de Padua L, Shpall EJ, Champlin R, de Lima M.. Low-dose azacitidine after allogeneic stem cell transplantation for acute leukemia. Cancer 115(9):1899-905, 5/2009. e-Pub 2/2009. PMID: 19235255.
16.	Jabbour E, Garcia-Manero G, Taher A, Kantarjian HM. Managing iron overload in patients with myelodysplastic syndromes with oral deferasirox therapy. Oncologist 14(5):489-96, 5/2009. e-Pub 4/2009. PMID: 19365094.
17.	Kilpivaara O, Mukherjee S, Schram AM, Wadleigh M, Mullally A, Ebert BL, Bass A, Marubayashi S, Heguy A, Garcia-Manero G, Kantarjian H, Offit K, Stone RM, Gilliland DG, Klein RJ, Levine RL. A germline JAK2 SNP is associated with predisposition to the development of JAK2(V617F)-positive myeloproliferative neoplasms. Nat Genet 41(4):385-386, 4/2009. e-Pub 3/2009. PMID: 19287384.
18.	Heinrichs S, Kulkarni RV, Bueso-Ramos CE, Levine RL, Loh ML, Li C, Neuberg D, Kornblau SM, Issa JP, Gilliland DG, Garcia-Manero G, Kantarjian HM, Estey EH, Look AT. Accurate detection of uniparental disomy and microdeletions by SNP array analysis in myelodysplastic syndromes with normal cytogenetics. Leukemia. e-Pub 4/2009. PMID: 19387468.
19.	Wierda WG, O'Brien S, Wang X, Faderl S, Ferrajoli A, Do Ka, Garcia-Manero G, Cortes J, Thomas D, Koller C, Burger J, Lerner S, Kantarjian H, Keating M.. Characteristics Associated With Important Clinical End Points in Patients With Chronic Lymphocytic Leukemia at Initial Treatment. J Clin Oncol 27(10):1637-43, 4/2009. e-Pub 2/2009. PMID: 19224852.
20.	Jabbour E, Kantarjian HM, Jones D, Shan J, O'Brien S, Reddy N, Wierda WG, Faderl S, Garcia-Manero G, Verstovsek S, Rios MB, Cortes J. Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia post cytogenetic failure on standard-dose imatinib therapy. Blood 113(10):2154-2160, 3/2009. e-Pub 12/2008. PMID: 19060245.
21.	Ravandi F, Estey E, Jones D, Faderl S, O'Brien S, Fiorentino J, Pierce S, Blamble D, Estrov Z, Wierda W, Ferrajoli A, Verstovsek S, Garcia-Manero G, Cortes J, Kantarjian H. Effective Treatment of Acute Promyelocytic Leukemia With All-Trans-Retinoic Acid, Arsenic Trioxide, and Gemtuzumab Ozogamicin. J Clin Oncol 27(4):504-510, 2/2009. e-Pub 12/2008. PMID: 19075265.
22.	Yang H, Kadia T, Xiao L, Bueso-Ramos CE, Hoshino K, Thomas DA, O'Brien S, Jabbour E, Pierce S, Rosner GL, Kantarjian HM, Garcia-Manero G. Residual DNA methylation at remission is prognostic in adult Philadelphia chromosome-negative acute lymphocytic leukemia. Blood 113(9):1892-8, 2/2009. e-Pub 12/2008. PMCID: PMC2651008.
23.	Garcia-Manero G, Yang H, Kuang SQ, O'Brien S, Thomas D, Kantarjian H. Epigenetics of acute lymphocytic leukemia. Semin Hematol 46(1):24-32, 1/2009. PMID: 19100365.
24.	Verma D, O'Brien S, Thomas D, Faderl S, Koller C, Pierce S, Kebriaei P, Garcia-Manero G, Cortes J, Kantarjian H, Ravandi F. Therapy-related acute myelogenous leukemia and myelodysplastic syndrome in patients with acute lymphoblastic leukemia treated with the hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimens. Cancer 115(1):101-6, 1/2009. PMID: 19090005.
25.	Jabbour E, Kantarjian HM, Jones D, Reddy N, O'Brien S, Garcia-Manero G, Burger J, Cortes J. Characteristics and outcome of chronic myeloid leukemia patients with F317L BCR-ABL kinase domain mutation after therapy with tyrosine kinase inhibitors. Blood 112(13):4839-4842, 12/2008. e-Pub 9/2008. PMID: 18818391.
26.	O'Brien S, Thomas D, Ravandi F, Faderl S, Cortes J, Borthakur G, Pierce S, Garcia-Manero G, Kantarjian HM. Outcome of adults with acute lymphocytic leukemia after second salvage therapy. Cancer 113(11):3186-91, 12/2008. PMID: 18846563.
27.	Gardner A, Mattiuzzi G, Faderl S, Borthakur G, Garcia-Manero G, Pierce S, Brandt M, Estey E. Randomized Comparison of Cooked and Noncooked Diets in Patients Undergoing Remission Induction Therapy for Acute Myeloid Leukemia. J Clin Oncol 26(35):5684-5688, 12/2008. e-Pub 10/2008. PMID: 18955453.
28.	Borthakur G, Kantarjian H, Wang X, Plunkett WK, Gandhi VV, Faderl S, Garcia-Manero G, Ravandi F, Pierce S, Estey EH. Treatment of core-binding-factor in acute myelogenous leukemia with fludarabine, cytarabine, and granulocyte colony-stimulating factor results in improved event-free survival. Cancer 113(11):3181-5, 12/2008. PMID: 18932257.
29.	Yanada M, Borthakur G, Garcia-Manero G, Ravandi F, Faderl S, Pierce S, Kantarjian H, Estey E. Blood counts at time of complete remission provide additional independent prognostic information in acute myeloid leukemia. Leuk Res 32(10):1505-9, 10/2008. e-Pub 4/2008. PMID: 18405972.
30.	Greenberg PL, Attar E, Battiwalla M, Bennett JM, Bloomfield CD, DeCastro CM, Deeg HJ, Erba HP, Foran JM, Garcia-Manero G, Gore SD, Head D, Maness LJ, Millenson M, Nimer SD, O'Donnell MR, Saba HI, Shami PJ, Spiers K, Stone RM, Tallman MS, Westervelt P, Westervelt P. Myelodysplastic syndromes. J Natl Compr Canc Netw 6(9):902-26, 10/2008. PMID: 18926100.
31.	Braiteh F, Soriano AO, Garcia-Manero G, Hong D, Johnson MM, Silva Lde P, Yang H, Alexander S, Wolff J, Kurzrock R. Phase I study of epigenetic modulation with 5-azacytidine and valproic acid in patients with advanced cancers. Clin Cancer Res 14(19):6296-301, 10/2008. PMCID: PMC2582814.
32.	Tam CS, Kantarjian H, Garcia-Manero G, Borthakur G, O'Brien S, Ravandi F, Shan J, Cortes J. Failure to achieve a major cytogenetic response by 12 months defines inadequate response in patients receiving nilotinib or dasatinib as second or subsequent line therapy for chronic myeloid leukemia. Blood 112(3):516-8, 8/2008. e-Pub 5/2008. PMID: 18492956.
33.	Garcia-Manero G, Assouline S, Cortes J, Estrov Z, Kantarjian H, Yang H, Newsome WM, Miller WH, Rousseau C, Kalita A, Bonfils C, Dubay M, Patterson TA, Li Z, Besterman JM, Reid G, Laille E, Martell RE, Minden M. Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia. Blood 112(4):981-9, 8/2008. e-Pub 5/2008. PMID: 18495956.
34.	Thomas DA, O'Brien S, Jorgensen JL, Cortes J, Faderl S, Garcia-Manero G, Verstovsek S, Koller C, Pierce S, Huh Y, Wierda W, Keating MJ, Kantarjian HM. Prognostic significance of CD20 expression in adults with de novo precursor B-lineage acute lymphoblastic leukemia. Blood 113(25). e-Pub 8/2008. PMID: 18703706.
35.	Jabbour E, Kantarjian H, Jones D, Breeden M, Garcia-Manero G, O'Brien S, Ravandi F, Borthakur G, Cortes J. Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation following failure of imatinib mesylate therapy. Blood 112(1):53-5, 7/2008. e-Pub 4/2008. PMID: 18403620.
36.	Kantarjian H, O'Brien S, Ravandi F, Cortes J, Shan J, Bennett JM, List A, Fenaux P, Sanz G, Issa JP, Freireich EJ, Garcia-Manero G. Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original international prognostic scoring system. Cancer 113(6):1351-61, 7/2008. PMID: 18618511.
37.	Aribi A, Kantarjian H, Koller C, Thomas D, Faderl S, Garcia-Manero G, Cortes J. The effect of interleukin 11 on thrombocytopenia associated with tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia. Cancer 113(6):1338-43, 7/2008. PMID: 18629842.
38.	Garcia-Manero G, Stoltz ML, Ward MR, Kantarjian H, Sharma S. A pilot pharmacokinetic study of oral azacitidine. Leukemia 22(9):1680-4, 6/2008. e-Pub 6/2008. PMID: 18548103.
39.	Faderl S, Ravandi F, Huang X, Garcia-Manero G, Ferrajoli A, Estrov Z, Borthakur G, Verstovsek S, Thomas DA, Kwari M, Kantarjian HM. A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome. Blood 112(5). e-Pub 6/2008. PMID: 18565853.
40.	Quintás-Cardama A, Tong W, Manshouri T, Vega F, Lennon PA, Cools J, Gilliland DG, Lee F, Cortes J, Kantarjian H, Garcia-Manero G. Activity of tyrosine kinase inhibitors against human NUP214-ABL1-positive T cell malignancies. Leukemia 22(6):1117-24, 6/2008. e-Pub 4/2008. PMID: 18401417.
41.	Jabbour E, Issa JP, Garcia-Manero G, Kantarjian H. Evolution of decitabine development: accomplishments, ongoing investigations, and future strategies. Cancer 112(11):2341-51, 6/2008. PMID: 18398832.
42.	Kuang SQ, Tong WG, Yang H, Lin W, Lee MK, Fang ZH, Wei Y, Jelinek J, Issa JP, Garcia-Manero G. Genome-wide identification of aberrantly methylated promoter associated CpG islands in acute lymphocytic leukemia. Leukemia 22(8):1529-38, 6/2008. e-Pub 6/2008. PMID: 18528427.
43.	Garcia-Manero G. In reply to 'Improving the prognostic evaluation of patients with lower-risk myelodysplastic syndromes' by Kuendgen et al. Leukemia, 6/2008. e-Pub 6/2008. PMID: 18548096.
44.	Fabbri M, Garzon R, Andreeff M, Kantarjian HM, Garcia-Manero G, Calin GA. MicroRNAs and noncoding RNAs in hematological malignancies: molecular, clinical and therapeutic implications. Leukemia 22(6):1095-105, 6/2008. e-Pub 3/2008. PMID: 18323801.
45.	Verstovsek S, Tefferi A, Cortes J, O'Brien S, Garcia-Manero G, Pardanani A, Akin C, Faderl S, Manshouri T, Thomas D, Kantarjian H. Phase II study of dasatinib in Philadelphia chromosome-negative acute and chronic myeloid diseases, including systemic mastocytosis. Clin Cancer Res 14(12):3906-15, 6/2008. PMID: 18559612.
46.	Quintás-Cardama A, Tong W, Kantarjian H, Thomas D, Ravandi F, Kornblau S, Manshouri T, Cortes JE, Garcia-Manero G, Verstovsek S. A phase II study of 5-azacitidine for patients with primary and post-essential thrombocythemia/polycythemia vera myelofibrosis. Leukemia 22(5):965-70, 5/2008. e-Pub 4/2008. PMID: 18385750.
47.	Yanada M, Garcia-Manero G, Borthakur G, Ravandi F, Kantarjian H, Estey E. Relapse and death during first remission in acute myeloid leukemia. Haematologica 93(4):633-4, 4/2008. PMID: 18379012.
48.	Garcia-Manero G, Shan J, Faderl S, Cortes J, Ravandi F, Borthakur G, Wierda WG, Pierce S, Estey E, Liu J, Huang X, Kantarjian H. A prognostic score for patients with lower risk myelodysplastic syndrome. Leukemia 22(3):538-43, 3/2008. e-Pub 12/2007. PMID: 18079733.
49.	Atallah E, Garcia-Manero G. Treatment strategies in myelodysplastic syndromes. Cancer Invest 26(2):208-16, 3/2008. PMID: 18259954.
50.	Kantarjian H, O'Brien S, Shan J, Huang X, Garcia-Manero G, Faderl S, Ravandi-Kashani F, Verstovsek S, Beth Rios M, Cortes J. Cytogenetic and molecular responses and outcome in chronic myelogenous leukemia: need for new response definitions? Cancer 112(4):837-45, 2/2008. PMID: 18085610.
51.	Garcia-Manero G, Yang H, Bueso-Ramos C, Ferrajoli A, Cortes J, Wierda WG, Faderl S, Koller C, Morris G, Rosner G, Loboda A, Fantin VR, Randolph SS, Hardwick JS, Reilly JF, Chen C, Ricker JL, Secrist JP, Richon VM, Frankel SR, Kantarjian HM. Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes. Blood 111(3):1060-6, 2/2008. e-Pub 10/2007. PMID: 17962510.
52.	Tsimberidou AM, Wierda WG, Plunkett W, Kurzrock R, O'Brien S, Wen S, Ferrajoli A, Ravandi-Kashani F, Garcia-Manero G, Estrov Z, Kipps TJ, Brown JR, Fiorentino A, Lerner S, Kantarjian HM, Keating MJ. Phase I-II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with Richter's syndrome or fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol 26(2):196-203, 1/2008. PMID: 18182662.
53.	Cortes J, Jabbour E, Kantarjian H, Yin CC, Shan J, O'Brien S, Garcia-Manero G, Giles F, Breeden M, Reeves N, Wierda WG, Jones D. Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors. Blood 110(12):4005-11, 12/2007. e-Pub 9/2007. PMID: 17785585.
54.	Yanada M, Garcia-Manero G, Borthakur G, Ravandi F, Kantarjian H, Estey E. Potential cure of acute myeloid leukemia : analysis of 1069 consecutive patients in first complete remission. Cancer 110(12):2756-60, 12/2007. PMID: 17948909.
55.	Garcia-Manero G, Yang AS, Jagasia M. Evaluating new treatment options for MDS. Clin Adv Hematol Oncol 5(11):1-9; quiz 10-2, 11/2007. PMID: 18185491.
56.	Jabbour E, Kantarjian H, Cortes J, Thomas D, Garcia-Manero G, Ferrajoli A, Faderl S, Richie MA, Beran M, Giles F, Verstovsek S. PEG-IFN-alpha-2b therapy in BCR-ABL-negative myeloproliferative disorders: final result of a phase 2 study. Cancer 110(9):2012-8, 11/2007. PMID: 17849460.
57.	Cortes J, Quintás-Cardama A, Garcia-Manero G, O'Brien S, Jones D, Faderl S, Ebarb T, Giles F, Thomas D, Kantarjian H. Phase 1 study of tipifarnib in combination with imatinib for patients with chronic myelogenous leukemia in chronic phase after imatinib failure. Cancer 110(9):2000-6, 11/2007. PMID: 17849425.
58.	Jabbour E, Kantarjian HM, Abruzzo LV, O'Brien S, Garcia-Manero G, Verstovsek S, Shan J, Rios MB, Cortes J. Chromosomal abnormalities in Philadelphia chromosome negative metaphases appearing during imatinib mesylate therapy in patients with newly diagnosed chronic myeloid leukemia in chronic phase. Blood 110(8):2991-5, 10/2007. e-Pub 7/2007. PMID: 17625066.
59.	Soriano AO, Yang H, Faderl S, Estrov Z, Giles F, Ravandi F, Cortes J, Wierda WG, Ouzounian S, Quezada A, Pierce S, Estey EH, Issa JP, Kantarjian HM, Garcia-Manero G. Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome. Blood 110(7):2302-8, 10/2007. e-Pub 6/2007. PMID: 17596541.
60.	Amin HM, Hoshino K, Yang H, Lin Q, Lai R, Garcia-Manero G. Decreased expression level of SH2 domain-containing protein tyrosine phosphatase-1 (Shp1) is associated with progression of chronic myeloid leukaemia. J Pathol 212(4):402-10, 8/2007. PMID: 17503411.
61.	Yanada M, Huang X, Garcia-Manero G, O'brien S, Ravandi F, Borthakur G, Faderl S, Issa JP, Kantarjian H, Estey E. Effect of haematological improvement on survival in patients given targeted therapy as initial treatment of acute myeloid leukaemia or high-risk myelodysplastic syndrome. Br J Haematol 138(4):555-7, 8/2007. e-Pub 6/2007. PMID: 17593249.
62.	Aribi A, Bueso-Ramos C, Estey E, Estrov Z, O'Brien S, Giles F, Faderl S, Thomas D, Kebriaei P, Garcia-Manero G, Pierce S, Cortes J, Kantarjian H, Ravandi F. Biphenotypic acute leukaemia: a case series. Br J Haematol 138(2):213-6, 7/2007. PMID: 17593028.
63.	Qin T, Youssef EM, Jelinek J, Chen R, Yang AS, Garcia-Manero G, Issa JP. Effect of cytarabine and decitabine in combination in human leukemic cell lines. Clin Cancer Res 13(14):4225-32, 7/2007. PMID: 17634552.
64.	Wierda WG, O'Brien S, Wang X, Faderl S, Ferrajoli A, Do KA, Cortes J, Thomas D, Garcia-Manero G, Koller C, Beran M, Giles F, Ravandi F, Lerner S, Kantarjian H, Keating M. Prognostic nomogram and index for overall survival in previously untreated patients with chronic lymphocytic leukemia. Blood 109(11):4679-85, 6/2007. e-Pub 2/2007. PMID: 17299097.
65.	Hoshino K, Quintás-Cardama A, Yang H, Sanchez-Gonzalez B, Garcia-Manero G. Aberrant DNA methylation of the Src kinase Hck, but not of Lyn, in Philadelphia chromosome negative acute lymphocytic leukemia. Leukemia 21(5):906-11, 5/2007. e-Pub 3/2007. PMID: 17344919.
66.	Jabbour E, O'Brien S, Kantarjian H, Garcia-Manero G, Ferrajoli A, Ravandi F, Cabanillas M, Thomas DA. Neurologic complications associated with intrathecal liposomal cytarabine given prophylactically in combination with high-dose methotrexate and cytarabine to patients with acute lymphocytic leukemia. Blood 109(8):3214-8, 4/2007. e-Pub 1/2007. PMID: 17209054.
67.	Kuang SQ, Ling X, Sanchez-Gonzalez B, Yang H, Andreeff M, Garcia-Manero G. Differential tumor suppressor properties and transforming growth factor-beta responsiveness of p57KIP2 in leukemia cells with aberrant p57KIP2 promoter DNA methylation. Oncogene 26(10):1439-48, 3/2007. e-Pub 8/2006. PMID: 16936778.
68.	Oki Y, Kantarjian HM, Gharibyan V, Jones D, O'brien S, Verstovsek S, Cortes J, Morris GM, Garcia-Manero G, Issa JP. Phase II study of low-dose decitabine in combination with imatinib mesylate in patients with accelerated or myeloid blastic phase of chronic myelogenous leukemia. Cancer 109(5):899-906, 3/2007. PMID: 17236224.
69.	Boumber YA, Kondo Y, Chen X, Shen L, Gharibyan V, Konishi K, Estey E, Kantarjian H, Garcia-Manero G, Issa JP. RIL, a LIM Gene on 5q31, Is Silenced by Methylation in Cancer and Sensitizes Cancer Cells to Apoptosis. Cancer Res 67(5):1997-2005, 3/2007. PMID: 17332327.
70.	Quintás-Cardama A, Kantarjian H, Garcia-Manero G, O'Brien S, Faderl S, Ravandi F, Giles F, Thomas D, Wierda W, Cortes J. A pilot study of imatinib, low-dose cytarabine and idarubicin for patients with chronic myeloid leukemia in myeloid blast phase. Leuk Lymphoma 48(2):283-9, 2/2007. PMID: 17325887.
71.	Aribi A, Kantarjian HM, Estey EH, Koller CA, Thomas DA, Kornblau SM, Faderl SH, Laddie NM, Garcia-Manero G, Cortes JE. Combination therapy with arsenic trioxide, all-trans retinoic acid, and gemtuzumab ozogamicin in recurrent acute promyelocytic leukemia. Cancer 109(7):1355-9, 2/2007. PMID: 17326049.
72.	Kantarjian HM, O'Brien S, Huang X, Garcia-Manero G, Ravandi F, Cortes J, Shan J, Davisson J, Bueso-Ramos CE, Issa JP. Survival advantage with decitabine versus intensive chemotherapy in patients with higher risk myelodysplastic syndrome: comparison with historical experience. Cancer 109(6):1133-7, 2/2007. PMID: 17315156.
73.	Han X, Garcia-Manero G, McDonnell TJ, Lozano G, Medeiros LJ, Xiao L, Rosner G, Nguyen M, Fernandez M, Valentin-Vega YA, Barboza J, Jones DM, Rassidakis GZ, Kantarjian HM, Bueso-Ramos CE. HDM4 (HDMX) is widely expressed in adult pre-B acute lymphoblastic leukemia and is a potential therapeutic target. Mod Pathol 20(1):54-62, 1/2007. e-Pub 11/2006. PMID: 17143258.
74.	Quintás-Cardama A, Kantarjian H, Garcia-Manero G, O'Brien S, Faderl S, Estrov Z, Giles F, Murgo A, Ladie N, Verstovsek S, Cortes J. Phase I/II study of subcutaneous homoharringtonine in patients with chronic myeloid leukemia who have failed prior therapy. Cancer 109(2):248-55, 1/2007. PMID: 17154172.
75.	Kantarjian H, Oki Y, Garcia-Manero G, Huang X, O'Brien S, Cortes J, Faderl S, Bueso-Ramos C, Ravandi F, Estrov Z, Ferrajoli A, Wierda W, Shan J, Davis J, Giles F, Saba HI, Issa JP. Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood 109(1):52-7, 1/2007. e-Pub 8/2006. PMID: 16882708.
76.	Atallah E, Kantarjian H, Garcia-Manero G. The role of decitabine in the treatment of myelodysplastic syndromes. Expert Opin Pharmacother 8(1):65-73, 1/2007. PMID: 17163808.
77.	Kantarjian HM, O'Brien S, Shan J, Aribi A, Garcia-Manero G, Jabbour E, Ravandi F, Cortes J, Davisson J, Issa JP. Update of the decitabine experience in higher risk myelodysplastic syndrome and analysis of prognostic factors associated with outcome. Cancer 109(2):265-73, 1/2007. PMID: 17133405.
78.	Garcia-Manero G. Modifying the epigenome as a therapeutic strategy in myelodysplasia. Hematology Am Soc Hematol Educ Program 2007:405-11, 2007. PMID: 18024658.
79.	Garcia-Manero G, Kantarjian HM, Sanchez-Gonzalez B, Yang H, Rosner G, Verstovsek S, Rytting M, Wierda WG, Ravandi F, Koller C, Xiao L, Faderl S, Estrov Z, Cortes J, O'brien S, Estey E, Bueso-Ramos C, Fiorentino J, Jabbour E, Issa JP. Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia. Blood 108(10):3271-9, 11/2006. PMID: 16882711.
80.	Jabbour E, Kantarjian H, Jones D, Talpaz M, Bekele N, O'Brien S, Zhou X, Luthra R, Garcia-Manero G, Giles F, Rios MB, Verstovsek S, Cortes J. Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate. Leukemia 20(10):1767-73, 10/2006. PMID: 16855631.
81.	Kovitz C, Kantarjian H, Garcia-Manero G, Abruzzo LV, Cortes J. Myelodysplastic syndromes and acute leukemia developing after imatinib mesylate therapy for chronic myeloid leukemia. Blood 108(8):2811-3, 10/2006. PMID: 16809614.
82.	Kantarjian HM, Talpaz M, O'Brien S, Jones D, Giles F, Garcia-Manero G, Faderl S, Ravandi F, Rios MB, Shan J, Cortes J. Survival Benefit with Imatinib Mesylate versus Interferon Alpha-Based Regimens in Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia. Blood 108(6):1835-40, 9/2006. PMID: 16709931.
83.	Giles F, Fischer T, Cortes J, Garcia-Manero G, Beck J, Ravandi F, Masson E, Rae P, Laird G, Sharma S, Kantarjian H, Dugan M, Albitar M, Bhalla K. A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies. Clin Cancer Res 12(15):4628-35, 8/2006. PMID: 16899611.
84.	Sanchez-Gonzalez B, Yang H, Bueso-Ramos C, Hoshino K, Quintas-Cardama A, Richon VM, Garcia-Manero G. Antileukemia activity of the combination of an anthracycline with a histone deacetylase inhibitor. Blood 108(4):1174-82, 8/2006. PMID: 16675713.
85.	Tsimberidou AM, Estey E, Kantarjian H, Keating MJ, Pierce S, Garcia-Manero G. Granulocyte colony stimulating factor administration associated with cerebral hemorrhage in acute promyelocytic leukemia. Leukemia 20(8):1452-3, 8/2006. PMID: 16728980.
86.	Tsimberidou AM, Catovsky D, Schlette E, O'Brien S, Wierda WG, Kantarjian H, Garcia-Manero G, Wen S, Do KA, Lerner S, Keating MJ. Outcomes in patients with splenic marginal zone lymphoma and marginal zone lymphoma treated with rituximab with or without chemotherapy or chemotherapy alone. Cancer 107(1):125-35, 7/2006. PMID: 16700034.
87.	Yee KW, Cortes J, Ferrajoli A, Garcia-Manero G, Verstovsek S, Wierda W, Thomas D, Faderl S, King I, O'brien SM, Jeha S, Andreeff M, Cahill A, Sznol M, Giles FJ. Triapine and cytarabine is an active combination in patients with acute leukemia or myelodysplastic syndrome. Leuk Res 30(7):813-22, 7/2006. PMID: 16478631.
88.	Giles F, Verstovsek S, Garcia-Manero G, Thomas D, Ravandi F, Wierda W, Ferrajoli A, Kornblau S, Jabbour E, Shan J, O'brien S, Albitar M, Kantarjian H. Validation of the European Prognostic Index for younger adult patients with acute myeloid leukaemia in first relapse. Br J Haematol 134(1):58-60, 7/2006. PMID: 16803568.
89.	Tibes R, Keating MJ, Ferrajoli A, Wierda W, Ravandi F, Garcia-Manero G, O'Brien S, Cortes J, Verstovsek S, Browning ML, Faderl S. Activity of alemtuzumab in patients with CD52-positive acute leukemia. Cancer 106(12):2645-51, 6/2006. PMID: 16688777.
90.	Yang AS, Doshi KD, Choi SW, Mason JB, Mannari RK, Gharybian V, Luna R, Rashid A, Shen L, Estecio MR, Kantarjian HM, Garcia-Manero G, Issa JP. DNA methylation changes after 5-aza-2'-deoxycytidine therapy in patients with leukemia. Cancer Res 66(10):5495-503, 5/2006. PMID: 16707479.
91.	Thomas DA, Giles FJ, Albitar M, Cortes JE, Verstovsek S, Faderl S, O'Brien SM, Garcia-Manero G, Keating MJ, Pierce S, Zeldis J, Kantarjian HM. Thalidomide therapy for myelofibrosis with myeloid metaplasia. Cancer 106(9):1974-84, 5/2006. PMID: 16583431.
92.	Estey E, Garcia-Manero G, Ferrajoli A, Faderl S, Verstovsek S, Jones D, Kantarjian H. Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia. Blood 107(9):3469-73, 5/2006. PMID: 16373661.
93.	Thomas DA, Faderl S, O'Brien S, Bueso-Ramos C, Cortes J, Garcia-Manero G, Giles FJ, Verstovsek S, Wierda WG, Pierce SA, Shan J, Brandt M, Hagemeister FB, Keating MJ, Cabanillas F, Kantarjian H. Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia. Cancer 106(7):1569-80, 4/2006. PMID: 16502413.
94.	Soper SA, Brown K, Ellington A, Frazier B, Garcia-Manero G, Gau V, Gutman SI, Hayes DF, Korte B, Landers JL, Larson D, Ligler F, Majumdar A, Mascini M, Nolte D, Rosenzweig Z, Wang J, Wilson D. Point-of-care biosensor systems for cancer diagnostics/prognostics. Biosens Bioelectron 21(10):1932-42, 4/2006. PMID: 16473506.
95.	Patel SP, Garcia-Manero G, Ferrajoli A, Faderl S, Verstovek S, Kantarjian H, Estey E. Cardiotoxicity in African-American patients treated with arsenic trioxide for acute promyelocytic leukemia. Leuk Res 30(3):362-3, 3/2006. PMID: 16168477.
96.	Kantarjian H, O'brien S, Cortes J, Giles F, Faderl S, Jabbour E, Garcia-Manero G, Wierda W, Pierce S, Shan J, Estey E. Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcome. Cancer 106(5):1090-8, 3/2006. PMID: 16435386.
97.	Cortes JE, Talpaz M, O'Brien S, Faderl S, Garcia-Manero G, Ferrajoli A, Verstovsek S, Rios MB, Shan J, Kantarjian HM. Staging of chronic myeloid leukemia in the imatinib era: an evaluation of the World Health Organization proposal. Cancer 106(6):1306-15, 3/2006. PMID: 16463391.
98.	Oki Y, Kantarjian HM, Zhou X, Cortes J, Faderl S, Verstovsek S, O'Brien S, Koller C, Beran M, Bekele BN, Pierce S, Thomas D, Ravandi F, Wierda WG, Giles F, Ferrajoli A, Jabbour E, Keating MJ, Bueso-Ramos CE, Estey E, Garcia-Manero G. Adult acute megakaryocytic leukemia: an analysis of 37 patients treated at M.D. Anderson Cancer Center. Blood 107(3):880-4, 2/2006. PMID: 16123215.
99.	Wierda W, O'brien S, Faderl S, Ferrajoli A, Wang X, Do KA, Garcia-Manero G, Thomas D, Cortes J, Ravandi-Kashani F, Giles F, Lerner S, Kantarjian H, Keating M. A retrospective comparison of three sequential groups of patients with Recurrent/Refractory chronic lymphocytic leukemia treated with fludarabine-based regimens. Cancer 106(2):337-45, 1/2006. PMID: 16353201.
100.	Faderl S, Verstovsek S, Cortes J, Ravandi F, Beran M, Garcia-Manero G, Ferrajoli A, Estrov Z, O'Brien S, Koller C, Giles FJ, Wierda W, Kwari M, Kantarjian HM. Clofarabine and cytarabine combination as induction therapy for acute myeloid leukemia (AML) in patients >= 50 years. Blood 108(1):45-51, 1/2006. PMID: 16403905.
101.	Borthakur G, Kantarjian H, Daley G, Talpaz M, O'Brien S, Garcia-Manero G, Giles F, Faderl S, Sugrue M, Cortes J. Pilot study of lonafarnib, a farnesyl transferase inhibitor, in patients with chronic myeloid leukemia in the chronic or accelerated phase that is resistant or refractory to imatinib therapy. Cancer 106(2):346-52, 1/2006. PMID: 16342165.
102.	Jabbour E, Kantarjian H, O'Brien S, Rios MB, Abruzzo L, Verstovsek S, Garcia-Manero G, Cortes J. Sudden blastic transformation in patients with chronic myeloid leukemia treated with imatinib mesylate. Blood 107(2):480-2, 1/2006. PMID: 16195326.
103.	Thomas DA, Sarris AH, Cortes J, Faderl S, O'Brien S, Giles FJ, Garcia-Manero G, Rodriguez MA, Cabanillas F, Kantarjian H. Phase II study of sphingosomal vincristine in patients with recurrent or refractory adult acute lymphocytic leukemia. Cancer 106(1):120-7, 2006. PMID: 16331634.
104.	Giles F, Verstovsek S, Thomas D, Gerson S, Cortes J, Faderl S, Ferrajoli A, Ravandi F, Kornblau S, Garcia-Manero G, Jabbour E, O'Brien S, Karsten V, Cahill A, Yee K, Albitar M, Sznol M, Kantarjian H. Phase I study of cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, combined with cytarabine in patients with refractory leukemia. Clin Cancer Res 11(21):7817-24, 11/2005. PMID: 16278404.
105.	Ravandi F, O'Brien S, Jones D, Lerner S, Faderl S, Ferrajoli A, Wierda W, Garcia-Manero G, Thomas D, Koller C, Verstovsek S, Giles F, Cortes J, Herling M, Kantarjian H, Keating M. T-cell prolymphocytic leukemia: a single-institution experience. Clin Lymphoma Myeloma 6(3):234-9, 11/2005. PMID: 16354329.
106.	Yee KW, Hagey A, Verstovsek S, Cortes J, Garcia-Manero G, O'Brien SM, Faderl S, Thomas D, Wierda W, Kornblau S, Ferrajoli A, Albitar M, McKeegan E, Grimm DR, Mueller T, Holley-Shanks RR, Sahelijo L, Gordon GB, Kantarjian HM, Giles FJ. Phase 1 study of ABT-751, a novel microtubule inhibitor, in patients with refractory hematologic malignancies. Clin Cancer Res 11(18):6615-24, 9/2005. PMID: 16166440.
107.	Jabbour E, Verstovsek S, Giles F, Gandhi V, Cortes J, O'Brien S, Plunkett W, Garcia-Manero G, Jackson CE, Kantarjian H, Andreeff M. 2-Chlorodeoxyadenosine and cytarabine combination therapy for idiopathic hypereosinophilic syndrome. Cancer 104(3):541-6, 8/2005. PMID: 15977212.
108.	Canalli AA, Yang H, Jeha S, Hoshino K, Sanchez-Gonzalez B, Brandt M, Pierce S, Kantarjian H, Issa JP, Garcia-Manero G. Aberrant DNA methylation of a cell cycle regulatory pathway composed of P73, P15 and P57KIP2 is a rare event in children with acute lymphocytic leukemia. Leuk Res 29(8):881-5, 8/2005. PMID: 15978938.
109.	Giles F, O'Brien S, Cortes J, Verstovsek S, Bueso-Ramos C, Shan J, Pierce S, Garcia-Manero G, Keating M, Kantarjian H. Outcome of patients with acute myelogenous leukemia after second salvage therapy. Cancer 104(3):547-54, 8/2005. PMID: 15973664.
110.	Yang H, Hoshino K, Sanchez-Gonzalez B, Kantarjian H, Garcia-Manero G. Antileukemia activity of the combination of 5-aza-2'-deoxycytidine with valproic acid. Leuk Res 29(7):739-48, 7/2005. PMID: 15927669.
111.	Giles FJ, Kantarjian HM, Cortes JE, Faderl S, Verstovsek S, Thomas D, Garcia-Manero G, Wierda W, Ferrajoli A, Kornblau S, Mattiuzzi GN, Tsimberidou AM, Albitar M, O'Brien SM, Estey E. Adaptive randomized study of idarubicin and cytarabine alone or with interleukin-11 as induction therapy in patients aged 50 or above with acute myeloid leukemia or high-risk myelodysplastic syndromes. Leuk Res 29(6):649-52, 6/2005. PMID: 15863204.
112.	Wierda W, O'Brien S, Wen S, Faderl S, Garcia-Manero G, Thomas D, Do KA, Cortes J, Koller C, Beran M, Ferrajoli A, Giles F, Lerner S, Albitar M, Kantarjian H, Keating M. Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. J Clin Oncol 23(18):4070-8, 6/2005. PMID: 15767647.
113.	Saba R, Jabbour E, Giles F, Cortes J, Talpaz M, O'Brien S, Freireich EJ, Garcia-Manero G, Kantarjian H, Verstovsek S. Interferon alpha therapy for patients with essential thrombocythemia: final results of a phase II study initiated in 1986. Cancer 103(12):2551-7, 6/2005. PMID: 15861412.
114.	Issa JP, Gharibyan V, Cortes J, Jelinek J, Morris G, Verstovsek S, Talpaz M, Garcia-Manero G, Kantarjian HM. Phase II study of low-dose decitabine in patients with chronic myelogenous leukemia resistant to imatinib mesylate. J Clin Oncol 23(17):3948-56, 6/2005. PMID: 15883410.
115.	Bueso-Ramos C, Xu Y, McDonnell TJ, Brisbay S, Pierce S, Kantarjian H, Rosner G, Garcia-Manero G. Protein expression of a triad of frequently methylated genes, p73, p57Kip2, and p15, has prognostic value in adult acute lymphocytic leukemia independently of its methylation status. J Clin Oncol 23(17):3932-9, 6/2005. PMID: 15851765.
116.	Cortes J, Talpaz M, O'Brien S, Jones D, Luthra R, Shan J, Giles F, Faderl S, Verstovsek S, Garcia-Manero G, Rios MB, Kantarjian H. Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate. Clin Cancer Res 11(9):3425-32, 5/2005. PMID: 15867244.
117.	Kantarjian H, Talpaz M, O'Brien S, Giles F, Faderl S, Verstovsek S, Garcia-Manero G, Shan J, Rios MB, Champlin R, de Lima M, Cortes J. Survival benefit with imatinib mesylate therapy in patients with accelerated-phase chronic myelogenous leukemia--comparison with historic experience. Cancer 103(10):2099-108, 5/2005. PMID: 15830345.
118.	Cortes J, Faderl S, Estey E, Kurzrock R, Thomas D, Beran M, Garcia-Manero G, Ferrajoli A, Giles F, Koller C, O'Brien S, Wright J, Bai SA, Kantarjian H. Phase I study of BMS-214662, a farnesyl transferase inhibitor in patients with acute leukemias and high-risk myelodysplastic syndromes. J Clin Oncol 23(12):2805-12, 4/2005. PMID: 15728224.
119.	Murai M, Toyota M, Satoh A, Suzuki H, Akino K, Mita H, Sasaki Y, Ishida T, Shen L, Garcia-Manero G, Issa JP, Hinoda Y, Tokino T, Imai K. Aberrant DNA methylation associated with silencing BNIP3 gene expression in haematopoietic tumours. Br J Cancer 92(6):1165-72, 3/2005. PMID: 15756280.
120.	Quintas-Cardama A, Kantarjian H, Talpaz M, O'Brien S, Garcia-Manero G, Verstovsek S, Rios MB, Hayes K, Glassman A, Bekele BN, Zhou X, Cortes J. Imatinib mesylate therapy may overcome the poor prognostic significance of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia. Blood 105(6):2281-6, 3/2005. PMID: 15572595.
121.	Faderl S, Gandhi V, O'Brien S, Bonate P, Cortes J, Estey E, Beran M, Wierda W, Garcia-Manero G, Ferrajoli A, Estrov Z, Giles FJ, Du M, Kwari M, Keating M, Plunkett W, Kantarjian H. Results of a phase 1-2 study of clofarabine in combination with cytarabine (ara-C) in relapsed and refractory acute leukemias. Blood 105(3):940-7, 2/2005. PMID: 15486072.
122.	Saba R, Jabbour E, Giles F, Cortes J, Talpaz M, O’Brien S, Freireich EJ, Garcia-Manero G, Kantarjian H, Verstovsek S. Interferon-alpha (IFN-a) Therapy for Patients with Essential Thrombocythemia (ET): Final Results of a Phase II Study Initiated in 1986. Cancer 103(12):2551-2557, 2005.
123.	Grosso D, Filicko J, Garcia-Manero G, Beardell F, Brunner J, Cohn J, Ferbér A, Martinez J, Mookerjee B, Rose L, Tice D, Wagner JL, Capizzi R, Flomenberg N. Cytoprotection in acute myelogenous leukemia (AML) therapy. Semin Oncol 31(6 Suppl 18):67-73, 12/2004. PMID: 15726527.
124.	Hennessy B, Giles F, Cortes J, O'brien S, Ferrajoli A, Ossa G, Garcia-Manero G, Faderl S, Kantarjian H, Verstovsek S. Management of patients with systemic mastocytosis: review of M. D. Anderson Cancer Center experience. Am J Hematol 77(3):209-14, 11/2004. PMID: 15495258.
125.	Kantarjian HM, Cortes JE, O'Brien S, Luthra R, Giles F, Verstovsek S, Faderl S, Thomas D, Garcia-Manero G, Rios MB, Shan J, Jones D, Talpaz M. Long-term survival benefit and improved complete cytogenetic and molecular response rates with imatinib mesylate in Philadelphia chromosome-positive chronic-phase chronic myeloid leukemia after failure of interferon-alpha. Blood 104(7):1979-88, 10/2004. PMID: 15198956.
126.	Tsimberidou AM, Estey E, Whitman GJ, Dryden MJ, Ratnam S, Pierce S, Faderl S, Giles F, Kantarjian HM, Garcia-Manero G. Extramedullary relapse in a patient with acute promyelocytic leukemia: successful treatment with arsenic trioxide, all-trans retinoic acid and gemtuzumab ozogamicin therapies. Leuk Res 28(9):991-4, 9/2004. PMID: 15234578.
127.	Tsimberidou AM, Medina J, Cortes J, Rios A, Bonnie G, Faderl S, Kantarjian H, Garcia-Manero G. Chronic myeloid leukemia in a patient with acquired immune deficiency syndrome: complete cytogenetic response with imatinib mesylate: report of a case and review of the literature. Leuk Res 28(6):657-60, 6/2004. PMID: 15120945.
128.	Quintas-Cardama A, Kantarjian H, O'Brien S, Garcia-Manero G, Rios MB, Talpaz M, Cortes J. Granulocyte-colony-stimulating factor (filgrastim) may overcome imatinib-induced neutropenia in patients with chronic-phase chronic myelogenous leukemia. Cancer 100(12):2592-7, 6/2004. PMID: 15197801.
129.	Thomas DA, Faderl S, Cortes J, O'Brien S, Giles FJ, Kornblau SM, Garcia-Manero G, Keating MJ, Andreeff M, Jeha S, Beran M, Verstovsek S, Pierce S, Letvak L, Salvado A, Champlin R, Talpaz M, Kantarjian H. Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate. Blood 103(12):4396-407, 6/2004. PMID: 14551133.
130.	Giles F, Thomas D, Garcia-Manero G, Faderl S, Cortes J, Verstovsek S, Ferrajoli A, Jeha S, Beran M, Koller C, Andreeff M, Cahill A, Clairmont C, Sznol M, Kantarjian H. A Phase I and pharmacokinetic study of VNP40101M, a novel sulfonylhydrazine alkylating agent, in patients with refractory leukemia. Clin Cancer Res 10(9):2908-17, 5/2004. PMID: 15131024.
131.	Cortes J, Thomas D, Koller C, Giles F, Estey E, Faderl S, Garcia-Manero G, McConkey D, Ruiz SL, Patel G, Guerciolini R, Wright J, Kantarjian H. Phase I study of bortezomib in refractory or relapsed acute leukemias. Clin Cancer Res 10(10):3371-6, 5/2004. PMID: 15161691.
132.	Tsao AS, Kantarjian H, Thomas D, Giles F, Cortes J, Garcia-Manero G, Huh Y, Yang Y, Shen Y, Albitar M, Estey E. C-kit receptor expression in acute leukemias-association with patient and disease characteristics and with outcome. Leuk Res 28(4):373-8, 4/2004. PMID: 15109537.
133.	Kantarjian H, Talpaz M, O'Brien S, Garcia-Manero G, Verstovsek S, Giles F, Rios MB, Shan J, Letvak L, Thomas D, Faderl S, Ferrajoli A, Cortes J. High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia. Blood 103(8):2873-8, 4/2004. PMID: 15070658.
134.	Youssef EM, Chen XQ, Higuchi E, Kondo Y, Garcia-Manero G, Lotan R, Issa JP. Hypermethylation and silencing of the putative tumor suppressor Tazarotene-induced gene 1 in human cancers. Cancer Res 64(7):2411-7, 4/2004. PMID: 15059893.
135.	Giles FJ, Tallman MS, Garcia-Manero G, Cortes JE, Thomas DA, Wierda WG, Verstovsek S, Hamilton M, Barrett E, Albitar M, Kantarjian HM. Phase I and pharmacokinetic study of a low-clearance, unilamellar liposomal formulation of lurtotecan, a topoisomerase 1 inhibitor, in patients with advanced leukemia. Cancer 100(7):1449-58, 4/2004. PMID: 15042679.
136.	Kurzrock R, Albitar M, Cortes JE, Estey EH, Faderl SH, Garcia-Manero G, Thomas DA, Giles FJ, Ryback ME, Thibault A, De Porre P, Kantarjian HM. Phase II study of R115777, a farnesyl transferase inhibitor, in myelodysplastic syndrome. J Clin Oncol 22(7):1287-92, 4/2004. PMID: 15051776.
137.	El-Zimaity MM, Kantarjian H, Talpaz M, O'Brien S, Giles F, Garcia-Manero G, Verstovsek S, Thomas D, Ferrajoli A, Hayes K, Nebiyou Bekele B, Zhou X, Rios MB, Glassman AB, Cortes JE. Results of imatinib mesylate therapy in chronic myelogenous leukaemia with variant Philadelphia chromosome. Br J Haematol 125(2):187-95, 4/2004. PMID: 15059141.
138.	Issa JP, Garcia-Manero G, Giles FJ, Mannari R, Thomas D, Faderl S, Bayar E, Lyons J, Rosenfeld CS, Cortes J, Kantarjian HM. Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in hematopoietic malignancies. Blood 103(5):1635-40, 3/2004. PMID: 14604977.
139.	Mattiuzzi GN, Kantarjian H, Faderl S, Lim J, Kontoyiannis D, Thomas D, Wierda W, Raad I, Garcia-Manero G, Zhou X, Ferrajoli A, Bekele N, Estey E. Amphotericin B lipid complex as prophylaxis of invasive fungal infections in patients with acute myelogenous leukemia and myelodysplastic syndrome undergoing induction chemotherapy. Cancer 100(3):581-9, 2/2004. PMID: 14745876.
140.	Zangari M, Anaissie E, Stopeck A, Morimoto A, Tan N, Lancet J, Cooper M, Hannah A, Garcia-Manero G, Faderl S, Kantarjian H, Cherrington J, Albitar M, Giles FJ. Phase II study of SU5416, a small molecule vascular endothelial growth factor tyrosine kinase receptor inhibitor, in patients with refractory multiple myeloma. Clin Cancer Res 10(1 Pt 1):88-95, 2004. PMID: 14734456.
141.	Kantarjian H, O'Brien S, Cortes J, Giles F, Shan J, Rios MB, Faderl S, Verstovsek S, Garcia-Manero G, Wierda W, Kornblau S, Ferrajoli A, Keating M, Talpaz M. Survival advantage with imatinib mesylate therapy in chronic-phase chronic myelogenous ;eukemia (CML-CP) after IFN-alpha failure and in late CML-CP, comparison with historical controls. Clin Cancer Res 10(1 Pt 1):68-75, 2004. PMID: 14734453.
142.	Hennessy BT, Garcia-Manero G, Kantarjian HM, Giles FJ. DNA methylation in haematological malignancies: the role of decitabine. Expert Opin Investig Drugs 12(12):1985-93, 12/2003. PMID: 14640942.
143.	Kantarjian HM, O'Brien S, Cortes J, Giles FJ, Rios MB, Shan J, Faderl S, Garcia-Manero G, Ferrajoli A, Verstovsek S, Wierda W, Keating M, Talpaz M. Imatinib mesylate therapy improves survival in patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in the chronic phase: comparison with historic data. Cancer 98(12):2636-42, 12/2003. PMID: 14669283.
144.	Tsimberidou AM, Estey E, Cortes JE, Garcia-Manero G, Faderl S, Verstovsek S, Thomas DA, Ferrajoli A, Keating MJ, O'Brien S, Kantarjian HM, Giles FJ. Mylotarg, fludarabine, cytarabine (ara-C), and cyclosporine (MFAC) regimen as post-remission therapy in acute myelogenous leukemia. Cancer Chemother Pharmacol 52(6):449-52, 12/2003. PMID: 13680159.
145.	Giles FJ, Fracasso PM, Kantarjian HM, Cortes JE, Brown RA, Verstovsek S, Alvarado Y, Thomas DA, Faderl S, Garcia-Manero G, Wright LP, Samson T, Cahill A, Lambert P, Plunkett W, Sznol M, DiPersio JF, Gandhi V. Phase I and pharmacodynamic study of Triapine, a novel ribonucleotide reductase inhibitor, in patients with advanced leukemia. Leuk Res 27(12):1077-83, 12/2003. PMID: 12921943.
146.	Medina J, Kantarjian H, Talpaz M, O'Brien S, Garcia-Manero G, Giles F, Rios MB, Hayes K, Cortes J. Chromosomal abnormalities in Philadelphia chromosome-negative metaphases appearing during imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase. Cancer 98(9):1905-11, 11/2003. PMID: 14584073.
147.	Yang AS, Estecio MR, Garcia-Manero G, Kantarjian HM, Issa JP. Comment on "Chromosomal instability and tumors promoted by DNA hypomethylation" and "Induction of tumors in nice by genomic hypomethylation". Science 302(5648):1153; author reply 1153, 11/2003. PMID: 14615517.
148.	Kantarjian H, O'Brien S, Cortes J, Shan J, Giles F, Garcia-Manero G, Verstovsek S, Faderl S, Rios MB, Talpaz M. Analysis of the impact of imatinib mesylate therapy on the prognosis of patients with Philadelphia chromosome-positive chronic myelogenous leukemia treated with interferon-alpha regimens for early chronic phase. Cancer 98(7):1430-7, 10/2003. PMID: 14508830.
149.	Tsimberidou A, Cortes J, Thomas D, Garcia-Manero G, Verstovsek S, Faderl S, Albitar M, Kantarjian H, Estey E, Giles FJ. Gemtuzumab ozogamicin, fludarabine, cytarabine and cyclosporine combination regimen in patients with CD33+ primary resistant or relapsed acute myeloid leukemia. Leuk Res 27(10):893-7, 10/2003. PMID: 12860008.
150.	Kantarjian H, Gandhi V, Cortes J, Verstovsek S, Du M, Garcia-Manero G, Giles F, Faderl S, O'Brien S, Jeha S, Davis J, Shaked Z, Craig A, Keating M, Plunkett W, Freireich EJ. Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia. Blood 102(7):2379-86, 10/2003. PMID: 12791647.
151.	Cortes J, Talpaz M, O'Brien S, Giles F, Beth Rios M, Shan J, Faderl S, Garcia-Manero G, Ferrajoli A, Wierda W, Kantarjian H. Effects of age on prognosis with imatinib mesylate therapy for patients with Philadelphia chromosome-positive chronic myelogenous leukemia. Cancer 98(6):1105-13, 9/2003. PMID: 12973833.
152.	O'Brien S, Giles F, Talpaz M, Cortes J, Rios MB, Shan J, Thomas D, Andreeff M, Kornblau S, Faderl S, Garcia-Manero G, White K, Mallard S, Freireich E, Kantarjian HM. Results of triple therapy with interferon-alpha, cytarabine, and homoharringtonine, and the impact of adding imatinib to the treatment sequence in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in early chronic phase. Cancer 98(5):888-93, 9/2003. PMID: 12942553.
153.	Kantarjian HM, O'Brien S, Cortes J, Giles FJ, Faderl S, Issa JP, Garcia-Manero G, Rios MB, Shan J, Andreeff M, Keating M, Talpaz M. Results of decitabine (5-aza-2'deoxycytidine) therapy in 130 patients with chronic myelogenous leukemia. Cancer 98(3):522-8, 8/2003. PMID: 12879469.
154.	Cortes J, Giles F, O'Brien S, Thomas D, Garcia-Manero G, Rios MB, Faderl S, Verstovsek S, Ferrajoli A, Freireich EJ, Talpaz M, Kantarjian H. Result of high-dose imatinib mesylate in patients with Philadelphia chromosome-positive chronic myeloid leukemia after failure of interferon-alpha. Blood 102(1):83-6, 7/2003. PMID: 12637317.
155.	Estey E, Giles F, Cortes J, Beran M, Verstovsek S, Garcia-Manero G, Faderl S, Kantarjian H. Empirical examination of the neutrophil criterion (>1500 microl(-1)) currently needed to declare CR in AML. Leuk Res 27(6):475-9, 6/2003. PMID: 12648505.
156.	Tsimberidou AM, Kantarjian HM, Estey E, Cortes JE, Verstovsek S, Faderl S, Thomas DA, Garcia-Manero G, Ferrajoli A, Manning JT, Keating MJ, Albitar M, O'Brien S, Giles FJ. Outcome in patients with nonleukemic granulocytic sarcoma treated with chemotherapy with or without radiotherapy. Leukemia 17(6):1100-3, 6/2003. PMID: 12764375.
157.	Cortes J, Giles F, O'Brien S, Thomas D, Albitar M, Rios MB, Talpaz M, Garcia-Manero G, Faderl S, Letvak L, Salvado A, Kantarjian H. Results of imatinib mesylate therapy in patients with refractory or recurrent acute myeloid leukemia, high-risk myelodysplastic syndrome, and myeloproliferative disorders. Cancer 97(11):2760-6, 6/2003. PMID: 12767088.
158.	Garcia-Manero G, Talpaz M, Giles FJ, Cortes J, Faderl S, O'Brien S, Thomas D, Verstovsek S, Beth Rios M, Shan J, Ferrajoli A, Wierda W, Kantarjian HM. Treatment of Philadelphia chromosome-positive chronic myelogenous leukemia with weekly polyethylene glycol formulation of interferon-alpha-2b and low-dose cytosine arabinoside. Cancer 97(12):3010-6, 6/2003. PMID: 12784336.
159.	Shen L, Toyota M, Kondo Y, Obata T, Daniel S, Pierce S, Imai K, Kantarjian HM, Issa JP, Garcia-Manero G. Aberrant DNA methylation of p57KIP2 identifies a cell-cycle regulatory pathway with prognostic impact in adult acute lymphocytic leukemia. Blood 101(10):4131-6, 5/2003. PMID: 12586619.
160.	Giles FJ, Kantarjian HM, Cortes JE, Garcia-Manero G, Verstovsek S, Faderl S, Thomas DA, Ferrajoli A, O'Brien S, Wathen JK, Xiao LC, Berry DA, Estey EH. Adaptive randomized study of idarubicin and cytarabine versus troxacitabine and cytarabine versus troxacitabine and idarubicin in untreated patients 50 years or older with adverse karyotype acute myeloid leukemia. J Clin Oncol 21(9):1722-7, 5/2003. PMID: 12721247.
161.	Faderl S, Thomas DA, O'Brien S, Garcia-Manero G, Kantarjian HM, Giles FJ, Koller C, Ferrajoli A, Verstovsek S, Pro B, Andreeff M, Beran M, Cortes J, Wierda W, Tran N, Keating MJ. Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies. Blood 101(9):3413-5, 5/2003. PMID: 12522009.
162.	Kantarjian H, Talpaz M, O'Brien S, Giles F, Rios MB, White K, Garcia-Manero G, Ferrajoli A, Verstovsek S, Wierda W, Kornblau S, Cortes J. Prediction of initial cytogenetic response for subsequent major and complete cytogenetic response to imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia. Cancer 97(9):2225-8, 5/2003. PMID: 12712475.
163.	Cortes JE, Talpaz M, Giles F, O'Brien S, Rios MB, Shan J, Garcia-Manero G, Faderl S, Thomas DA, Wierda W, Ferrajoli A, Jeha S, Kantarjian HM. Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapy. Blood 101(10):3794-800, 5/2003. PMID: 12560227.
164.	Tsimberidou AM, Kantarjian HM, Cortes J, Thomas DA, Faderl S, Garcia-Manero G, Verstovsek S, Ferrajoli A, Wierda W, Alvarado Y, O'Brien SM, Albitar M, Keating MJ, Giles FJ. Fractionated cyclophosphamide, vincristine, liposomal daunorubicin, and dexamethasone plus rituximab and granulocyte-macrophage-colony stimulating factor (GM-CSF) alternating with methotrexate and cytarabine plus rituximab and GM-CSF in patients with Richter syndrome or fludarabine-refractory chronic lymphocytic leukemia. Cancer 97(7):1711-20, 4/2003. PMID: 12655528.
165.	Apostolidou E, Estey E, Cortes J, Garcia-Manero G, Faderl S, Thomas D, Tsimberidou A, Kantarjian H, Giles FJ. Mitoxantrone and prolonged infusion gemcitabine as salvage therapy in patients with acute myelogenous leukemia. Leuk Res 27(4):301-4, 4/2003. PMID: 12531220.
166.	Giles FJ, Cooper MA, Silverman L, Karp JE, Lancet JE, Zangari M, Shami PJ, Khan KD, Hannah AL, Cherrington JM, Thomas DA, Garcia-Manero G, Albitar M, Kantarjian HM, Stopeck AT. Phase II study of SU5416--a small-molecule, vascular endothelial growth factor tyrosine-kinase receptor inhibitor--in patients with refractory myeloproliferative diseases. Cancer 97(8):1920-8, 4/2003. PMID: 12673719.
167.	Cortes J, Kantarjian H, Albitar M, Thomas D, Faderl S, Koller C, Garcia-Manero G, Giles F, Andreeff M, O'Brien S, Keating M, Estey E. A randomized trial of liposomal daunorubicin and cytarabine versus liposomal daunorubicin and topotecan with or without thalidomide as initial therapy for patients with poor prognosis acute myelogenous leukemia or myelodysplastic syndrome. Cancer 97(5):1234-41, 3/2003. PMID: 12599230.
168.	Cortes J, Albitar M, Thomas D, Giles F, Kurzrock R, Thibault A, Rackoff W, Koller C, O'Brien S, Garcia-Manero G, Talpaz M, Kantarjian H. Efficacy of the farnesyl transferase inhibitor R115777 in chronic myeloid leukemia and other hematologic malignancies. Blood 101(5):1692-7, 3/2003. PMID: 12411300.
169.	Tsimberidou A, Estey E, Cortes J, Thomas D, Faderl S, Verstovsek S, Garcia-Manero G, Keating M, Albitar M, O'Brien S, Kantarjian H, Giles F. Gemtuzumab, fludarabine, cytarabine, and cyclosporine in patients with newly diagnosed acute myelogenous leukemia or high-risk myelodysplastic syndromes. Cancer 97(6):1481-7, 3/2003. PMID: 12627513.
170.	Tsimberidou AM, Medina J, Earl M, Sierra M, Shriki JE, Bueso-Ramos C, Giralt S, Beran M, Giles FJ, Garcia-Manero G. Metastatic gastric adenocarcinoma following allogeneic stem cell transplantation in a patient with acute myelogenous leukemia. Bone Marrow Transplant 31(5):413-4, 3/2003. PMID: 12634736.
171.	Giles FJ, Faderl S, Thomas DA, Cortes JE, Garcia-Manero G, Douer D, Levine AM, Koller CA, Jeha SS, O'Brien SM, Estey EH, Kantarjian HM. Randomized phase I/II study of troxacitabine combined with cytarabine, idarubicin, or topotecan in patients with refractory myeloid leukemias. J Clin Oncol 21(6):1050-6, 3/2003. PMID: 12637470.
172.	Garcia-Manero G, Jeha S, Daniel J, Williamson J, Albitar M, Kantarjian HM, Issa JP. Aberrant DNA methylation in pediatric patients with acute lymphocytic leukemia. Cancer 97(3):695-702, 2/2003. PMID: 12548613.
173.	Kantarjian HM, Talpaz M, O'Brien S, Giles F, Garcia-Manero G, Faderl S, Thomas D, Shan J, Rios MB, Cortes J. Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia. Blood 101(2):473-5, 1/2003. PMID: 12393385.
174.	Kantarjian HM, Cortes JE, O'Brien S, Giles F, Garcia-Manero G, Faderl S, Thomas D, Jeha S, Rios MB, Letvak L, Bochinski K, Arlinghaus R, Talpaz M. Imatinib mesylate therapy in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia: high incidence of early complete and major cytogenetic responses. Blood 101(1):97-100, 2003. PMID: 12393600.
175.	Alvarado Y, Tsimberidou A, Kantarjian H, Cortes J, Garcia-Manero G, Faderl S, Thomas D, Estey E, Giles FJ. Pilot study of Mylotarg, idarubicin and cytarabine combination regimen in patients with primary resistant or relapsed acute myeloid leukemia. Cancer Chemother Pharmacol 51(1):87-90, 2003. PMID: 12497211.
176.	Shen L, Kondo Y, Issa JP, Garcia-Manero G. Lack of p21(CIP1) DNA methylation in acute lymphocytic leukemia. Blood 100(9):3432-3; author reply 3433-4, 11/2002. PMID: 12412576.
177.	Giles F, Garcia-Manero G, Cortes J, Thomas D, Kantarjian H, Estey E. Ursodiol does not prevent hepatic venoocclusive disease associated with Mylotarg therapy. Haematologica 87(10):1114-6, 10/2002. PMID: 12368170.
178.	Kantarjian HM, O'Brien S, Cortes JE, Giralt SA, Rios MB, Shan J, Giles FJ, Thomas DA, Faderl S, De Lima M, Garcia-Manero G, Champlin R, Arlinghaus R, Talpaz M. Imatinib mesylate therapy for relapse after allogeneic stem cell transplantation for chronic myelogenous leukemia. Blood 100(5):1590-5, 9/2002. PMID: 12176876.
179.	Garcia-Manero G, Kantarjian HM, Kornblau S, Estey E. Therapy-related myelodysplastic syndrome or acute myelogenous leukemia in patients with acute promyelocytic leukemia (APL). Leukemia 16(9):1888, 9/2002. PMID: 12200720.
180.	Garcia-Manero G, Faderl S, Giles F, Thomas D, Cortes J, O'Brien S, Davis J, Kantarjian HM, Estey E. A phase I study of idarubicin dose escalation with amisfostine and high-dose cytarabine in patients with relapsed acute myelogenous leukemia and myelodysplastic syndromes. Haematologica 87(8):804-7, 8/2002. PMID: 12161355.
181.	Garcia-Manero G, Daniel J, Smith TL, Kornblau SM, Lee MS, Kantarjian HM, Issa JP. DNA methylation of multiple promoter-associated CpG islands in adult acute lymphocytic leukemia. Clin Cancer Res 8(7):2217-24, 7/2002. PMID: 12114423.
182.	Kantarjian HM, Talpaz M, O'Brien S, Smith TL, Giles FJ, Faderl S, Thomas DA, Garcia-Manero G, Issa JP, Andreeff M, Kornblau SM, Koller C, Beran M, Keating M, Rios MB, Shan J, Resta D, Capdeville R, Hayes K, Albitar M, Freireich EJ, Cortes JE. Imatinib mesylate for Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon-alpha: follow-up results. Clin Cancer Res 8(7):2177-87, 7/2002. PMID: 12114418.
183.	Giles FJ, Cortes JE, Thomas DA, Garcia-Manero G, Faderl S, Jeha S, De Jager RL, Kantarjian HM. Phase I and pharmacokinetic study of DX-8951f (exatecan mesylate), a hexacyclic camptothecin, on a daily-times-five schedule in patients with advanced leukemia. Clin Cancer Res 8(7):2134-41, 7/2002. PMID: 12114413.
184.	Kantarjian HM, O'Brien S, Cortes JE, Smith TL, Rios MB, Shan J, Yang Y, Giles FJ, Thomas DA, Faderl S, Garcia-Manero G, Jeha S, Wierda W, Issa JP, Kornblau SM, Keating M, Resta D, Capdeville R, Talpaz M. Treatment of philadelphia chromosome-positive, accelerated-phase chronic myelogenous leukemia with imatinib mesylate. Clin Cancer Res 8(7):2167-76, 7/2002. PMID: 12114417.
185.	Garcia-Manero G, Bueso-Ramos C, Daniel J, Williamson J, Kantarjian HM, Issa JP. DNA methylation patterns at relapse in adult acute lymphocytic leukemia. Clin Cancer Res 8(6):1897-903, 6/2002. PMID: 12060634.
186.	Faderl S, Keating MJ, Do KA, Liang SY, Kantarjian HM, O'Brien S, Garcia-Manero G, Manshouri T, Albitar M. Expression profile of 11 proteins and their prognostic significance in patients with chronic lymphocytic leukemia (CLL). Leukemia 16(6):1045-52, 6/2002. PMID: 12040436.
187.	Kantarjian HM, Cortes J, O'Brien S, Giles FJ, Albitar M, Rios MB, Shan J, Faderl S, Garcia-Manero G, Thomas DA, Resta D, Talpaz M. Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase. Blood 99(10):3547-53, 5/2002. PMID: 11986206.
188.	Verstovsek S, Lin H, Kantarjian H, Saglio G, De Micheli D, Pane F, Garcia-Manero G, Intrieri M, Rotoli B, Salvatore F, Guo JQ, Talpaz M, Specchia G, Pizzolo G, Liberati AM, Cortes J, Quackenbush RC, Arlinghaus RB. Neutrophilic-chronic myeloid leukemia: low levels of p230 BCR/ABL mRNA and undetectable BCR/ABL protein may predict an indolent course. Cancer 94(9):2416-25, 5/2002. PMID: 12015767.
189.	O'Brien S, Talpaz M, Cortes J, Shan J, Giles FJ, Faderl S, Thomas D, Garcia-Manero G, Mallard S, Beth M, Koller C, Kornblau S, Andreeff M, Murgo A, Keating M, Kantarjian HM. Simultaneous homoharringtonine and interferon-alpha in the treatment of patients with chronic-phase chronic myelogenous leukemia. Cancer 94(7):2024-32, 4/2002. PMID: 11932905.
190.	Giles FJ, Garcia-Manero G, Cortes JE, Baker SD, Miller CB, O'Brien SM, Thomas DA, Andreeff M, Bivins C, Jolivet J, Kantarjian HM. Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with refractory leukemia. J Clin Oncol 20(3):656-64, 2/2002. PMID: 11821445.
191.	Giles F, Garcia-Manero G, O'Brien S, Estey E, Kantarjian H. Fatal hepatic veno-occlusive disease in a phase I study of mylotarg and troxatyl in patients with refractory acute myeloid leukemia or myelodysplastic syndrome. Acta Haematol 108(3):164-7, 2002. PMID: 12373091.
192.	Giles FJ, Kantarjian HM, Kornblau SM, Thomas DA, Garcia-Manero G, Waddelow TA, David CL, Phan AT, Colburn DE, Rashid A, Estey EH. Mylotarg (gemtuzumab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantation. Cancer 92(2):406-13, 7/2001. PMID: 11466696.
193.	Garcia-Manero G. Chromosomal abnormalities in chronic lymphocytic leukemia. N Engl J Med 344(16):1254, 4/2001. PMID: 11314693.
194.	Giles F, Cortes J, Garcia-Manero G, Kornblau S, Estey E, Kwari M, Murgo A, Kantarjian H. Phase I study of irofulven (MGI 114), an acylfulvene illudin analog, in patients with acute leukemia. Invest New Drugs 19(1):13-20, 2001. PMID: 11291829.
195.	García-Manero G, Schuster SJ, Patrick H, Martinez J. Pulmonary hypertension in patients with myelofibrosis secondary to myeloproliferative diseases. Am J Hematol 60(2):130-5, 2/1999. PMID: 9929105.
196.	Chowdhury ZA, Barsigian C, Chalupowicz GD, Bach TL, Garcia-Manero G, Martinez J. Colocalization of tissue transglutaminase and stress fibers in human vascular smooth muscle cells and human umbilical vein endothelial cells. Exp Cell Res 231(1):38-49, 2/1997. PMID: 9056410.
197.	García-Manero G, Dómine M. Daunomicine inhibits the catenation activity of the enzyme DNA topoisomerase II in an in vitro system. Oncología (Spain) 15:305-310, 1992.
198.	García-Manero G. Chromosomal Fragile Sites and the enzyme DNA topoisomerase II. Graduation thesis, Faculty of Medicine, University of Zaragoza. Annals of the Faculty of Medicine of the University of Zaragoza, 11/1991.
Invited Articles
1.	Garcia-Manero G. Improving survival in myelodysplastic syndromes. Lancet Oncology:223-232, 3/2009.
2.	Jain N, Rossi A, Garcia-Manero G. Epigenetic therapy of leukemia: An update. Int J Biochem Cell Biol 41(1):72-80, 1/2009. e-Pub 10/2008. PMID: 18948224.
3.	Garcia-Manero G, Yang H, Kuang SQ, O'Brien S, Thomas D, Kantarjian H. Epigenetics of acute lymphocytic leukemia. Semin Hematol 46(1):24-32, 1/2009. PMID: 19100365.
4.	Garcia-Manero G. All MDS Patients Are Not the Same. Clinical Advances in Hematology & Oncology 6(12):8-10, 12/2008.
5.	Garcia-Manero G. Advances in MDS Management. Medical Progress 7(11):15-16, 11/2008.
6.	Garcia-Manero G. Demethylating agents in myeloid malignancies. Curr Opin Oncol 20(6):705-10, 11/2008. PMID: 18841054.
7.	Kim H, Garcia-Manero G. Management of Myelodysplastic Syndromes: Just the Beginning. Oncology 22(12):1360-1368, 11/2008.
8.	Kantarjian H, O'Brien S, Cortes J, Wierda W, Faderl S, Garcia-Manero G, Issa JP, Estey E, Keating M, Freireich EJ. Therapeutic advances in leukemia and myelodysplastic syndrome over the past 40 years. Cancer 113(7 Suppl):1933-52, 10/2008. PMID: 18798533.
9.	Atallah E, Garcia-Manero G. Treatment strategies in myelodysplastic syndromes. Cancer Investigation 26(2):208-216, 2008.
10.	Atallah E, Garcia-Manero G. Use of hypomethylating agents in myelodysplastic syndromes. Clin Adv Hematol Oncol 5(7):544-52, 7/2007. PMID: 17679928.
11.	Garcia-Manero G. Recent Advances in the Treatment of MDS. A review of selected presentations from the 48th Annual Meeting of the American Society of Hematology, December 9-12, 2006, Orlando, Florida. Clin Adv Hematol Oncol 5(3 Suppl 6):1-13; quiz 15-6, 3/2007. PMID: 17519888.
12.	Garcia-Manero G, Yang AS, Jagasia M. Evaluating new treatment options for MDS. Clin Adv Hematol Oncol 5(11):1-9, 2007.
13.	Garcia-Manero G. Histone Deacetylases: Transcriptional regulation and other cellular functions. Br J Cancer 96(7):1153, 2007.
14.	Garcia-Manero G. Recent advances in the treatment of MDS. Clinical Advances in Hematology & Oncology 3(6):1-16, 2007.
15.	Garcia-Manero, G. Using combination therapy to improve control: DNA methylation and HDAC inhibition. The Promise of Epigenetic Therapy:14-18, 2007.
16.	Garcia-Manero G. Decitabine in myelodysplastic syndromes: a viewpoint by Guillermo Garcia-Manero. Drugs 66(7):959-60, 2006.
17.	Garcia-Manero G, Gore SD. Future directions for the use of hypomethylating agents. Semin Hematol 42(3 Suppl 2):S50-9, 7/2005. PMID: 16015506.
18.	Garcia-Manero G, Issa JP. Histone deacetylase inhibitors: a review of their clinical status as antineoplastic agents. Cancer Invest 23(7):635-42, 2005. PMID: 16305991.
19.	Garcia-Manero G, Glantz M. Leukemia and lymphoma: what is the role for intrathecal prophylactic treatment in adults? Expert Rev Neurother 4(4 Suppl):S25-31, 7/2004. PMID: 15853552.
20.	Garcia-Manero G. Alteraciones epigeneticas en leucemias agudas. Haematologia 1:44, 2004.
21.	Garcia-Manero G. Avances en leucemia linfocitica cronica. Haematolologia 1:34, 2004.
22.	Garcia-Manero G. Front line therapy for patients with chronic myelogenous leukemia in chronic phase in the year 2004. Haematologica 89:57-61, 2004.
23.	Garcia-Manero G. on DNA Hypomethylation in the Treatment of MDS. Clinical Advances in Hematology & Oncology 4(4):3, 2004.
24.	Garcia-Manero G, Faderl S, O'Brien S, Cortes J, Talpaz M, Kantarjian HM. Chronic myelogenous leukemia: a review and update of therapeutic strategies. Cancer 98(3):437-57, 8/2003. PMID: 12879460.
25.	Faderl S, Garcia-Manero G, Thomas DA, Kantarjian HM. Philadelphia chromosome-positive acute lymphoblastic leukemia- current concepts and future perspectives. Rev Clin Exp Hematol 6(2):142-60; discussion 200-2, 6/2002. PMID: 12196213.
26.	Garcia-Manero G, Talpaz M, Kantarjian HM. Current therapy of chronic myelogenous leukemia. Intern Med 41(4):254-64, 4/2002. PMID: 11993784.
27.	Garcia-Manero G Kantarjian H. Imatinib mesylate in accelerated-phase Philadelphia chromosome positive chronic myelogenous leukemia. American Journal Oncology Review 1:208-228, 2002.
28.	Garcia-Manero G Kantarjian H. Treatment innovations in chronic myelogenous leukemia. Hematologia (Argentina) supl II:19-25, 2002.
29.	Garcia-Manero G Kantarjian H. Treatment innovations in chronic myelogenous leukemia. Oncology Special 5:139-143.3, 2002.
30.	Garcia-Manero G, Thomas DA. Salvage therapy for refractory or relapsed acute lymphocytic leukemia. Hematol Oncol Clin North Am 15(1):163-205, 2/2001. PMID: 11253606.
31.	Garcia-Manero G, Keating MJ, O’Brien S. Fludarabine, cyclophosphamide, and rituximab in chronic lymphocytic leukemia. Biological Therapy of Lymphoma 4:7-9, 2001.
32.	Garcia-Manero G, Kantarjian HM. The hyper-CVAD regimen in adult acute lymphocytic leukemia. Hematol Oncol Clin North Am 14(6):1381-96, x-xi, 12/2000. PMID: 11147229.
33.	Garcia-Manero G, Issa J-P. CpG island methylation in cancer. Cancer Research Alert 1:133-144, 2000.
34.	Garcia-Manero G, Schuster SJ, Agha ME. Should autologous or allogeneic stem-cell therapy be a part of consolidation therapy for all cases of adult acute myelogenous leukemia? Semin Oncol 26(1):xvi-xvii, xxi-xxii, 2/1999. PMID: 10073556.
35.	Sorensen SC, García-Manero G, Mastrangelo MJ, Soltan A. Does lymph node dissection still have a role in cancer therapy? Semin Oncol 24(3):xxxiii-xxxiv, xxxix, xli-xlii, xlv, 6/1997. PMID: 9208880.
36.	Garcia-Manero G, Domine M, Delgado C, Cunningham JM, Francis GE. The polymerase chain reaction (PCR): a new technique for the molecular study of cancer. Oncologia 15:501-516, 1991.
Editorials
1.	Garcia-Manero G. Prognostic implications of epigenetic silencing of p15INK4B in acute promyelocytic leukemia. Leukemia 17(5):839-40, 5/2003. PMID: 12750694.
2.	Garcia-Manero, G. Methylation, aging and pediatric acute lymphocytic leukemia. Leukemia 17:2063-2064, 2003.
3.	Garcia-Manero, G. Prognostic implications of epigenetic silencing of p15INK4b in acute promyelocytic leukemia. Leukemia 17:839-840, 2003.
Abstracts
1.	G. Garcia-Manero, S. Luger, P. Venugopal, L. Maness, M. Wetzler, S. Courtre, W. Stock, G. Borthakur, J. Chiao, H. Kantarjian. A randomized phase II study of sapacitabine, an oral nucleosite analogue, in elderly patients with AML previously untreated or in first relapse or previously treated MDS. Journal of Clinical Oncology 2009 ASCO Annual Meeting Proceedings 27(15S, Part I of II):361s (#7021), 5/2009.
2.	N. Pemmaraju, H. Kantarjian, F. Ravandi, S. O'Brien, W. Wierda, D. Thomas, G. Garcia-Manero, G. Borthakur, S. Pierce, J. Cortes. Acute myeloid leukemia (AML) in adolescents and young adults (AYA): The M.D. Anderson Cancer Center experience. Journal of Clinical Oncology 2009 ASCO Annual Meeting Proceedings 27(15S, Part I of II):368s, 5/2009.
3.	D. Verma, H. Kantarjian, D. Jones, G. Borthakur, G. Garcia-Manero, D.A. Thomas, S. Verstovsek, M. Rios, J. Cortes,. Chronic myeloid leukemia (CML) with e1a2 BCR-ABL fusion transcript type: Analysis of characteristices, outcomes, and prognostic significance. Journal of Clinical Oncology 2009 ASCO Annual Meeting Proceedings 27(15S, Part I of II):363s (#7030), 5/2009.
4.	K. Naqvi. J. Oh, G. Garcia-Manero, S. Pierce, M.E. Suarez-Almazor. Comorbidities and prognosis of myelodysplastic syndromes. Journal of Clinical Oncology 2009 ASCO Annual Meeting Proceedings 27(15S, Part I of II):376s, 5/2009.
5.	G. Batty, H. Kantarjian, J.J. Issa, G. Garcia-Manero, S. Pierce, S. O'Brien, E. Jabbour, J. Cortes, F. Ravandi. Feasibility of hypomethylating therapy in patients with renal insufficiency. Journal of Clinical Oncology 27(15S, Part I of II) (#7089), 5/2009.
6.	F. Ravandi-Kashani, J. Cortes, S. Faderl, D. Jones, A. Byrd, M. Brandt, G. Garcia-Manero, M. Levis, M. Andreeff, H. Kantarjian. Phase I/II study of idarubicin (Ida), high-dose ara-C, and sorafenib (S) in patients (pts) younger than 65 years with acute myeloid leukemia (AML). Journal of Clinical Oncology 2009 ASCO Annual Meeting Proceedings 27(15S, Part I of II):360s (#7018), 5/2009.
7.	K.R. Sampat, V. Garcia-Gutierrez, A. Rossi, S. Pierce, J. Cortes, H. Kantarjian, G. Garcia-Manero. Prevalence and therapeutic relationships of pericardial effusions in patients with leukemia. Journal of Clinical Oncology 2009 ASCO Annual Meeting Proceedings 27(15S, Part I of II):372s (#7067), 5/2009.
8.	E. Laille, R. Ward, A. Nasser, M. Stoltz, C. Cogle, S. Gore, B.S. Skikne, G. Garcia-Manero. The pharmacokinetics of azacitidine following subcutaneous treatment in patients with myelodysplastic syndromes (MDS) or acute myelogenous leukemia (AML). Journal of Clinical Oncology 2009 ASCO Annual Meeting Proceedings 27(15S, Part I of II):377s (#7087), 5/2009.
9.	E. Jabbour, S. Faderl, F. Ravandi, M. Konopleva, S. Verstovsek, J. Cortes, W. Wierda, W.M. Newsome, H. Yang, H. Kantarjian, G. Garcia-Manero. Phase II study of vorinostat (V) in combination with idarubicin and high-dose cytarabine (IA) as front-line therapy in patients (pts) with high-risk myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML). Journal of Clinical Oncology 2009 ASCO Annual Meeting Proceedings 27(15S, Part I of II):327s (#7004), 2/2009.
10.	Santos FP.S., Faderl S, Garcia-Manero G, Koller C, Beran M, Borthakur G, Bueso-Ramos C, Keating M, Cortes J, Kantarjian H, & Ravandi F. Acute Erythroleukemia: An Analysis of 108 Patients Treated with Cytarabine-Containing Regimens at the M.D. Anderson Cancer Center. Blood 112(11):342-343, 11/2008.
11.	Tong W, Wei Y, Stevenson W, Kuang SQ, Arts J, & Garcia-Manero G. Antileukemia Activity of JNJ-26481585, a Potent Second-Generation Histone Deacetylase Inhibitor. Blood 112(11):910-911, 11/2008.
12.	Santos F P.S, Kantarjian H, Fava C, O'Brien S, Garcia-Manero G, Kornblau S, Ravandi F, Wierda W, & Cortes J. Clinical significance of dose Reductions of Second-Generation Tyrosine Kinase Inhibitors (TKI) in Patients (Pts) with Chronic Myeloid Leukemia (CML). Blood 112(11):1104, 11/2008.
13.	Quintas-Cardama A, Kantarjian H, Thomas DA, Garci-Manero G, Borthakur G, Bell N, Byrne C, & Verstovsek S. Combined Therapy with Lenalidomide and Prednisone Renders Durable Clinical, Histopathological, and Molecular Responses in Patients with Myelofibrosis. Blood 112(11):247, 11/2008.
14.	Ravandi F, Cortes J, Faderl S, Garcia-Manero G, O'Brien S, Brandt M, Lang M, Zhang W, Luthra R, Jones D, Levis M, Konopleva M, Andreeff M, & Karjian H. Combionation of Sorafenib, Idarubicin, and Cytarabine Has a HIgh Response Rate in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) YOnger Thank 65 Years. Blood 112(11):285, 11/2008.
15.	Borthakur G, Estrov Z, Garcia-Manero G, Williams B, Wathen JK, Konopleva M, Burger J, Ferrajoli A, George S, & Kantarjian H. Decitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia and High-Risk Myelodysplastic Syndrome. Blood 112(11):1026, 11/2008.
16.	Kantarjian H, O'Brien S, Ravandi F, Cortes J, Shan J, Bennett JM, List AF, Fenaux P, & Garcia-Manero G. Development and Validation of a New Prognostic Model for Myelodysplastic Syndrome (MDS) That Accounts for Events Not Considered by the International Prognostic Scoring System (IPSS). Blood 112(11):236, 11/2008.
17.	Kantarjian H, Giles F, Greenberg P, Paquette R, Wang E, Gbrilove J, Garcia-Manero G, Gray J, Hu K, & Franklin J. Effect of Romiplostime in Patients (pts) with Low or Intermediate Risk Myelodysplastic Syndrome (MDS) Receiving Azacytidine. Blood 112(11):89, 11/2008.
18.	Cortes J, O'Brien S, Jone D, Ferrajoli A, Konopleva M, Borthakur G, Garcia-Manero G, Letvak L, & Kantarjian H. Efficacy of Nilotinib (formerly AMN107) in Patients (Pts) with Newly Diagnosed, Previously Untreated Philadelphia Chromosome (Ph)-Positive Chronic Myelogenous Leukemia in Early Chronic Phase (CML-CP). Blood 112(11):170, 11/2008.
19.	Kuang S, Mckay PZ, Yang H, Fang ZH, Tong W, & Garcia-Manero G. Epigenetic Inactivation of Notch Signaling Target Genes HES in B Cell Acute Lymphoblastic Leukemia. Blood 112(11):1157, 11/2008.
20.	Maddipoti SC, Bueso-Ramos C, Yang H, Fernandez M, Kuang S, F Z, Stevenson W,Wei Y, Pierce S, & Garcia-Manero G. Epigenetic Silencing of the RUNX3 Gene by Promoter Hypermethylation in Patients with Myeloid Leukemia. Blood 112(11):1148, 11/2008.
21.	Ravandi F, Issa JP, Garcia-Manero G, O'Brien S, Pierce S, Shan J, Verstovsek S, Faderly S, Cortes J, & Kantarjian H. Hypomethylating Therapy in Patients with AML and Hig-Risk MDS and Chromosome 5 and 7 Abnormalities Is Associated with An Improved Outcome Compared to Conventional Chemotherapy. Blood 112(11):1015, 11/2008.
22.	Tong W, Kuang SQ, Wierda W, Keating MJ, & Garcia-Manero G. Identification of Multiple Promoter Associated CpG Islands Commonly Methylated in Both Acute Lymphocytic Leukemia (ALL) and Chronic Lymphocytic Leukema (CLL) Using Novel Genome-Wide Mircorarray Technique: Implicatons for Common Primordial Molecular Pathways in Lymphoid Leukemias. Blood 112(11):789, 11/2008.
23.	Kantarjian H, Pierce S, Garcia-Manero G, Cortes J, Faderl S, & Ravandi F. Increase in the Incidence of Secondary Acute Myeloid Leukemia (2-AML): A Single Institution Experience Over 20 Years. Blood 112(11):533, 11/2008.
24.	Henderson JD, O'Brien SM, Wang X, Faderl S, Ferrajoli A, Garcia-Manero G, Tam CS, Burger JA, Abruzzo LV, Schlette E, Lerner S, Keating MJ, & Wierda WG. Integrating Newer Prognostic Factors in Evaluation of Previously Treated Patient with CLL Receiving Salvage Treatiment. Blood 112(11):723, 11/2008.
25.	Wierda WG, O'Brien SM, Wang X, Faderl SH, Ferrajoli A, Garcia-Manero G, Cortes J, Tam CS, Burger JA, Abruzzo LV, Schlette E, Lerner S, & Keating MJ. Integrating Newer with Traditional Prognostic Factors in Evaluating Patients with CLL Receiving Frontline Chemoimmunotherapy. Blood 112(11):729, 11/2008.
26.	De Lima M, de Padua Silva L, Giralt S, Komaduri K, Andersson BS, Hosing C, Qazilbash M, Shpall E, Thall P, Zhang W, McCormic G, Wang X, Popat U, Soriano A, Alousi A, Champlin R, & Garcia-Manero G. Maintenance Therapy with Low-Dose Azacitidine(AZA) after Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for Relapsed or Refractory AML or MDS: A Dose and Schedule Finding Study. Blood 112(11):414, 11/2008.
27.	Verma D, Kantarjian HM, Rios MB, O'Brien S, Ault P, Burton EM, Estrov Z, Borthakur G, Verstovsek S, Garcia-Manero G, Ravandi F, Cortes J. Malignancies Occurring during Therapy with Tyrosine Kinase Inhibitors (TKI) for Chronic Myeloid Leukemia (CML) and Other Hematologic Malignancies. Blood 112(11):740, 11/2008.
28.	Faderl S, Garcia-Manero G, Ravandi F, Borthakur g, Estrov Z, Thomas D, Gandhi V, Plunkett W, Byrd A, Kwari M, & Kantarjian H. Oral (po) and Intravenous (iv) Clofarabine for Patients (pts) with Myelodysplastic Syndrome (MDS). Blood 112(11):89, 11/2008.
29.	Thomas DA, Katarjian H, Faderl S, Wierda W, Garcia-Manero G, Ferrajoli A, Burger J, Cortes J, Koller C, Borhakur G, Estrov Z, Knopleva M, & O'Brien S. Outcome after Frontline therapy with the Modified Hyper-CVAD Regime with or without Rituximab for De Novo Acute Lyphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LL). Blood 112(11):674, 11/2008.
30.	Fava C, Blamble D, O'Brien S, Garcia-Manero G, Pierce S, Kantarjian H, & Borthakur G. Outcome of First Salvage Therapy in core Binding Factor Associated Acute Myelogenous Leukemia Is Less Than Optimal. Blood 112(11):1014, 11/2008.
31.	Jabbour E, Garcia-Manero G, Shan J, O'Brien S, Cortes J, Ravandi F, Issa JP, & Kantarjian H. Outcome of Patients (pst) with Myelodysplastic Syndrome (MD) and Chronic Myelomonocytic Leukemia (CMML) Post Decitabine Failure. Blood 112(11):585-586, 11/2008.
32.	Quintas-Cardama A, Kantarjian HM, Borhakur G, Faderl S, Garcia-Manero G, Wierda W, Burton EM, & Cortes J. Outocme of Patient with Chronic Myeloid Leukemia 9CML) with Multiple ABL1 Kinase Domain Mutations during Tyrosine Kinase Inhibitor Therapy. Blood 112(11):735, 11/2008.
33.	Ravandi F, Sampath D, Plunkett W, Williams B, Burton M, Verstovsek S, Faderl S, Garcia-Manero G, Alvarez V, Becker MD, List AF, Sebti S, Kantarjian H, & Lancet J. Phase I Study of the Akt-Inhibito Triciribine Phosphate Monohydrate in Patients with Advanced Hematologic Malignancy. Blood 112(11):1026, 11/2008.
34.	Issa J-P, Castoro R, Ravandi-Kashani F, Faderl S, Huang X, Estey E, Borhakur G, Morris G, Garcia-Manero G, & Kantarjian H. Randomized Phase II Study of Combined Epigenetic Therapy: Decitabine Vs. Decitabine and Valproic Acid in MDS and AML. Blood 112(11):91, 11/2008.
35.	Borthakur G, de Lima M, Kantarjian H, Xiao L, de Padua Silva L, Garcia-Manero G, Giralt S, Ravandi-Kashani F, Pierce S, & Champlin R. Stem Cell Tansplantation in Remission Improves Survival in Acute Myelogenous Leukemia Associated with FLT3 Mutations. Blood 112(11):1134, 11/2008.
36.	Wei Y, Kadia T, Tong W, O'Brien S, Viallet J, & Garcia-Manero G. The Combination of a Histone Deacetylase (HDAC) Inhibitor with the BCL-2 Inhibitor GX15-070 Has Synergistic Antileukemia Effect by Inducing Both Apoptotic and Autophagic Pathways. Blood 112(11):577, 11/2008.
37.	Kantarjian H, O'Brien S, Ravandi F, Borthakur G, Faderl S, Bueso-Ramos C, Abruzzo L, Pierce S, Shan J, Issa JP, & Garcia-Manero G. The Heterogeneous Prognosis of Patients with Myelodysplastic Syndrome (MDS) and Chromosome 5 Abnormalities: How Does It Relate to the Original Lenalidomide Experience in MDS? Blood 112(11):580, 2008, 11/2008.
38.	Skikne BS, Ward MR, Nasser A, Aukerman L, Garcia-Manero G. A phase I, open-label, dose-escalation study to evaluate the safety, pharmacokinetics, and pharmacodynamics of oral azacitidine in subjects with myelodysplastic syndromes (MDS) or acute myelogenous leukemia (AML). Proceedings of the Annual American Society of Clinical Oncology 26(15s):394s (#7091), 5/2008.
39.	Conley AP, Stevenson W, Pierce S, Cortes JE, O’Brien SM Ravandi F, Kantarjian HM, Garcia-Manero G. Cause of death in patients with lower-risk myelodysplactic syndrome (MDS). Proceedings of the Annual American Society of Clinical Oncology 26(15s):395s (#7096), 5/2008.
40.	Borthakur G, Kantarjian HM, O’Brien SM, Jones D, Koller C, Nicaise C, Garcia-Manero G, Ferrajoli A, Cortes JE. Efficacy of dasatinib in patients (pts) with previously untreated chronic myelogenous leukemia (CML) in early chronic phase (CML-CP). Proceedings of the Annual American Society of Clinical Oncology 26(15s):375s (#7013), 5/2008.
41.	Cortes JE, O’Brien SM, Ferrajoli A, Borthakur G, Burger J, Wierda W, Garcia-Manero G, Letvak L, Kantarjian HM. Efficacy of nilotinib (AMN107) in patients (pts) with newly diagnosed, previously untreated philadelphia chromosome (Ph)- positive chronic myelogenous leukemia in early chronic phase (CML-CP). Proceedings of the Annual American Society of Clinical Oncology 26(15s):376s (#7016), 5/2008.
42.	Garg RJ, Shah N, Garcia-Manero G, Faderl S, Cortes JE, Koller C, Beran M, Borthakur G, Kantarjian HM, Ravandi F. Phase II study of thymoglobulin, cyclosporine and G-CSF for initial treatment of aplastic anemia and low risk myelodysplastic syndrome. Proceedings of the Annual American Society of Clinical Oncology 26(15s):395s (#7093), 5/2008.
43.	Yanada M, Borthakur G, Garcia-Manero G, Ravandi F, Faderl S, Pierce S, Kantarjian HM, Estey E. Prognostic significance of blood counts at time of complete remission in acute myeloid leukemia. Proceedings of the Annual American Society of Clinical Oncology 26(15s):391s (#7078), 5/2008.
44.	Gardner A, Mattiuzzi G, Faderl S, Borthakur G, Garcia-Manero G, Estey E. Randomized comparison of “neutropenic” and non-neutropenic diet in pts undergoing remission induction therapy for AML. Proceedings of the Annual American Society of Clinical Oncology 26(15s):385s (#7052), 5/2008.
45.	Jain N, Kantarjian HM, Garcia-Manero G, Borthakur G, Ebarb T, Cortes JE. Synthetic tumor-specific breakpoint peptide vaccine in patients (pts) with chronic myeloid leukemia (CML) and minimal residual disease: A phase II trial. Proceedings of the Annual American Society of Clinical Oncology 26(15s):386s (#7056), 5/2008.
46.	Estey E, Sun Z, Rowe J, Faderl S, Cassileth P, Sartiano G, Tartaglia A, Garcia-Manero G, Cripe L, Bennett J, Kantarjian H, Tallman M. A 3,239 -Patient Combined Eastern Cooperative Oncology Group (ECOG), M.D. Anderson Cancer Center (MDA) Analysis of the Effect of CR vs. Responses < CR on Long-Term Survival in Newly-Diagnosed AML Treated with Ara-C-Containing Regimens: Implications for Targeted Drug Development. Blood 110(11) (#298), 11/2007.
47.	de Lima M, Padua L, Giralt S, Hosing C, Komanduri K, Qazilbash M, Shpall EJ, Thall P, Qureshi S, McCormick G, Tong W, Popat U, Soriano A, Champlin R, Garcia-Manero G. A Dose and Schedule Finding Study of Maintenance Therapy with Low-Dose 5-Azacitidine (AZA) after Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for High-Risk AML or MDS. Blood 110(11) (#3012), 11/2007.
48.	Kadia TM, Ferrajoli A, Ravandi F, Cortes J, Thomas D, Wierda W, Verstovsek S, Newsome W, Zwiebel J, Egorin M, Kantarjian H, Garcia-Manero G. A Phase I Study of the Combination of the Histone Deacetylase Inhibitor Vorinostat with Idarubicin in Advanced Acute Leukemia. Blood 110(11) (#1842), 11/2007.
49.	Tsimberidou AM, Kantarjian H, O'Brien S, Garcia-Manero G, Koller C, Jones D, Pierce S, Brandt M, Keating M, Estey E. All-Trans Retinoic Acid (ATRA) and Arsenic Trioxide (As2O3) Combination Therapy Induces High Rates of Durable Molecular Remission in Newly Diagnosed Acute Promyelocytic Leukemia (APL). Blood 110(11) (#1834), 11/2007.
50.	Garcia-Manero G, Quesada AS, Maddipoti S, Kuang SQ, Tong W, Wierda WG, Bueso-Ramos CM, Yang H. Analysis of Class I and II Histone Deacetylase Fails To Identify a Human Leukemia Specific Expression Profile. Blood 110(11) (#2130), 11/2007.
51.	Jain N, Mattiuzzi GN, Cortes J, Cassat J, Garcia-Manero G, Ravandi-Kashani F, Pierce S, Borthakur G, O'Brien S, Kantarjian HM. Benefit of Anti-Infectious Prophylaxis in Patients with Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome Receiving Frontline “Targeted Therapy”. Blood 110(11) (#2858), 11/2007.
52.	Vega-Ruiz A, Kantarjian H, Shan J, Wierda W, Burger J, Verstovsek S, Garcia-Manero G, Cortes J. Better Molecular Response to Imatinib for Patients (pts) with Chronic Myeloid Leukemia (CML) in Chronic Phase (CP) Carrying the b3a2 Transcript Compared to b2a2. Blood 110(11) (#1939), 11/2007.
53.	Jabbour E, Kantarjian H, Jones D, O'Brien S, Garcia-Manero G, Burger J, Cortes J. Clinical Characteristics and Outcome of Patients (pts) with F317L BCR-ABL Kinase Domain (KD) Mutation after Therapy with Tyrosine Kinase Inhibitors (TKIs). Blood 110(11) (#1947), 11/2007.
54.	Wierda WG, O'Brien S, Ferrajoli A, Faderl S, Koller C, Estrov Z, Garcia-Manero G, Verstovsek S, Browning M, Lerner S, Keating M. Combined Cyclophosphamide, Fludarabine, Alemtuzumab, and Rituximab (CFAR), an Active Frontline Regimen for High-Risk Patients with CLL. Blood 110(11) (#628), 11/2007.
55.	Wierda WG, O'Brien S, Faderl S, Ferrajoli A, Garcia-Manero G, Burger J, Schlette E, Abruzzo L, Lerner S, Keating M. Complex Karyotypic Abnormalities Detected by Conventional Cytogenetic Analysis More Strongly Predict Survival Than FISH, ZAP70, or IgVH Mutation Status for Previously Treated Patients with CLL. Blood 110(11) (#2065), 11/2007.
56.	Jabbour E, Giralt S, Kantarjian H, Garcia-Manero G, Shpall E, Kebriaei P, Silva LDP, Champlin R, de Lima N. Efficacy of Azacytidine (5-AC) Given as Maintenance or Salvage Therapy for Patients (pts) with Acute Leukemia Post Allogeneic Stem Cell Transplantation (HSCT). Blood 110(11) (#3013), 11/2007.
57.	Cortes J, O'Brien S, Jabbour E, Ferrajoli A, Borthakur G, Burge Jr, Wierda W, Garcia-Manero G, Thomas M, Letvak L, Kantarjian H. Efficacy of Nilotinib (AMN107) in Patients (Pts) with Newly Diagnosed, Previously Untreated Philadelphia Chromosome (Ph)-Positive Chronic Myelogenous Leukemia in Early Chronic Phase (CML-CP). Blood 110(11) (#29), 11/2007.
58.	Kuang SQ, Fang ZH, Lopez G, Tong W, Yang H, Garcia-Manero G. Eph Receptor Tyrosine Kinases and Ephrin Ligands Are Epigenetically Inactivated in Acute Lymphoblastic Leukemia and Are Potential New Tumor Suppressor Genes in Human Leukemia. Blood 110(11) (#2128), 11/2007.
59.	Delmonte, Jr. J, Kantarjian HM, Garcia-Manero G, Estrov Z, Ravandi F, Verstovsek S, O'Brien S, Koller CA, Faderl S, Thomas DA, Wright JJ, Cortes J. Final Update of Phase I-II Study of the Farnesyltransferase Inhibitor Tipifarnib in Combination with Idarubicin and Cytarabine for Patients with Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome. Blood 110(11) (#441), 11/2007.
60.	Tong W, Wierda WG, Bekele N, Kuang SQ, Keating MJ, Garcia-Manero G. Genome-Wide DNA Methylation Profile of CLL with 17p del Allowed Identification of Multiple Epigenetically Inactivated Molecular Pathways with Prognostic Value in Human Leukemia. Blood 110(11) (#492), 11/2007.
61.	Kuang SQ, Tong W, Yang H, Lee MK, Fang ZH, Jelinek J, Issa JP, Garcia-Manero G. Genome-Wide Identification of Aberrant Promoter Associated CpG Island Methylation in Acute Lymphoblastic Leukemia. Blood 110(11) (#2127), 11/2007.
62.	Faderl S, Thomas DA, Ravandi F, Garcia-Manero G, Beran M, Rytting M, Koller CA, Verstovsek S, Borthakur G, Andreeff M, Kornblau S, O'Brien S, Vu K, Kwari M, Bretz J, Kantarjian HM. Intensification of Hyper-CVAD with L-Asparaginase, Vincristine, and Dexamethasone ("Augmented Hyper-CVAD") Has Activity in Adult Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL). Blood 110(11) (#4324), 11/2007.
63.	Rytting M, Verstovsek S, Garcia-Manero G, Ravandi-Kashani F, Pierce S, Estey E. Intensively Timed Induction (ITI) Chemotherapy in Adults with Acute Myelogenous Leukemia (AML). Blood 110(11) (#1851), 11/2007.
64.	Yanada M, Garcia-Manero G, Ravandi F, Faderl S, Kantarjian H, Estey E. Kinetics of Bone Marrow Blasts during Remission Induction Course in Acute Myeloid Leukemia: Effect on Complete Remission and Relapse-Free Survival. Blood 110(11) (#1852), 11/2007.
65.	Borthakur G, Garcia-Manero G, Faderl S, Estrov Z, Verstovsek S, Hood M, Kantarjian H. Lenalidomide in High-Risk Myelodysplastic Syndrome and Acute Myelogenous Leukemia Associated with Chromosome 5 Abnormalities. Blood 110(11) (#1459), 11/2007.
66.	Thomas DA, Kantarjian HM, Ravandi F, Faderl S, Garcia-Manero G, Wierda W, Ferrajoli A, Verstovsek S, Jones D, Letvak L, Champlin R, Cortes J, O'Brien S. Long-Term Follow-Up after Frontline Therapy with the Hyper-CVAD and Imatinib Mesylate Regimen in Adults with Philadelphia (Ph) Positive Acute Lymphocytic Leukemia (ALL). Blood 110(11) (#9), 11/2007.
67.	Fava C, Kantarjian HM, Jabbour E, Rios MB, Garcia-Manero G, O'Brien S, Cortes J. Long-Term Significance of Achieving a Major Cytogenetic Response (MCyR) without a Complete Hematologic Response (CHR) among Patients (pts) with Chronic Myeloid Leukemia (CML) in Advanced Phase Treated with Second Generation Tyrosine Kinase Inhibitors (TKI). Blood 110(11) (#1944), 11/2007.
68.	Schanz J, Estey E, Steidl C, Germing U, Hildebrandt B, Garcia-Manero G, Kantarjian HM, Haase D. Multivariate Analysis Suggests That the Prognostic Impact of Poor Cytogenetics Is Potentially Underestimated in the IPSS. Blood 110(11) (#248), 11/2007.
69.	Haase D, Estey EH, Steidl C, Germing U, Garcia-Manero G, Kantarjian HM, Schanz J. Multivariate Evaluation of the Prognostic and Therapeutic Relevance of Cytogenetics in a Merged European-American Cohort of 3860 Patients with MDS. Blood 110(11) (#247), 11/2007.
70.	Silva LDP, de Lima M, Kantarjian H, Champlin R, Faderl S, Giralt S, Kebriaei P, Davisson J, Estey E, Garcia-Manero G, Issa JP, Ravandi F. Outcome of Allogeneic Stem Cell Transplantation after Hypomethylating Therapy with 2'-Deoxy-5 Azacytidine for Patients with Myelodysplastic Syndrome. Blood 110(11) (#1468), 11/2007.
71.	Lim Z, Ho AYL, Samuel J, Hayden J, Garcia-Manero G, Mufti GJ. Outcomes of MDS Patients with Chromosome 7 Abnormalities Treated with 5-Azacytidine. Blood 110(11) (#1449), 11/2007.
72.	Quintás-Cardama A, Kantarjian H, Garcia-Manero G, Cortes J, Richie MA, Borthakur G, Verstovsek S. Pegylated Interferon-alfa-2a (PEG-IFN-α-2A; PEGASYS™) for Essential Thrombocythemia (ET) and Polycythemia Vera (PV): An Update of an Ongoing Phase II Study. Blood 110(11) (#3542), 11/2007.
73.	Garcia-Manero G, Thomas D, Rytting M, Zweidler-McKay P, Estrov Z, Brown DL, Yang G, Kantarjian H, O'Brien S. Phase I Study of 5-aza-2'-Deoxycitidine, Alone or in Combination with Hyper-CVAD, in Relapsed or Refractory Acute Lymphocytic Leukemia (ALL). Blood 110(11) (#2826), 11/2007.
74.	Kantarjian H, Garcia-Manero G, Faderl S, Cortes J, Estrov Z, Boone P, Stuart I, Westwood R, Green S, Chiao JH, Plunkett W. Phase I Study of Sapacitabine, an Oral Nucleoside Analogue, in Patients with Advanced Leukemias or Myelodysplastic Syndromes (MDS). Blood 110(11) (#884), 11/2007.
75.	Ravandi F, Faderl S, Thomas D, Burger J, Koller C, Garcia-Manero G, Morris G, Torma R, Kantarjian H, Issa JP. Phase I Study of Suberoylanilide Hydroxamic Acid (SAHA) and Decitabine in Patients with Relapsed, Refractory or Poor Prognosis Leukemia. Blood 110(11) (#897), 11/2007.
76.	Garcia-Manero G, Yang AS, Klimek V, Cortes J, Ravandi F, Newsome WM, Dumouchel J, Dubay M, Li Z, Maroun C, Laille E, Kantarjian H, Martell RE, Luger S. Phase I/II Study of MGCD0103, an Oral Isotype-Selective Histone Deacetylase (HDAC) Inhibitor, in Combination with 5-Azacitidine in Higher-Risk Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML). Blood 110(11) (#444), 11/2007.
77.	Verstovsek S, Tefferi A, Kornblau S, Thomas D, Cortes J, Ravandi-Kashani F, Garcia-Manero G, Kantarjian H. Phase II Study of CEP701, an Orally Available JAK2 Inhibitor, in Patients with Primary Myelofibrosis and Post Polycythemia Vera/Essential Thrombocythemia Myelofibrosis. Blood 110(11) (#3543), 11/2007.
78.	Verstovsek S, Ayalew T, Jorge C, O'Brien S, Garcia-Manero G, Pardanani A, Akin C, Faderl S, Thomas D, Kantarjian H. Phase II Study of Dasatinib (SPRYCEL™) in Philadelphia Chromosome-Negative Acute and Chronic Myeloid Diseases, Including Systemic Mastocytosis. Blood 110(11) (#3551), 11/2007.
79.	Quintás-Cardama A, Tefferi A, Thomas D, Cortes J, Ravandi F, Faderl S, Garcia-Manero G, Borthakur G, Bell N, Byrne C, Kantarjian H, Verstovsek S. Phase II Study of Lenalidomide and Prednisone for Patients with Myelofibrosis. Blood 110(11) (#3545), 11/2007.
80.	Ravandi F, Issa JP, Faderl S, Garcia-Manero G, Hood M, Jorgensen J, Lee M, O'Brien S, Estey E, Borthakur G, Ferrajoli A, Verstovsek S, Cortes J, Kantarjian H. Randomized Study of Decitabine Versus Observation or Continued Cytotoxic Chemotherapy in Patients with Intermediate and Poor Risk Acute Myeloid Leukemia in First or Subsequent Complete Remission. Blood 110(11) (#2859), 11/2007.
81.	Faderl S, Garcia-Manero G, Gandhi V, Ravandi F, Borthakur G, Thomas DA, Ferrajoli A, Estrov Z, Plunkett W, Byrd A, Kwari M, Kantarjian HM. Results of an Exploratory Study of Oral (po) and Intravenous (iv) Clofarabine in Patients with Myelodysplastic Syndrome. Blood 110(11) (#1455), 11/2007.
82.	Borthakur G, Kantarjian H, Garcia-Manero G, Pierce Sy, Estey E. Salvage Therapy with Standard Dose Cytarabine Is Appropriate for Patients with Acute Myelogenous Leukemia Refractory to Front-Line Therapy with Hypomethylating Agents. Blood 110(11) (#4382), 11/2007.
83.	Alvarado Y, Kantarjian H, Faderl S, Burger J, Borthakur G, O'Brien S, Wierda W, Garcia-Manero G, Cortes J. Significance of Suboptimal Response to Imatinib, as Defined by the European LeukemiaNet, in Long-Term Outcome for Patients (Pts) with Chronic Phase (CP) Chronic Myeloid Leukemia (CML). Blood 110(11) (#1932), 11/2007.
84.	Kantarjian H, Garcia-Manero G, O'Brien S, Estrov Z, Ravandi F, Cortes J, Shan J, Davisson J, Issa JP. Survival and Efficacy of Decitabine in Myelodysplastic Syndromes (MDS), Analysis of the 5-Day IV Dosing Regimen. Blood 110(11) (#115), 11/2007.
85.	Dushyant Verma, Hagop Kantarjian, Zeev Estrov, Guillermo Garcia-Manero, Charles Koller, Gautam Borthakur, Jorge Cortes. Survival Outcomes for Patients (Pts) with Chronic Myeloid Leukemia (CML) with Clonal Evolution (CE) Treated with 2nd Generation Tyrosine Kinase Inhibitors (TKI) after Imatinib Failure. Blood 110(11) (#2949), 11/2007.
86.	Kuang S, Ling X, Sanchez-Gonzalez B, Yang H, Garcia-Manero G. The Cyclin-Dependent Kinase Inhibitor p57KIP2 Functions as a Tumor Supresor Gene in Human Leukemia. Blood 106(11) (#1604), 11/2007.
87.	Verma D, Thomas D, O'Brien S, Faderl S, Koller C, Pierce S, Estey E, Garcia-Manero G, Cortes J, Kantarjian H, Ravandi F. Therapy Related Acute Myelogenous Leukemia and Myelodysplastic Syndrome in Patients with Acute Lymphoblastic Leukemia Treated with the Hyper-CVAD Regimen. Blood 110(11) (#2832), 11/2007.
88.	Kadia TM, Kantarjian H, Verstovsek S, Newman B, Garcia-Manero G, Borthakur G. Treatment of Myelodysplastic Syndrome (MDS) with Cytokine Immunotherapy for Low-Risk MDS. Blood 110(11) (#1463), 11/2007.
89.	Estey E, Issa JP, Garcia-Manero G, Faderl S, Kantarjian H. Use of Post-Treatment Clinical Data To Predict Response to Decitabine. Blood 110(11) (#1448), 11/2007.
90.	Kadia TM, Borthakur G, Wierda W, Ravandi F, Faderl S, Newsome W, Zwiebel J, Egorin M, Garcia-Manero G. Proceedings from the annual American Society of Clinical Oncology 25(18s) (#7066), 5/2007.
91.	Shan J, Kantarjian H, Pierce S, Estey E, Garcia-Manero G. A new prognostic score for patients with lower-risk myelodysplastic syndrome (MDS) allows the identification of a subset of patients with poor prognosis. Proceedings from the annual American Society of Clinical Oncology 25(18s) (#7076), 5/2007.
92.	Ward MR, Stoltz ML, Etter JB, Patton LM, Garcia-Manero G, Sharma S. An oral dosage formulation of azacitidine: A pilot pharmacokinetic study. Proceedings from the annual Americal Society of Clinical Oncology 25(18s) (#7084), 5/2007.
93.	Solh MM, Kantarjian H, O’Brien S, Giles F, Faderl S, Garcia-Manero G, Rios M, Shan J, Cortes J, Ravandi-Kashani F. Central nervous system (CNS) leukemia alter imatinib mesylate therapy for chronic myelogenous leukemia (CML). Proceedings from the annual American Society of Clinical Oncology 25(18s) (#7042), 5/2007.
94.	Soriano AO, Braiteh F, Garcia-Manero G, Camacho LH, Hong D, Moulder S, Ng C, Kurzrock R. Combination of 5-azacytidine (5-AZA) and valproic acid (VPA) in advanced solid cancers: A phase I study. Proceedings from the annual American Society of Clinical Oncology 25(18s) (#3547), 5/2007.
95.	Issa J, Saba HI, Garcia-Manero G, Shan J, Kantarjian HM. Decitabine in older patients with acute myelogenous leukemia (AML). Proceedings from the annual American Society of Clinical Oncology 25(18s) (#7021), 5/2007.
96.	O’Brien S, Garcia-Manero G, Ravandi F, Borthakur G, Issa J, Giles F, Kantarjian H, Estey. Effect of hematologic improvement (HI) on survival in patients (pts) given targeted therapy (TT) as initial treatment of acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (HR-MDS). Proceedings from the annual American Society of Clinical Oncology 25(18s) (#7059), 5/2007.
97.	Yang H, Thomas DA, Rytting ME, Zweidler-McKay PA, Brown DL, Kantarjian H, Garcia-Manero G. Phase I study of frequent low-dose administration of decitabine, alone or in combination with hyperCVAD, in relapsed or refractory acute lymphocytic leukemia (ALL). Proceedings from the annual American Society of Clinical Oncology 25(18s) (#7072), 5/2007.
98.	Plunkett W, Garcia-Manero G, Faderl S, Cortes J, Boone P, Hilbe C, Green S, Chiao JH, Kantarjian H. Phase I study of sapacitabine, an oral nucleoside analogue, in patients with advanced leucemias or myelodysplastic síndromes. Proceedings from the annual American Society of Clinical Oncology 25(18s) (#7063), 5/2007.
99.	Garcia-Manero G, Yang AS, Klimek V, Luger S, Newsome WM, Berman N, Patterson T, Maroun C, Li Z, Ward R, Martell R. Phase I/II study of a novel oral isotype-selective histone deacetylase (HDAC) inhibitor MGCD0103 in combination with azacitidine in patients (pts) with high-risk myelodysplastic syndrome (MDS) ora cute myelogenous leukemia (AML). Proceedings from the annual American Society of Clinical Oncology 25(18s) (#7059), 5/2007.
100.	Alvarado Y, Kantarjian H, Freireich EJ, Garcia-Manero G, Ferrajoli A, Koller C, Estrov Z, Kornblau S, Laddie N, Smith L, Cortes J. Phase II doping study of cytarabine chemotherapy in combination with cenersen (EL625) and idarubicin in refractory and relapsed acute myelogenous leukemia (AML). Proceedings from the annual American Society of Clinical Oncology 25(18s) (#7070), 5/2007.
101.	Garcia-Manero G. Epigenetic Therapy of High Risk Myelodysplastic Syndrome and Acute Myelogenous Leukemia. Cancer Investigation 25(Supplement 1), 2007.
102.	Tong W, Kuang SQ, Wierda WG, Garcia-Manero G. Global Gene Methylation of CLL Patients and its Implication in Therapy. American Association of Cancer Research (#1112), 2007.
103.	Kuang SQ, Yang H, Jelinek J, Tong W, Issa JP, Garcia-Manero G. Identification of Novel Differentially Methylated Markers in Adult Acute Lymphocytic Leukemias. American Association for Cancer Research (#1131), 2007.
104.	Quintas-Cardama A, Manshouri T, Tong W, Kantarjian H, Cortes J, Garcia-Manero G. The Dual ABL/SRC Inhibitors Dasatinib, SKI-606, and INNO-406 are Potent Inhibitors or T Cell Acute Lymphoblastic Leukemia Cell Lines Expressing the NUP214-ABL1 Fusion Kinase. American Association for Cancer Research (#1825), 2007.
105.	Atallah E, Kantarjian H, Garcia-Manero G. The role of decitabine in the treatment of myelodysplastic syndromes. Expert Opin Pharmacother 8(1):65-73, 2007.
106.	Quintas-Cardama A, Kantarjian H, Garcia-Manero G, Thomas D, Kornblau S, Estey E, Nemri M, Cortes J, Giles F, Verstovsek. A Phase II Study of Azacitidine (VidazaTM) for Patients with Myelofibrosis (MF). Blood 108(11) (#2706), 11/2006.
107.	Choi SH, Byun H-M, Jiang JY, Garcia-Manero G, Yang AS. Changes in DNA Methylation of Repetitive Elements during the Progression of Chronic Myelogenous Leukemia. Blood 108(11) (#4302), 11/2006.
108.	Tam CA, Giles F, Cortes J, Garcia-Manero G, Estey E, Kantarjian H, Verstovsek S. Characteristics and Outcomes of 38 Patients with Acute Myeloid Leukemia Evolving from Previous Well Characterized Myeloproliferative Disorder. Blood 108(11) (#2705), 11/2006.
109.	Atallah E, Kantarjian H, Cortes J, Pierce S, Estey E, Garcia-Manero G, Thomas D, Ravandi-Kashani F, Giles F, Verstovsek S. Clinical Features and Prognosis of Patients with Myelodysplastic/Myeloproliferative Syndrome-Unclassified (MDS/MPD-U): Refractory Anemia with Ringed Sideroblasts with Thrombocytosis (RARS-T) Is a Favorable Prognostic Subgroup. Blood 108(11) (#2612), 11/2006.
110.	Loboda A, Fantin VR, Bueso-Ramos CE, Randolph S, Hardwick JS, Ricker JL, Richon VM, Issa JP, Kantarjian HM, Frankel SR, Garcia-Manero G. Clinical Responses to Oral Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) Are Associated with Specific Gene Expression Signatures in Patients with Advanced Leukemias: Results of a Phase I Trial. Blood 108(11) (#2320), 11/2006.
111.	Jabbour E, Kantarjian H, Ravandi-Kashani F, Garcia-Manero G, O’Brien S, Cortes J. Clinical Significance of Loss of Chromosome Y (–Y) in Patients with Chronic Myeloid Leukemia (CML): Is It Clonal Evolution? Blood 108(11) (#2117), 11/2006.
112.	Quintas-Cardama A, Kantarjian HM, Nicaise C, Garcia-Manero G, O’Brien S, Ravandi-Kashani F, Faderl S. Cytopenias in Patients (pts) with Chronic Myelogenous Leukemia (CML) in Chronic Phase (CP) Treated with Dasatinib (SPRYCEL®): Clinical Features and Management, Including Outcome after Hematopoietic Growth Factor Therapy. Blood 108(11) (#2163), 11/2006.
113.	Jabbour E, O’Brien S, Ravandi-Kashani F, Cortes J, Borthakur G, Verstovsek S, Garcia-Manero G, Giles F, Zanoria L, Davisson J, Issa JP, Kantarjian H. Decitabine Induces High Response Rates in Patients with Chronic Myelomonocytic Leukemia (CMML). Blood 108(11) (#2655), 11/2006.
114.	Borthakur G, Ravandi-Kashani F, Cortes J, Jabbour E, Faderl S, O’Brien S, Verstovsek S, Garcia-Manero G, Newman BA, Giles F, Issa JP, Kantarjian H. Decitabine Induces Responses in Patients with Myelodysplastic Syndrome (MDS) after Failure of Azacitidine Therapy. Blood 108(11) (#518), 11/2006.
115.	Quintas-Cardama A, Kantarjian HM, Jones D, Garcia-Manero G, O’Brien S, Shan J, Ravandi-Kashani F, Wierda W, Cortes. Delayed Achievement of Molecular Responses Is Associated with Increased Risk of Progression among Patients (pts) with Chronic Myelogenous Leukemia (CML) In Chronic Phase (CP) Treated with Imatinib (IM). Blood 108(11) (#432), 11/2006.
116.	Garcia-Manero G, Bueso-Ramos C, Xiao L, Hoshino K, Rosner G, Pierce S, Yang H. Detection of Residual p73 DNA Methylation Predicts for Shorter Disease Free and Overall Survival in Patients (pts) with Philadelphia (Ph) Chromosome Negative Acute Lymphocytic Leukemia (ALL) in Remission. Blood 108(11) (#2333), 11/2006.
117.	Jabbour E, Jones D, Kantarjian H, O’Brien S, Garcia-Manero G, Giles F, Wierda W, Cortes J. Dynamics of BCR-ABL Kinase Domain Mutations in Patients with Chronic Myeloid Leukemia (CML) after Treatment with One, Two or Three Tyrosine Kinase Inhibitors (TKI). Blood 108(11) (#750), 11/2006.
118.	Jabbour E, Jones D, Kantarjian H, O’Brien S, Garcia-Manero G, Giles F, Wierda W, Cortes J. Dynamics of BCR-ABL Kinase Domain Mutations in Patients with Chronic Myeloid Leukemia (CML) after Treatment with One, Two or Three Tyrosine Kinase Inhibitors (TKI). Blood 108(11) (#750), 11/2006.
119.	Estey EH, Garcia-Manero G, Giles F, Kantarjian H. Effect of Failure To Respond to Targeted Therapy on Response to Cytotoxic Therapy in Pts Age =/> 60 with Newly-Diagnosed AML. Blood 108(11) (#1965), 11/2006.
120.	Alvarez RH, Kantarjian H, Garcia-Manero G, Estrov Z, Ravandi-Kashani F, Verstovsek S, Giles F, O’Brien S, Koller CA, Faderl S, Thomas D, Wright JJ, Cortes J. Farnesyl Transferase Inhibitor (Tipifarnib, Zarnestra; Z) in Combination with Standard Chemotherapy with Idarubicin (Ida) and Cytarabine (ara-C) for Patients (pts) with Newly Diagnosed Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS). Blood 108(11) (#1999), 11/2006.
121.	Quintas-Cardama A, Tong W, Manshouri T, Cools J, Gilliland DG, Kantarjian HM, Cortes J, Garcia-Manero G. Frequency of NUP214-ABL1 Oncogene in Patients with T-Cell Acute Lymphoblastic Leukemia (T-ALL) and Analysis of the Activity of Imatinib and Nilotinib in NUP214-ABL1-Expressing T-ALL Cell Lines. Blood 108(11) (#710), 11/2006.
122.	Aoki t, Kantarjian H, O’Brien S, Talpaz M, Giles F, Verstovsek S, Wierda W, Salavado A, Letvak L, Garcia-Manero G, Jones D, Luthra R, Shan J, Cortes J. High-Dose (HD) Imatinib Provides Better Responses in Patients with Untreated Early Chronic Phase (CP) CML. Blood 108(11) (#2143), 11/2006.
123.	Quintas-Cardama A, Kantarjian HM, Ravandi-Kashani F, Garcia-Manero G, O’Brien S, Verstovsek S, Koller CA, Pate O, Cortes J. Immune Modulation of Minimal Residual Disease (MRD) in Patients (pts) with Chronic Myelogenous Leukemia (CML) in Early Chronic Phase (CP): A Randomized Trial of Frontline High-Dose (HS) Imatinib Mesylate (IM) with or without Pegylated-Interferon (PEG-IFN) and GM-CSF. Blood 108(11) (#2207), 11/2006.
124.	Vu KD, Thomas D, Hubbard JC, Faderl S, Cortes J, Cabanillas ME, Garcia-Manero G, O’Brien S, Kantarjian H. Incidence of Venothromboembolism (VTE) in Patients (pts) with Acute Lymphocytic Leukemia (ALL), Burkitt’s Leukemia/Lymphoma (BL) or Lymphoblastic Leukemia (LL). Blood 108(11) (#4534), 11/2006.
125.	Soriano AO, Champlin R, McCormick G, Giralt S, Thall P, Komanduri K, Qazilbash M, Garcia-Manero G, De Lima M. Maintenance Therapy with 5-Azacytidine (5-AC) after Allogeneic Stem Cell Transplantation (allo-SCT) for Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS): A Dose and Schedule Finding Study. Blood 108(11) (#3668), 11/2006.
126.	Byun HM, Eshaghian S, Jiang JY, Choi SH, Ramezani L, Douer D, Garcia-Manero G, Issa JP, Yang D, Trent J, Yang AS. Methylation Profiling of Three Homogenous Cancers: Chronic Myelogenous Leukemia (CML), Acute Promyelocytic Leukemia (APL) and Gastrointestinal Stromal Tumors (GIST). Blood 108(11) (#736), 11/2006.
127.	Giles F, Freedman SJ, Xiao A, Borthakur G, Garcia-Manero G, Wierda W, Kornblau SM, O’Brien S,. Bergstrom DA, Rizzieri DA. MK-0457, a Novel Multikinase Inhibitor, Has Activity in Refractory AML, Including Transformed JAK2 Positive Myeloproliferative Disease (MPD), and in Philadelphia-Positive ALL. Blood 108(11) (#1967), 11/2006.
128.	Giles F, Bergstrom DA, Garcia-Manero G, Kornblau S, Andreeff M, Kantarjian H, Jones D, Freedman SJ, Verstovsek S. MK-0457 Is a Novel Aurora Kinase and Janus Kinase 2 (JAK2) Inhibitor with Activity in Transformed JAK2-Positive Myeloproliferative Disease (MPD). Blood 108(11) (#4893), 11/2006.
129.	Garcia-Manero G, Yang AS, Giles F, Faderl S, Ravandi F, Cortes J, Newsome, WM, Issa JP, Patterson TA, Dubay M, Li Z, Kantarjian H, Martell RE. Oral Isotype-Selective Histone Deacetylase (HDAC) Inhibitor MGCD0103 in Combination with Azacitidine in Patients (pts) with High-Risk Myelodysplastic Syndrome (MDS) or Acute Myelogenous Leukemia (AML). Blood 108(11) (#1954), 11/2006.
130.	Thomas D, Kantarjian HM, Jorgensen JL, Faderl S, Cortes J, Giles F, Garcia-Manero G, Wierda W, Ferrajoli A, Ravandi-Kashani F, Koller CA, Beran M, Kornblau SM, Andreeff M, Jones D, O’Brien S. Outcome after Detection of Minimal Residual Disease during Treatment with the Modified Hyper-CVAD Regimen with or without Rituximab in Newly Diagnosed Adult Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic Lymphoma (LL). Blood 108(11) (#1861), 11/2006.
131.	Thomas D, Kantarjian HM, Cortes J, Faderl S, Giles F, Garcia-Manero G, Wierda W, Ferrajoli A, Ravandi-Kashani F, Verstovsek S, Andreeff M, Letvak LA, Jones D, Champlin R, O’Brien. Outcome with the Hyper-CVAD and Imatinib Mesylate Regimen as Frontline Therapy for Adult Philadelphia (Ph) Positive Acute Lymphocytic Leukemia (ALL). Blood 108(11) (#284), 11/2006.
132.	Mattiuzzi GN, Cortes JE, Faderl S, Cabanillas ME, Giles FJ, O’Brien S, Garcia-Manero G, Kantarjian H. Patients with Acute Myelogenous Leukemia (AML) or High-Risk Myelodysplastic Syndrome (HR-MDS) Treated with Targeted Therapy May Benefit from Prophylactic Measures Against Infections. Blood 108(11) (#4483), 11/2006.
133.	Jabbour E, Kantarjian H, Koller CA, Faderl S, Ferrajoli A, Richie MA, Garcia-Manero G, Cortes J, Estrov Z, Ravandi-Kashani F, Giles F, Verstovsek S. PEG-Intron Therapy in Patients with Philadelphia Chromosome-Negative Myeloproliferative Disorders (MPD): Final Result of a Phase II Study. Blood 108(11) (#3636), 11/2006.
134.	Giles FJ, Ravandi-Kashani F, Cortes J, Estrov Z, Faderl S, Ferrajoli A, Garcia-Manero G, Thomas D, Wierda W, Verstovsek S. Phase I Study of XL-119, a Rebeccamycin Analog, in Patients with Refractory Hematological Malignancies. Blood 108(11) (#1969), 11/2006.
135.	Thomas DA, Kantarjian H, Heffner L, Stock W, Garcia-Manero G, Faderl S, Ferrajoli A, Giles F, Wierda W, Ravandi-Kashani F, Choy G, Berk GI, O’Brien S. Phase I Trial of Sphingosomal Vincristine (SV, Marqibo®) and Dexamethasone in Relapsed or Refractory Acute Lymphocytic Leukemia (ALL). Blood 108(11) (#4539), 11/2006.
136.	Quintas-Cardama A, Kantarjian HM, Munden R, Talpaz M, Bruzzi J, O’Brien S, Garcia-Manero G, Nicaise C, Cortes J. Pleural Effusion in Patients (pts) with Chronic Myelogenous Leukemia (CML) Treated with Dasatinib after Imatinib Failure. Blood 108(11) (#2164), 11/2006.
137.	Tsimberidou AM, Kantarjian HM, Keating MJ, O’Brien S, Wen S, Cortes J, Giles F, Koller CA, Garcia-Manero G, Pierce S, Brandt M, Freireich EJ, Estey EH. Prognostic Significance of ß-2 Microglobulin Levels in Acute Myeloid Leukemia: Analysis of 1293 Patients. Blood 108(11) (#802), 11/2006.
138.	Takahashi N, Pastural E, Lowsky R, Torlakovic E, Czader M, Garcia-Manero G, Amin HM, Geyer CR, DeCoteau J. RIZ1 Is Downregulated during CML Progression and Displays Tumor Suppressor Properties in CML Cell Lines. Blood 108(11) (#2134), 11/2006.
139.	Soriano AO, Yang H, Tong W, Faderl S, Wierda W, Andreeff M, Estrov Z, Ouzounian S, Clavell J, Kantarjian H, Issa JP, Garcia-Manero G. Significant Clinical Activity of the Combination of 5-Azacytidine, Valproic Acid and All-Trans Retinoic (ATRA) Acid in Leukemia: Results of a Phase I/II Study. Blood 108(11) (#160), 11/2006.
140.	Jabbour E, Kantarjian HM, Cortes J, Wierda W, Ferrajoli A, Faderl S, O’Brien S, Ravandi-Kashani F, Verstovsek S, Garcia-Manero G, Davisson J, Giles F, Shan J, Issa JP. Survival Benefit with Decitabine Compared to Historical Experience with Intensive Chemotherapy in Patients with Higher Risk Myelodysplastic Syndrome (MDS). Blood 108(11) (#2652), 11/2006.
141.	Aribi AM, Kantarjian H, Ault P, Koller CA, Thomas D, Faderl S, Garcia-Manero G, Cortes J. The Effect of Interleukin-11 (Oprelvekin, Neumega®) on Thrombocytopenia Associated with Tyrosine Kinase Inhibitors (TKI) in Patients with Chronic Myeloid Leukemia (CML). Blood 108(11) (#2148), 11/2006.
142.	Quintas-Cardama A, Kantarjian H, Ravandi F, Garcia-Manero G, O’Brien S, Pierda W, Faderl S, Cortes J. A Pilot Trial of Imainib, Low-Dose Cytarabine (ara-C) and Idarubicin (Ida) in Patients (pts) with Chronic Myeloid Leukemia (CML) in Myeloid Blastic (BP). Blood 106(11) (#4840), 11/2005.
143.	Cortes J, Talpaz M, O’Brien S, Ravandi F, Verstovsek S, Garcia-Manero G, Koller C, Andreeff M, Estrov Z, Kantarjian H. A Randomized Trial of High-Dose (HD) Imatinib Mesylate (IM) with or without Peg-Interferon (PEG-IFN) and GM-CSF as Frontline Theraphy for Patients with Chronic Myeloid Leukemia (CML) in Early Chronic Phase (CP). Blood 106(11) (#1084), 11/2005.
144.	Yang H, Hoshino K, Xiao L, Rosner G, Garcia-Manero G. Aberrant DNA Methylation of a Cell Cycle Regulatory Pathway Componed of p73, p15 and P57kip2 is Associated with Poor Prognosis in Adult Patients with Philadelphia Chromosome Negative Acute Lymphocytic Leukemia (ALL). Blood 106(11) (#481), 11/2005.
145.	Faderl S, Thomas D, Garcia-Manero G, Ravandi F, Beran M, Rytting M, Koller C, Verstovsek S, Borthakur G, Andreeff M, Kornblau S, Vu K, Jarmon R, Kantarjian H. Augmented Hyper-CVAD in Acute Lymphoblastic Leukemia (ALL): The MDACC Experience with Intesified L-Asparaginase and Vincristine in Adult ALL Salvage. Blood 106(11) (#1840), 11/2005.
146.	Kornblau S, Búnker D, Lemker E, Estrov Z, Faderl S, Verstovsek S, Cortes J, Garcia-Manero G, Koller C, Ravandi-Kashani F, Andreeff M, Jackson CE, Chen W, Petersdorf S, Estey E, Appelbaum F. Blockade of Adaptive Defensive Changes in Colesterol Uptake and Síntesis in AML by the Addition of Pravastatin to Idarubicin + High Dose Ara-C: A Phase I Study. Blood 106(11) (#405), 11/2005.
147.	Thomas D, Faderl S, O’Brien S, Bueso-Ramos C, Cortes J, Garcia-Manero G, Giles F, Verstovsek S, Wierda W, Pierce S, Shan J, Brandt M, Hagemeister F, Cabanillas F, Keating M, Kantarjian H. Chemo-Immunotheraphy with Hypr-CVAD Plus Ritixumab for Adult Burkitt’s and Burkitt’s Type Lymphoma (BL) or Acute Lymphoblastic Leukemia (B-ALL). Blood 106(11) (#149), 11/2005.
148.	Jabbour E, Kantarjian H, O’Brien S, Verstovsek S, Garcia-Manero G, Rios MB, Cortes J. Chromosomal Abnormalities in Philadelphia Chromosome (Ph)-Negative Metaphases Appearing during Imatinib Mesylate (IM)Therapy in Patients (pts) with Newly Diagnosed Chronic Myeloid Leukemia (CML) in Chronic Phase. Blood 106(11) (#1090), 11/2005.
149.	Estey E, Garcia-Manero G, Giles F, Cortes J, O’Brien S, Kantarjian H. Clincial Relevance of CRp in Untreated AML. Blood 106(11) (#541), 11/2005.
150.	Faderl S, Ravandi F, Ferrajoli A, Garcia-Manero G, Estrov Z, Thomas D, O’Brien S, Verstovsek S, Wierda W, Cortes J, Giles F, Kwari M, Jarmon R, Kantarjian H. Clofarabine and Clofarabine Plus Low-Dose Cytarabine (ara-C) as Induction Theraphy for Patients (pts) > 60 Years with Newly Diagnosed Acute Myeloid Leukemia (AML). Blood 106(11) (#2804), 11/2005.
151.	Faderl S, Ferrajoli A, Wierda W, Ravandi F, Estrov Z, Verstovsek S, Thomas D, Garcia-Manero G, Kwari M, Kantarjian H. Clofarabine Combination in Acute Myeloid Leukemia (AML) Salvage: A Dose-Finding Phase I Study of Clofarabine Plus Idarubicin and Clofarabine/Idarubicin Plus Cytarabine (ara-C). Blood 106(11) (#2803), 11/2005.
152.	Faderl S, Ferrajoli A, Wierda W, Ravandi F, O’Brien S, Garcia-Manero G, Thomas D, Browning M, Keating M. Continuous Infusion/Subcutaneous Alemtuzumab (Campath-1H) Plus Rituximab Is Active for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL). Blood 106(11) (#2963), 11/2005.
153.	Auki E, Kantarjian H, O’Brien S, Rios MB, Ravandi F, Verstovsek S, Garcia-Manero G, Shan J, Cortes J. Correlation of Different Respones to Imatinib on Survival of Patients (pts) with Chronic Myelogenous Leukemia (CML) in Accelerated (AP) and Blast Phase (BP). Blood 106(11) (#1103), 11/2005.
154.	Kantarjian H, O’Brien S, Giles F, Ravandi-Kashani F, Faderl S, Garcia-Manero G, Davis J, Issa JP. Decitabine Low-Dose Schedule (100 mg/m2/Course) in Myelodysplastic Syndrome (MDS). Comparison of 3 Different Dose Schedule. Blood 106(11) (#2522), 11/2005.
155.	Cortes J, Garcia-Manero G, O’Brien S, Verstovsek S, Estrov Z, Giles F, Ravandi F, Wright J, Kantarjian H. Farnesyl Transferase Inhibitor (Tipifarnib, Zarnestra; Z) in Combination with Standard Chemotheraphy with Idarubicin (Ida) and Cytarabine (ara-C) for Patients (pts) with Newly Diagnosed Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS). Blood 106(11) (#2796), 11/2005.
156.	Garcia-Manero G, Yang H, Sanchez-Gonzalez B, Verstovsek S, Ferrajoli A, Keating M, Andreeff M, O’Brien S, Cortes J, Wierda W, Faderl S, Koller C, Davis J, Morris G, Issa JP, Frankel S, Richon V, Fine B, Kantarjian H. Final Results of a Phase I Study of the Histone Daecetylase Inhibitor Vorinostat (Suberoyanilide Hydroxamic Acid, SAHA) in Patients with Leukemia and Myelodysplastic Syndrome. Blood 106(11) (#2801), 11/2005.
157.	Garcia-Manero G, Kantarjian H, Sanchez-Gonzalez B, Yang H, Rosner G, Verstovsek S, Rytting M, Ravandi F, Faderl S, Estrov Z, Cortes J, O’Brien S, Fiorentino J, Issa JP. Final Results of a Phase I/II Study of the Combination of the Hypomethylating Agen 5-aza-2’-Deoxycytidine (DAC) and the Histone Deacetylase Inhibitor Valproic Acid (VPA) in Patients with Leukemia. Blood 106(11) (#408), 11/2005.
158.	Han X, Garcia-Manero G, McDonnell T, Lozano G, Medeiros LJ, Rosner G, Hayes K, Bueso-Ramos C. MDMX is Widely Expressed in Adult Pre-Cursor B Cell B Acute Lymphoblastic Leukemia and is a Potencial Therapeutic Target. Blood 106(11) (#3280), 11/2005.
159.	Garcia-Manero G, Minden M, Estrov Z, Verstovsek S, Fiorentino J, Kantarjian H. Oral Dose in Patients with Leukemia or Myelodysplastic Syndromes (MDS). Blood 106(11) (#4639), 11/2005.
160.	Thomas D, Faderl S, Cortes J, O’Brien S, Giles F, Garcia-Manero G, Kornblau S, Andreeff M, Beran M, Verstovsek S, Pierce S, Letvak L. Outcome with the Hyper-CVAD and Imatinib Mesylate Regimen in Philadelphia (Ph) Positive Acute Lymphocytic Leukemia (ALL). Blood 106(11) (#1830), 11/2005.
161.	Yee K, Cortes J, Garcia-Manero G, Verstovsek S, Ferrajoli S, Wierda W, Thomas D, Faderl S, Kina I, O’Brien S, Sznol M, Giles F. Phase I Study of Triapine and Cytarabine (ara-C) in Patients with Relapsed or Refractory Acute Leucemias and High-Risk Myelodysplastic Síndrome (MDS). Blood 106(11) (#4925), 11/2005.
162.	Oki Y, Kantarjian H, O’Brien S, Verstovsek S, Gharibyan V, Cortes J, Morris G, Garcia-Manero G, Issa JP. Phase II Study of Decitabine in Combination with Imatinib Mesylate in Patients with Accelerated (AP) or Blastic Phase (BP) of Chronic Myeloid Leukemia (CML). Blood 106(11) (#1099), 11/2005.
163.	Jabbour E, Kantarjian H, O’Brien S, Cortes J, Giles F, Faderl S, Garcia-Manero G, Wierda W, Pierce S, Shan J, Estey E. Results of Intensive Chemotheraphy in 998 Patients Aged 65 Years or Older with Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome–Predictive Prognostic Models for Outcome. Blood 106(11) (#1846), 11/2005.
164.	Wierda W, O’Brien S, Ferrajoli A, Faderl S, Koller C, Giles F, Cortes J, Thomas D, Ravandi F, Garcia-Manero G, Andreeff M, Lerner S, Kantarjian H, Keating M. Salvage Therapy with Combined Cyclophosphamide [C] , Fludarabine (F), Alemtuzumab (A), and Rituximab (R) (CFAR) for Heavily Pre-Treated Patients with CLL. Blood 106(11) (#719), 11/2005.
165.	Kovitz C, Kantarjian H, Garcia-Manero G, Abruzzo L, Cortes J. Secondary Leukemia after Imatinib Mesylate (IM) Therapy for Chronic Myelogenous Leukemia (CML). Blood 106(11) (#4862), 11/2005.
166.	Borthakur G, Kantarjian H, Estey E, Verstovsek S, Garcia-Manero G, Cortes J. Study of Intra-Venous Homoharringtonine (HHT) in the Treatment of Myelodysplastic Syndrome (MDS). Blood 106(11) (#4903), 11/2005.
167.	Thomas D, Cortes J, O’Brien S, Faderl S, Ravandi F, Garcia-Manero G, Giles F, Beran M, Koller C, Wierda W, Verstovsek S, Ferrajoli A, Kornblau S, Keating M, Andreeff M, Kantarjian H. Update of the Modified Hyper-CVAD Regimen with or without Rituximab in Newly Diagnosed Adult Acute Lymphocytic Leukemia (ALL). Blood 106(11) (#1831), 11/2005.
168.	Rytting M, Sanchez-Gonzalez B, Fiorentino J, McDonald L, Yan H, Issa Kantarjian H, Garcia-Manero G. A Phase I/II Study of 5-AZA-2’ deoxycytidine combined with valproic acid in patients with Leukemia: A pediatric subset analysis. Pediatric Blood and Cancer 45(4), 10/2005.
169.	O’Brien S, Issa JP, Ravandi-Kashani F, Giles F, Faderl S, Garcia-Manero G, Davis J, Estey E, Kantarjian H. Decitabine low-dose schedule (100mg/m2/course) in myelodysplastic syndrome (MDS). Comparison of 3 different dose schedules. Proceedings of the American Society of Clinical Oncology 23:6545, 2005.
170.	Tsimberidou AM, O’Brein S, Wierda W, Garcia-Manero G, Lerner S, Keating M. Effects of immunotherapy on survival and progression-free survival in patients with splenic marginal zone lymphoma or marginal zone leukemia/lymphoma. Proceedings of the American Society of Clinical Oncology 23:6583, 2005.
171.	Oki Y, Kantarjian H, Davis J, Ravandi-Kashani F, Vertovsek S, Cortes J, Garcia-Manero G, Issa JP. Hypomethylation induction in MDS after treatment with decitabine at three different doses. Proceedings of the American Society of Clinical Oncology 23:6546, 2005.
172.	Han X, McDonnell TJ, Lozano G, Garcia-Manero G, Medeiros LJ, Rassidakis GS, Bueso-Ramos C. MDMX is widely expressed in adult pre-B acute lymphocytic leucemia (ALL) and is a potencial therapeutic target. Modern Pathology 18:1081, 2005.
173.	Freireich E, Kantarjian H, Garcia-Manero G, Ferrajoli A, Koller C, Estrov Z, Kornblau S, Laddie N, Smith L, Cortes J. Phase II study of EL625, a p53 antisense oligonucleotide, and chemotherapy in refactory and relapsed acute myelogenous leukemis (AML). Proceedings of the American Society of Clinical Oncology 23:6617, 2005.
174.	Faderl S, Favandi-Kashani F, Ferrajoli A, Estrov Z, Wierda W, Verstovsek S, Garcia-Manero G, Estey E, Kwari M, Kantarjian H. Randomized phase II study of clofarabine versus clofarabine plus low-dose cytarabine (ara-C) for patients (pts) ³ 60 years (yrs) with newly diagnosed acute myeloid leukemia (AML). Proceedings of the American Society of Clinical Oncology 23:6627, 2005.
175.	Garcia-Manero G, Kantarjian H, Sanchez-Gonzalez B, Verstovsek S, Ravandi F, Ryttling M, Cortes J, Yang H, Fiorentino J, Ronser G, Issa JP. Results of a phase I/II study of the combination of 5-aza-2’-deoxycytidine and valproic acid in patients with acute myeloid leukemia and myelodysplastic syndrome. Proceedings of the American Society of Clinical Oncology 23:6544, 2005.
176.	Jabbour E, Verstovsek S, Gandhi V, Cortes J, Giles F, Koller C, O'Brien S, Plunkett W, Garcia-Manero G, Jackson E, Kantarjian H, Andreeff M. 2 Chlorodeoxyadenosine (2-CdA) and Cytarabine (ara-C) Combination Is Effective and Safe in Idiopathic Hypereosinophilic Syndrome (HES). Blood 104(11) (#4764), 11/2004.
177.	Cortes J, Garcia-Manero G, O'Brien S, Hernandez I, Rackoff W, Faderl S, Thomas D, Ferrajoli A, Talpaz M, Kantarjian H. A Phase I Study of Tipifarnib in Combination with Imatinib Mesylate (IM) for Patients (Pts) with Chronic Myeloid Leukemia (CML) in Chronic Phase (CP) Who Failed IM Therapy. Blood 104(11) (#1011), 11/2004.
178.	Yee K, Garcia-Manero G, Thomas D, Ravandi-Kashani F, Verstovsek S, Andreeff M, Dancey J, Giles F. A Phase II Study of Temsirolimus (CCI-779) in Patients with Advanced Leukemias. Blood 104(11):4523, 11/2004.
179.	Hoshino K, Yang H, Santos-Malave C, Sanchez-Gonzalez B, Garcia-Manero G. Aberrant DNA Methylation of the Src Tyrosine Kinase Hck Is a Frequent Event in Human Leukemia and May Predict for Poor Prognosis in Adult Acute Lymphocytic Leukemia (ALL). Blood 104(11) (#1542), 11/2004.
180.	Hoshino K, Yang H, Santo-Malave C, Sanchez-Gonzalez B, Garcia-Manero G. Aberrant DNA Methylation of the Src Tyrosine Kinase Hck is a Frequent Event in Human Leukemia and May Predict for Poor Prognosis in Adult Acute Lymphocytic Leukemia (ALL). Blood 104(11) (#1542), 11/2004.
181.	Shikami M, Konopleva M, Samudio I, Hoshino K, Garcia-Manero G, Kojima K, Tsao T, McQueen T, Andreeff M. ARTS, a Pro-Apoptotic Mitochondrial Septin-Like Protein That Binds to XIAP, Is Silenced in Acute Lymphoblastic and Primitive Acute Myeloblastic Leukemia Cells. Blood 104(11) (#3378), 11/2004.
182.	Oki Y, Estey E, Kantarjian H, Cortes J, Faderl S, O'Brien S, Koller C, Beran M, Keating M, Pierce S, Garcia-Manero G. Characteristics and Prognosis of Patients (pts) with Acute Megakaryocytic Leukemia (AMegL) Treated at M.D. Anderson Cancer Center Since 1987. Blood 104(11) (#3003), 11/2004.
183.	Cortes J, Talpaz M, O'Brien S, Jones D, Luthra R, Garcia-Manero G, Giles F, Shan J, Verstovsek S, Rios MB, Kantarjian H. Clinical Significance of Molecular Monitoring in Chronic Myeloid Leukemia (CML) in Chronic Phase (CP) with Imatinib Therapy. Blood 104(11) (#272), 11/2004.
184.	Faderl S, Gandhi V, Verstovsek S, Cortes J, Ravandi-Kashani F, Beran M, Garcia-Manero G, Koller C, O'Brien S, Ferrajoli A, Estrov Z, Kwari M, Plunkett W, Kantarjian H. Clofarabine Plus Cytarabine (ARA-C) Combination Is Active in Newly Diagnosed Patients (pts) = Age 50 with Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS). Blood 104(11) (#875), 11/2004.
185.	Kantarjian H, Ravandi F, O'Brien S, Giles F, Faderl S, Garcia-Manero G, Davis J, Estey E, Issa JP. Decitabine Low-Dose Schedule (100 mg/m2/course) in Myelodysplastic Syndrome (MDS). Blood 104(11) (#1437), 11/2004.
186.	Hoshino K, Yang H, Sanchez-Gonzalez B, Garcia-Manero G. Detection of Aberrant DNA Methylation in Acute Lymphocytic Leukemia (ALL) Using a Real-Time Polymerase Chain Reaction (PCR) Assay. Blood 104(11) (#998), 11/2004.
187.	Issa JP, Gharibyan V, Jelinek J, Morris G, Verstovsek S, Talpaz M, Garcia-Manero G, Kantarjian H. Hypomethylation Dynamics Following Decitabine Therapy in Chronic Myelogenous Leukemia. Blood 104(11) (#2956), 11/2004.
188.	Gonzalez-Sanchez B, Hoshino K, Bueso-Ramos C, Yang H, Youssef E, Boumber Y, Santos-Malave C, Garcia-Manero G. In Vitro Effects of the Combination of Idabubicin (IDA) with Suberoylanilide Hydroxamic Acid (SAHA) or Valproic Acid (VPA) in Leukemia Cell Lines. Blood 104(11) (#1173), 11/2004.
189.	Oki Y, Jabbour E, Kantarjian H, Estey E, Cortes J, Faderl S, Pierce S, Zhou X, Bekele BN, Garcia-Manero G. Intracranial Hemorrhage (ICH) in Patients (pts) with Newly Diagnosed Leukemia: Incidence and Effect on Outcome. Blood 104(11) (#4530), 11/2004.
190.	Cortes J, O'Brien S, Garcia-Manero G, Faderl S, Shan J, Verstovsek S, Rios MB, Talpaz M, Kantarjian H. Is the Proposed World Health Organization (WHO) Classification for Chronic Myeloid Leukemia (CML) of Clinical Value in the Imatinib Era? Blood 104(11) (#1014), 11/2004.
191.	Jabbour E, Kantarjian H, Jones D, O'Brien S, Luthra R, Garcia-Manero G, Giles F, Rios MB, Verstovsek S, Cortes J. Long-Term Incidence and Outcome of BCR-ABL Mutations in Patients (pts) with Chronic Myeloid Leukemia (CML) Treated with Imatinib Mesylate – P-Loop Mutations Are Not Associated with Worse Outcome. Blood 104(11) (#1007), 11/2004.
192.	Thomas D, Cortes J, Faderl S, O'Brien S, Beran M, Koller C, Garcia-Manero G, Younes A, Fayad L, Wierda W, Pierce S, Giles F, Kantarjian H. Outcome with the Hyper-CVAD and Rituximab Regimen in Burkitt (BL) and Burkitt-Like (BLL) Leukemia/Lymphoma. Blood 104(11) (#3297), 11/2004.
193.	Verstovsek S, Lawhorn K, Giles F, Cortes J, Thomas D, Garcia-Manero G, Ferrajoli A, Faderl S, Beran M, Talpaz M, Kantarjian H. PEG-Intron for Myeloproliferative Diseases: An Update of Ongoing Phase II Study. Blood 104(11) (#1517), 11/2004.
194.	Faderl S, Ferrajoli A, Wierda W, Verstovsek S, Ravandi-Kashani S, Garcia-Manero G, Estey E, Thomas D, Kornblau S, Kwari M, Gandhi V, Kantarjian H. Phase I Study of Clofarabine Plus Idarubicin and Clofarabine Plus Idarubicin Plus Cytarabine (ARA-C) in Patients (PTS) with Relapsed and Primary Refractory Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), and Myeloid Blast Phase of Chronic Myeloid Leukemia (CML). Blood 104(11) (#1809), 11/2004.
195.	Giles F, Fischer T, Cortes J, Beck J, Ravandi-Kashani F, Garcia-Manero G, Kantarjian H, Peng B, Rae P, Laird G, Sharma S, Dugan M, Albitar M, Bhalla KA. Phase I/II Study of Intravenous LBH589, a Novel Histone Deacetylase (HDAC) Inhibitor, in Patients (pts) with Advanced Hematologic Malignancies. Blood 104(11) (#1802), 11/2004.
196.	Estey E, Wang X, Thall P, Pierce S, Koller C, Faderl S, Verstovsek S, Cortes J, Garcia-Manero G, Kantarjian H. Plausibility of Delaying Induction Therapy in Untreated AML. Blood 104(11) (#879), 11/2004.
197.	Beran M, Verstovsek S, Kornblau S, Estey E, Giles F, Garcia-Manero G, Kantarjian H. Prolonged Administration of Arsenic Trioxide (Trisenox®) for Patients with Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML) at MD Anderson Cancer Center: A Phase II Study. Blood 104(11) (#4731), 11/2004.
198.	Garcia-Manero G, Kantarjian HM, Gonzalez-Sanchez B, Faderl S, Verstovsek S, Ravandi F, Ryttling M, Cortes J, Wierda W, Hoshino K, Yang H, Santos-Malave C, Fiorentino J, Jabbour E, Rosner G, Issa JPJ. Results of a Phase I/II Study of the Combination of 5-aza-2-deoxycytidine (DAC) and Valproic Acid (VPA) in Patients (pts) with Leukemia. Blood 104(11) (#263), 11/2004.
199.	Cortes J, Talpaz M, O'Brien S, Garcia-Manero G, Ravandi-Kashami F, Giles F, Faderl S, Wierda W, Shan J, Rios MB, Kantarjian H. Survival Advantage for Patients (pts) with Chronic Myeloid Leukemia (CML) in Accelerated Phase (AP) Treated with Imatinib. Blood 104(11) (#1006), 11/2004.
200.	Estey E, Garcia-Manero G, Ferrajoli A, Faderl S, Verstovsek S, Kantarjian H. Use of All-Transretinoic Acid (ATRA) + Arsenic Trioxide (ATO) To Eliminate or Minimize Use of Chemotherapy (CT) in Untreated Acute Promyelocytic Leukemia (APL). Blood 104(11) (#393), 11/2004.
201.	Yang H, Hoshino K, Canalli A, Sanchez-Gonzalez B, Kantarjian H, Issa JP, Garcia-Manero G. Additive effect of the combination of 5-aza-2’-deoxycytidine and valproic acid in leukemia cell systems. Proc AACR:abs 4435, 2004.
202.	Qin T, Youssef, Yang A, Garcia-Manero G, Issa JP. Antagonistic effect of 1-beta-D-arabinofuramosylcytosine and 5-aza-2’-deoxycytidine in human leukemic cells through regulation of DNA methylation. Proc AACR:abs 1601, 2004.
203.	Faderl S, Gandhi V, Giles F, Estey E, Garcia-Manero G, O’Brien S, Wierda W, Kwari M, Craig A, Kantarjian H. Clofarabine plus cytarabine (ara-C) is an active induction regimen for newly diagnosed patients (pts) ³ age 50 with acute myeloid leucemia (AML) and high-risk myelodysplastic síndrome (MDS). Proceedings of the American Society of Clinical Oncology 23:6609, 2004.
204.	Donato N, Ji Y, Koyu H, Kantarjian H, Talpaz M, Garcia-Manero G. Control of Bcr-ABL activation by SHP-1: role in chronic myelogenous leukemia disease progression and imatinib resistance. Proc AACR:abs 2422, 2004.
205.	Yang A, Doshi K, Mannari R, Garcia-Manero G, Kantarjian H, Issa JP. DNA methylation changes in leukemia patients treated with 5-aza-2’-deoxycytidine. Proc AACR:abs 1599, 2004.
206.	Boumber Y, Kondo Y, Shen LL, Ahmed S, Yang A, Garcia-Manero G, Issa JP. Hypermethylation of glycine N-methyltransferase promoter in cancer cell lines and primary AML samples. Proc AACR:abs 4189, 2004.
207.	Cabanillas M, Mattiuzzi G, Thomas D, Vu K, Ossa G, Garcia-Manero G, Cortes J, Giles F, O’Brien S, Kantarjian H. Invasive fungal infections (IFI) in patients (pts) receiving hyper-CVAD. Proceedings of the American Society of Clinical Oncology 23:6727, 2004.
208.	Sanchez-Gonzalez B, Yang H, Hoshino K, Garcia-Manero G. La combinacion de idarrubicina con inhibidores de la deacetilacion de histones posse actividad antileucemica in vitro. Haematologica 89:10 (C-22), 2004.
209.	Giles F, Verstovsek S, Cortes J, Faderl S, Garcia-Manero G, Ravandi-Kashami F, Kornblau S, Gerson S, Sznol M, Kantarjian H. Phase I study of NVP40101M (101M) and AraC in patients (pts) with refractory leukemia. Proceedings of the American Society of Clinical Oncology 23:6617, 2004.
210.	Garcia-Manero G, Issa JP, Cortes J, Koller C, O’Brien S, Estey E, Canalli A, Chiao J, Richon V, Kantarjian H. Phase I study of oral suberoylanilide hydroxamic acid (SAHA), a histone deacetylase inhibitor, in patients (pts) with advanced leucemias or myelodysplastic síndromes (MDS). Proceedings of the American Society of Clinical Oncology 23:3027, 2004.
211.	Hoshino K, Yang H, Canalli A, Sanchez-Gonzalez B, Kantarjian H, Issa JP, Donato N, Garcia-Manero G. The protein-tyrosine phosphatase SHP1 is downregulated with disease progression in Philadelphia (Ph) chromosome positive chronic myelogenous leukemia (CML), an effect not mediated by DNA methylation. Proc AACR:abs 4436, 2004.
212.	Alvarez RH, Kantarjian H, Faderl S, Giles F, O’Brien S, Garcia-Manero G, Rios MB, Talpaz M, Cortes J. A phase II study of imatinib, idarubicin and low dose of cytarabine in patients (pts) with chronic myeloid leukemia (CML) in blastic phase (BP). Proceedings of the American Society of Clinical Oncology 22:617, 2003.
213.	Canalli A, Yang H, Jeha S, Albitar M, Shen L, Hocino K, Sanchez-Gonzalez B, Kantarjian H, Issa JP, Garcia-Manero G. Aberrant DNA Mehtylation of a Cell Cycle Regulatory Pathway Componed of p73, p15, and p57KIP2 Is an Infrequent Event in Pediatric Acute Lymphocytic Leucemia (ALL) and May Explain Prognostic Differences with Adult Patients (pts). Blood 102:30a, 2003.
214.	Giles F, Kantarjian H, Cortes J, Tsimberidou A, Faderl S, Verstovsek S, Thomas D, Garcia-Manero G, Wierda W, Ferrajoli A, Kornblau S, Andreeff M, O’Brien S, Beran M, Estey E. Adaptive Randomized Study of Idarubicin and Cytarabine (IA) Alone or with Interleukin 11 (IL-11) as Induction therapy in Patients Aged 50 or above with Untreated Acute Myeloid Leucemia (AML) or High-Risk Myelodysplastic Syndromes (HR-MDS). Blood 102:30a, 2003.
215.	Quintas-Cardama A, Kantarjian H, O’Brien S, Vu K, Garcia-Manero G, Giles F, Rios MB, Talpaz M, Cortes J. Administration of G-CSF (Filgrastim, Neopogen) for Imatinib Mesylate (Gleevec)-Induced Neutropenia in Chronic Phase Chronic Myeloid Leucemia (CML) Patients (pts) Is Safe and Facilitates the Achievement of Cytogenetic Responses. Blood 102:30a, 2003.
216.	Estey E, Faderl S, Giles F, Thomas D, Ferrajoli A, Wierda W, Verstovsek S, Garcia-Manero G, Kantarjian H. All-Trans Retinoic Acid (ATRA) + Arsenci Trioxide (ATO) to Minimize or Eliminate Chemotherapy in Untreated APL. Blood 102:30a, 2003.
217.	Estey E, Giles F, Cortes J, Garcia-Manero G, Faderl S, Verstovsek S, Wierda W, Thomas D, Ryttig M, Kantarjian H. Application of successful but intensive, childrens AML protocol to adults. Proceedings of the American Society of Clinical Oncology 22:587, 2003.
218.	Cortes J, O’Brien S, Talpaz M, Luthra R, Garcia-Manero G, Verstovsek S, Giles F, Rios MB, Ferrajoli A, Wierda W, Thomas D, Faderl S, Kantarjian H. Clinical Significance of Molecular Response in Chronic Meylogenous Leucemia (CML) after Imatinib Mesylate (Gleevec) Therapy: Low Levels of Residual Disease Predict for Response Duration. Blood 102:30a, 2003.
219.	Yang AS, Garcia-Manero G, Kantarjian H, Issa J-P. Combined bisulfite restriction analysis of Alu repeats to detect demethylation in patients treated with 5-aza-2’-deoxycytidine. Proc AACR 44:940, 2003.
220.	Faderl S, Albitar M, Wierda W, Ferrajoli A, Manshouri T, Garcia-Manero G, O’Brien S, Thomas D, Kantarjian H, Browning M, Keating M. Continuos I.V. Infusión (C.I.) Followed by Subcutaneous (S.C.) Alemtuzumab Plus Rituximab is Active in Patients with Relapsed/Refractory Chronic Lymphoproliferative Disorders (LPD). Blood 102:30a, 2003.
221.	Quintas-Cardama A, Kantarjian H, Talpaz M, O’Brien S, Garcia-Manero G, Hayes K, Glassman A, Rios MB, Shan J, Cortes J. Deletion of Derivative Chromosome 9 Has No Prognostic Impact on Patients (pts) with Chronic Myeloid Leukemia (CML) Treated with Imatinib Mesylate (Gleevec). Blood 102:30a, 2003.
222.	Hoshino K, Yang H, Canalli A, Sanchez-Gonzalez B, Donato N, Kantarjian H, Issa JP, Garcia-Manero G. DNA Methylation of the Protein-Tyrosine Phosphatase SHP1in Philadelphia (Ph) Chromosome Positive Chronic Myelogenous Luekemia (CML). Blood 102:30a, 2003.
223.	Garcia-Manero G, Boumber Y, Mannari R, Vilaything J, Youssef E, Yang H, Estey E, Strom S, Kantarjian H, Issa J-P. DNA Methylation Profiling of Patients (PTS) with Myelodysplastic Syndromes (MDS) Identified Methylation of RIL as an Independent Marker of Poor Prognosis. Proceedings of the American Society of Clinical Oncology 22:578, 2003.
224.	Wierda W, O’Brien S, Ferrajoli A, Faderl S, Kornblau S, Andreef M, Koller C, Garcia-Manero G, Thomas D, Kantarjian H, Keating M. Early Analysis of Combined Cyclophosphamide, Fludarabine, Alemtuzumab, and Ritiuximab for Relapsed and Refractory Patients with CLL. Blood 102:30a, 2003.
225.	Faderl S, Kantarjian H, Estey E, Verstovsek S, Garcia-Manero G, Kwari M, Callander N, Emanuel P, Piro L, Keck J, Jameson A, Patel K, Brown G, Estrov Z. Hematlogic Improvement Following Treatment with TLK199 (A Novel Gluththione Analog Inhibitor of GST P1-1) in Myelodysplastic Síndrome (MDS): Interim Results of a Phase 1-2ª Study. Blood 102:30a, 2003.
226.	Cortes J, Talpaz M, Garcia-Manero G, Giles F, O'Brien S, Rios MB, Verstovsek S, Faderl S, Thomas D, Koller C, Wierda W, Andreeff M, Letvak L, Salvado A, Kantarjian H. High Rates of Major Cytogenetic Response in Patients with Newly Diagnosed Chronic Myeloid Leukemia (CML) in Early Chronic Phase Treated with High-Dose Imatinib 800 mg Daily. Blood 102:30a, 2003.
227.	Wierda W, O’Brien S, Faderl S, Ferrajoli A, Lerner S, Wang X, Thomas D, Garcia-Manero G, Cortes J, Kantarjian H, Keating M. Improved Survival in Patients with Relapsed – Refractory Chronic Lymphocytic Leucemia (CLL) Treated with Fludarabine, Cyclophosphamide, and Rituximab (FCR) Combination. Blood 102:30a, 2003.
228.	Cabanillas M, Mattiuzzi G, Weiser M, Ossa G, Fowler E, Pierce S, Kantarjian H, Garcia-Manero G, Thomas D. Incidente of Invasive Fangal Ainfections (IFI) in Patients (pts) Receiving Hyper-CVAD. Blood 102:30a, 2003.
229.	Saba R, Jwied M, Quintas-Cardama A, Talpaz M, Giles F, Cortes J, Keating M, Estey E, O’Brien S, Garcia-Manero G, Kantarjian H, Freireich E, Verstovsek S. Interferon alpha therapy for Patients with Essential Thrombocythemia: Final Results of Phase II Study Initiated in 1986. Blood 102:30a, 2003.
230.	Wierda W, Garcia-Manero G, O’Brien S, Faderl S, Lerner S, Albitar M, Plunkett W, Giles F, Cortes J, Keating M. Molecular remissions in patients with relapsed or refractory CLL treated with combined fludarabine, cyclophosphamide, and rituximab. Proceedings of the American Society of Clinical Oncology 22:581, 2003.
231.	Verstovsek S, Lawhorn K, Giles F, Cortes J, Thomas D, Garcia-Manero G, Ferrajoli A, Koller C, Beran M, Talpaz M, Freireich E, Kantarjian H. PEG Intron Therapy for Patients with Myeloproliferative Diseases (MPD): Interim Analysis of Phase II Study. Blood 102:30a, 2003.
232.	Giles F, Tallman M, Garcia-Manero G, Cortes J, Thomas D, Wierda W, Verstovsek S, Hamilton M, Barrett E, Albitar M, Kantarjian H. Phase I and Pharmacokinetic Study of OSI-211, a Liposomal Formulation of Lurtotecan, a Topoisomerase 1 Inhibitor, in Patients with Advanced Leucemia. Blood 102:30a, 2003.
233.	Cortes J, Garcia-Manero G, O’Brien S, Hernandez I, Rackoff W, Faderl S, Thomas D, Talpaz M, Kantarjian H. Phase I Study of a Imatinib and Tipifarnib (Zarnestra, R115777) in Patients with Chronic Myeloid Leucemia in Chronic Phase Refractory to Imatinib. Blood 102:30a, 2003.
234.	Giles F, Cortes J, Thomas D, Verstovsek S, Garcia-Manero G, Faderl S, Ferrajoli A, Hagey A, Gordon G, Kantarjian H. Phase I Study of ABT-751, a Novel Tubulin-Binding Agent, in Patients with Refractory Hematological Malignancies. Blood 102:30a, 2003.
235.	Garcia-Manero G, Canalli A, Wierda W, Cortes J, O’Brien S, Cupo A, Secrist AP, Davis J, Faderl S, Giles F, Chiao J, Richon V, Issa JP. Phase I Study of Oral suberoylanilide Hydroxamic Acid (SAHA) in Patients (pts) with Advanced Leucemias or Myelodysplastic Síndromes (MDS). Blood 102:30a, 2003.
236.	Cortes J, O’Brien S, Verstovsek S, Thomas D, Giles F, Garcia-Manero G, Murgo A, Newman R, Rios MB, Talpaz M, Kantarjian H. Phase I Study of Subcutaneous (SC) Homoharringtonine (HHT) for Patients (pts) with Chronic Myelogenous Leucemia (CML). Blood 102:30a, 2003.
237.	Alvarado Y, Kantarjian H, Cortes J, Verstovsek S, Faderl S, Garcia-Manero G, Tsimberidou A, Sznol M, Giles F. Phase I study of VNP4010M, a novel alkylating agent in patients with refractory hematologic malignancies. Proceedings of the American Society of Clinical Oncology 22:585, 2003.
238.	Issa JP, Garcia-Manero G, Talpaz M, Cortes J, Giles F, Verstovsek S, Faderl S, O’Brien S, Morris G, Kantarjian H. Phase II Study of 5-aza-2’-Deoxycytidine (decitabine) in Patients (pts) with Philadelphia (Ph) Chromosome Positivie Chronic Myelogenous Leucemia (CML) Resistant or Intolerant to Imatinib Mesylate. Blood 102:30a, 2003.
239.	Yang H, Hocino K, Canalli A, Sanchez-Gonzalez B, Kantarjian H, Issa JP, Garcia-Manero G. Preclinical Studies of the Combination of the Hypomethylating Agent 5-aza-2’-Deoxycytidine (Decitabine) and the Histone Deacetylase Inhibitor (HDI) Valproic Acid (VPA) in Leukemic Cell Systems. Blood 102:30a, 2003.
240.	Tsimberidou A, Estey E, Cortes J, Verstovsek S, Faderl S, Thomas D, Wierda W, Garcia-Manero G, Kantarjian H, Giles F. Randomized comparison of idarubicin and ara-C (IA)+- interleukin (IL11) in patients with newly diagnosed acute myelogenous leukemia (AML) or high-risk myelodysplastic syndrome (MDS). Proceedings of the American Society of Clinical Oncology 22:585, 2003.
241.	Thomas D, Garcia-Manero G, Cortes J, O’Brien S, Jeha S, Andreeff M, Kornblau S, Letvak L, Talpaz M, Kantarjian H. Results of intensive chemotherapy with hyper-CVAD and imatinib mesylate in Philadelphia (Ph) positive acute lymphocytic leukemia (ALL). Proceedings of the American Society of Clinical Oncology 22:588, 2003.
242.	Boumber Y, Kondo Y, Chen X, Shen LL, Garcia-Manero G, Youssef E, Issa J-P. RIL, a LIM domain protein and candidate 5q31 tumor supresor gene frequently silenced by methylation in cancer and sensitizes colorectal cell to apoptsis. Proc AACR 44:942, 2003.
243.	Ossa G, Hennessy B, Cortes J, Giles F, Medina J, Ferrajoli A, Garcia-Manero G, Faderl S, O’Brien S, Kantarjian H, Verstovsek S. Systemic Mastocytosis: A Review of M.D. Anderson Experience. Blood 102:30a, 2003.
244.	Hoshino K, Yang H, Canalli A, Sanchez-Gonzalez B, Donato N, Kantarjian H, Issa JP, Garcia-Manero G. The Transcription Factor JunB Is Not Methylated in Philadelphia (Ph) Chromosome Positive Chronic Myelogenous Leukemia (CML). Blood 102:30a, 2003.
245.	Thomas D, Faderl S, Cortes J, O’Brien S, Giles F, Garcia-Manero G, Keating M, Kornblau S, Andreeff M, Jeha S, Beran M, Verstovsek S, Pierce S, Letvak L, Salvado A, Champlin R, Kantarjian H. Update of the Hyper-CVAD and Imatinib Mesylate Regimen in Philadelphia (Ph) Positive Acute Lymphocytic Leucemia (ALL). Blood 102:30a, 2003.
246.	Thomas D, Cortes J, Giles F, O’Brien S, Faderl S, Garcia-Manero G, Beran M, Koller C, Andreeff M, Kornblau S, Keating M, Kantarjian H. Update of the Modified Hyper-CVAD Regimen in Newly Diagnosed Adult Acute Lymphocytic Leucemia (ALL). Blood 102:30a, 2003.
247.	Ault P, Kantarjian H, O’Brien S, Garcia-Manero G, Rios MB, Cortes J. Use of darbepoetin alfa for the treatment of anemia occurring during imatinib therapy for CML: Preliminary evidence of safety and efficacy. Proceedings of the American Society of Clinical Oncology 22:613, 2003.
248.	Cortes J, Kantarjian H, Garcia-Manero G, Thomas D, Yazji S, Bivins C, Jolivet J, Giles F. A phase II study of troxacitabine, a novel nucleoside analog, in patients with leukemia. Proceedings of the American Society of Clinical Oncology 20:304a, 2002.
249.	Kornblau S, Womble M, Qiu YH, Cade J, Thomas D, Cortes J, Garcia-Manero G, Jackson CE, Andreeff M. A Prospective Study of Apoptosis Related Proteins BCL2, Bax, PKCa, ERK2 & perk in AML. Blood 100:329a, 2002.
250.	Borthakur G, Estey E, Kantarjian H, Koller C, Giles F, Garcia-Manero G, Cortes J. A randomized trail of interferon alfa (IFN) and granulocyte macrophage colony stimulating factor (GM-CSF) versus IFN and cytarabine (Ara-C) versus idarubicin (Ida) and ara-c for maintenance therapy in acute myelogenous leukemia (AML), refractory anemia with excess of blasts (RAEB), refractory anemia with excess of blasts in transformation (RAEB-T) in first complete remission (CR). Blood 100:261b, 2002.
251.	Garcia-Manero G, Shen L, Toyota M, Kondo Y, Obata T, Daniel S, Pierce S, Imai K, Kantarjian H, Issa JP. Aberrant DNA Methylation of a Cell Cycle Regulatory Pathway Composed of P73, P15 and P57KIP2 Identifies Adult Patients (pts) with Philadelphia (Ph) Chromosome Negative Acute Lymphocytic Leukemia (ALL) and Poor Prognosis. Blood 100:755a, 2002.
252.	Shen L, Toyota M, Daniels S, Obata T, Imai K, Kantarjian H, Issa JP, Garcia-Manero G. Aberrant DNA methylation of P57KIP2 is frequent in primary and relapsed adult acute lymphocytic leukemia (ALL). Proceedings of the American Association for Cancer Research 43:1119, 2002.
253.	Tsimberidou AM, Estey E, Cortes J, Thomas D, Garcia-Manero G, Faderl S, Verstovsek S, O’Brien S, Kantarjian H, Giles F. Adaptive randomization of idarubicin and ara-C (IA) ± interleukin (IL11) in patients with newly diagnosed (ND) acute myelogenous leukemia (AML) or high-risk myelodysplastic syndrome (MDS). Blood 100:264b, 2002.
254.	Medina J, Kantarjian H, Talpaz M, O’Brien S, Garcia-Manero G, Faderl S, Giles F, Rios MB, Hayes K, Cortes J. Chromosomal abnormalities in Philadelphia chromosome (Ph) negative metaphases appearing during treatment with imatinib mesylate in patients (pts) with Ph positive chronic myeloid leukemia (CML) in chronic phase (CP). Blood 100:368a, 2002.
255.	Cortes J, Gandhi V, Plunkett W, Keating M, Faderl S, O’Brien S, Giles F, Garcia-Manero G, Thomas D, Du M, Davis J, Craig A, Estey E, Kantarjian H. Clofarabine {2-chloro-9-(2-deoxy-2-fluoro-b-d-arabinofuranosyl) adenine} is active for patients with refractory or relapsed acute leukemias, myelodysplastic syndromes (MDS) and chronic myeloid leukemia in blast phase (CML-BP). Blood 100:197a, 2002.
256.	Faderl S, Thomas D, O’Brien S, Wierda W, Kantarjian H, Garcia-Manero G, Giles F, Koller C, Beran M, Ferrajoli A, Lerner S, Keating M. Combined use of alemtuzumab and rituximab in patients with relapsed and refractory chronic lymphoid malignancies – an updated of the MD Anderson experience. Blood 100:206a, 2002.
257.	Garcia-Manero G, Faderl S, Giles F, Verstovsek S, Beran M, Andreeff M, Cortes J, Thomas D, Koller C, Pierce S, Ouzonian S, Kantarjian H, Estey E. Double induction (DI) chemotherapy for patients (pts) with newly diagnosed acute myelogenous leukemia (AML) or myelodysplastic syndromes (MDS). Blood 100:342a, 2002.
258.	Tsimberidou A, Estey E, Cortes J, Thomas D, Garcia-Manero G, Faderl S, Verstovsek S, O’Brien S, Kantarjian H, Giles F. Feasibility of mylotarg, fludarabine, ara-c and cyclosporine (MFAC) regimen as post-remission therapy in acute myelogenous leukemia (AML). Blood 100:339a, 2002.
259.	Estey E, Cortes J, Garcia-Manero G, Thomas D, Faderl S, Verstovsek S, Pierce S, O’Brien S, Beran M, Kantarjian H, Giles F. Further observations on use of gemtuzumab ozogamycin (GO) and all-trans retinoic acid (ATRA) in untreated APL: median additional 8 months of follow-up. Blood 100:340a, 2002.
260.	Kantarjian H, Cortes J, O’Brien S, Giles F, Thomas D, Faderl S, Garcia-Manero G, Rios MB, Letvak L, Bochinski K, Shan J, Talpaz M. High rates of early major and complete cytogenetic responses with imatinib mesylate therapy given at 400 mg or 800 mg orally daily in patients with newly diagnosed philadelphia chromosome-positive chronic myeloid leukemia in chronic phase (Ph + CML-CP). Proceedings of the American Society of Clinical Oncology 21:261a, 2002.
261.	Cortes J, Talpaz M, O’Brien S, Giles F, Garcia-Manero G, Rios M, Thomas D, Ferrajoli A, Verstovsek S, Faderl S, Letvak L, Bochinski K, Kantarjian H. High rates of major cytogenetic response in patients with newly diagnosed chronic myeloid leukemia (CML) in early chronic phase treated with imatinib at 400 mg or 800 mg daily. Blood 100:95a, 2002.
262.	Cortes J, Talpaz M, Giles F, Rios MB, Thomas D, Garcia-Manero G, O’Brien S, Verstovsek S, Kantarjian H. High-dose, imatinib mesylate (STI571, Gleevec) in patients with chronic myeloid leukemia (CML) resistant or intolerant to interferon-alpha (IFN). Proceedings of the American Society of Clinical Oncology 21:262a, 2002.
263.	Cortes J, Talpaz M, Giles F, O’Brien S, Rios M, Thomas D, Garcia-Manero G, Verstovsek S, Kantarjian H. High-dose imatinib mesylate (STI571, Gleevec) in patients with chronic myeloid leukemia (CML) resistant or intolerant to interferon-alpha (IFN) induces molecular remissions. Blood 100:164a, 2002.
264.	Mattiuzzi G, Riehl T, Pierce S, Rex J, Cortes J, Giles F, Garcia-Manero G, Verstovsek S, Malekshamran K, Kantarjian H, Estey E. Intravenous itraconazole (ITRA) versus caspofungin (CASPO) for prophylaxis of invasive fungal infections (IFI) in patients (PTS) with acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS) undergoing induction chemotherapy (IC). Blood 100:332a, 2002.
265.	Estey E, Kantarjian H, Cortes J, Thomas D, Verstovsek S, Pierce S, Garcia-Manero G, Faderl S, Keating M, Beran M, Giles F. Is the absence of circulating blasts a valid criterion for CR in AML? Blood 100:88a, 2002.
266.	Thomas D, Cortes J, Garcia-Manero G, Faderl S, O’Brien S, Pierce S, Verstovsek S, Giles F, Andreeff M, Kornblau S, Letvak L, Kantarjian H. Minimal residual disease (MRD) after hyper-cvad and imatinib mesylate (STI571) for Philadelphia (Ph) positive adult acute lymphoblastic leukemia (ALL). Blood 100:764a, 2002.
267.	Tsimberidou A, Estey E, Cortes J, Thomas D, Garcia-Manero G, Faderl S, Verstovsek S, O’Brien S, Kantarjian H, Giles F. Mylotarg, fludarabine, ara-c and cyclosporine (MFAC) in patients with newly diagnosed acute myelogenous leukemia (AML) or high-risk myelodysplastic syndrome (MDS). Blood 100:339a, 2002.
268.	Tsimberidou A, Estey E, Cortes J, Thomas D, Garcia-Manero G, Faderl S, Verstovsek S, O’Brien S, Kantarjian H, Giles F. Mylotarg, fludarabine, cytarabine (Ara-C) and cyclosporine (MFAC) combination regimen in patients with cd33-postive primary resistant or relapsed acute myeloid leukemia (AML). Blood:339a, 2002.
269.	Tsimberidou AM, Estey E, Cortes J, Thomas D, Garcia-Manero G, Faderl S, Verstovsek S, Beran M, Keating M, O’Brien S, Kantarjian H, Giles F. Nonleukemic granulocytic sarcoma (GS) in a single institution: frequency, presentation and clinical outcome. Blood 100:243b, 2002.
270.	Apostolidou E, Garcia-Manero G, Cortes J, Thomas D, Andreeff M, Keating M, Tallman M, Kantarjian H, Giles F. Phase I study of OSI-211, a novel liposomal topoisomerase 1 (Topo 1) inhibitor, in patients with refractory leukemia. Blood 100:262b, 2002.
271.	Cortes J, Daley G, Talpaz M, O’Brien S, Garcia-Manero G, Giles F, Faderl S, Pate O, Zaknoen S, Kantarjian H. Pilot study of SCH 66336 (Lonafarnib) a farnesyl transferase inhibitor (FTI), in patients with chronic myeloid leukemia (CML) in chronic or accelerated phase resistant or refractory to imatinib. Blood 100:164a, 2002.
272.	El-Zimaity MMT, Kantarjian H, Talpaz M, Garcia-Manero G, O’Brien S, Giles F, Verstovsek S, Ferrajoli A, Rios MB, Hayes K, Cortes J. Response to imatinib in patients with chronic myeloid leukemia (CML) with variant Philadelphia chromosome (Ph). Blood 100:788a, 2002.
273.	Thomas D, Cortes J, Giles F, Faderl S, O’Brien S, Garcia-Manero G, Verstovsek S, Pierce S, Keating M, Cabanillas F, Kantarjian H. Rituximab and hyper-cvad for adult burkitt’s (BL) or burkitt’s like (BLL) leukemia or lymphoma. Blood 100:763a, 2002.
274.	Tsao A, Kantarjian H, Thomas D, Giles F, Issa JP, Cortes J, Garcia-Manero G, Huh YO, Shen Y, Yang Y, Albitar M, Estey E. Surface antigen expression in acute leukemias – association with patient and disease characteristics and with outcome. Blood 100:253b, 2002.
275.	Cortes J, Giles F, O’Brien S, Talpaz M, Thomas D, Keating M, Garcia-Manero G, Faderl S, Estey E, Letvak L, Bochinski K, Kantarjian H. Treatment with imatinib mesylate in patients with refractory or relapsed acute myeloid leukemia (AML), high-risk myelodysplastic syndrome (MDS) or myeloproliferative disorders (MPD). Blood 100:800a, 2002.
276.	Martins JT, Garcia-Manero G, Daniel J, Kantarjian H, Issa JP. 06-methylguanine-dna-methyltransferase (MGMT) is infrequently methylated in acute lymphocytic leukemia (ALL). Blood 98:180b, 2001.
277.	Gharibyan V, Jiao L, Shen L, Kantarjian H, Garcia-Manero G, Issa JP. ABL methylation in chronic myelogenous leukemia (CML) spreads from a methylation center normally present in the 5 prime region of the CPG island. Blood 98:147a, 2001.
278.	Tsimberidou A, Thomas D, Faderl S, Cortes J, Garcia-Manero G, O’Brien S, Albitar M, Kantarjian H, Keating M, Giles F. Alternating cyclophosphamide, vincristine, liposomal daunorubicin (DaunoXome), and dexamethasone (hCVXD) with methotrexate (MTX), and ara-C (A) regimen plus rixtuimab and GM-CSF in patients with refractory chronic lymphocytic leukemia (CLL) or richter’s syndrome (RS). Blood 98:294b, 2001.
279.	Faderl S, Thomas D, O’Brien S, Giles F, Koller C, Beran M, Williams M, Garcia-Manero G, Kantarjian H, Keating M. An exploratory study of the combination of monoclonal antibodies campath-1h and rituximab in the treatment of CD52- and CD20- positive chronic lymphoid disorders. Blood 98:365a, 2001.
280.	Giles F, Thomas D, Cortes J, Garcia-Manero G, Kornblau S, Waddelow T, Kantarjian H. An ursodiol and methylprednisone (MP) regimen does not reduce mylotarg-associated hepatic veno-occlusive disease (VOD) in patients with acute myeloid leukemia (AML) not receiving stem cell transplantation (SCT). Blood 98:721a, 2001.
281.	Thomas D, Cortes J, Giles F, Faderl S, O’Brien S, Rios MB, Issa JP, Garcia-Manero G, Koller C, Talpaz M, Kantarjian H. Combination of hyper-CVAD with gleevec for Philadelphia (Ph)- positive adult acute lymphoblastic leukemia (ALL) or chronic myelogenous leukemia in lymphoid blast crisis (CML-BP). Blood 98:803a, 2001.
282.	Kantarjian H, Arlinghaus RB, Quackenbush RC, Guo JQ, Cortes J, Giles F, Garcia-Manero G, Thomas D, Faderl S, Ford JM, Talpaz M. Competitive quantitative polymerase chain reaction (CQPCR) studies in Philadelphia chromosome positive chronic phase myelogenous leukemia (Ph + CML CP) on imatinib mesylate (STI571) therapy. Blood 98:614a, 2001.
283.	Garcia-Manero G, Jeha S, Williamson J, Daniel J, Gold D, Rosner G, Albitar M, Kantarjian H, Issa JP. DNA methylation in pediatric acute lymphocytic leukemia (ALL): no distinct differences compared to adult patterns. Blood 98:318a, 2001.
284.	Garcia-Manero G, Bueso-Ramos C, Daniels J, Williamson J, Kantarjian H, Issa JP. DNA-methylation patterns at relapse in acute lymphocytic leukemia (ALL): simultaneous hypermethylation of p15 an p16. Proceedings of the Amercian Association of Cancer Research:Poster A-11, 2001.
285.	Garcia-Manero G, Bueso-Ramos C, Daniel J, Williamson J, Kantarjian H, Issa JP. DNA-methylation patterns at relapse in acute lymphocytic leukemia (ALL): simultaneous hypermethylation of p15 and p16. Blood 98:314a, 2001.
286.	Cortes J, O’Brien S, Beran M, Koller C, Garcia-Manero G, Giles F, Kantarjian H. Efficacy of topoisomerase I inhibitor, 9-nitro-20-(S)-camptothecin (9-NC RFS2000) in chronic myelomonocytic leukemia (CMML) and high-risk myelodysplastic syndromes (MDS). Blood 98:621a, 2001.
287.	Estey E, Giles F, Cortes J, Thomas D, Garcia-Manero G, Faderl S, O’Brien S, Kantarjian H. Gemtuzumab ozogomycin (Mylotarg) in untreated acute promyelocytic leukemia (APL). Blood 98:766a, 2001.
288.	Garcia-Manero G, Daniels J, Mannari R, Chen XQ, Kantarjian H, Issa J-P. HOXA5 is hypermethylated at a high frequency and density in human leukemias. Proceedings of the American Association of Cancer Research 42:poster 1859, 2001.
289.	Kantarjian HM, Cortes J, O’Brien S, Giles F, Thomas D, Garcia-Manero G, Faderl S, Rios MB, Shan J, Hayes K, Keating MJ, Freireich E, Talpaz M. Imatinib mesylate (STI571) therapy of Philadelphia chromosome-positive chronic myelogenous leukemia (CML) in early chronic phase (ph + CML early CP). Blood 98:137a, 2001.
290.	Garcia-Manero G, Kwari M, Cortes J, Faderl S, Giles F, O’Brien S, Koller C, Quackenbush R, Andreeff M, Beran M, Kantarjian H, Berd B, Estey E. Immunotherapy with autologous cell vaccine in patients with acute myelogenous leukemia (AML) in second remission. Blood 98:212b, 2001.
291.	Mannari R, Kantarjian H, Garcia-Manero G, Cortes J, Beran M, Issa JP. Methylation analysis in patients with CML treated with the hypomethylating drug decitabine. Proceedings of the American Association of Cancer Research 42:poster 3809, 2001.
292.	Dai D, Shen LL, Habib N, Garcia-Manero G, Issa J-P. Methylation profiling in liver metastasis of colon cancer. Proceedings of the Amercian Association of Cancer Research:Poster A-33, 2001.
293.	Issa JP, Garcia-Manero G, Mannari R, Thomas D, Giles F, Cortes J, Estey E, Kantarjian H. Minimal effective dose of the hypomethylating agent decitabine in hematopoietic malignancies. Blood 98:594a, 2001.
294.	Cortes J, Kurzrock R, O’Brien S, Thomas D, Faderl S, Garcia-Manero G, Wright J, Sonnichsen D, Cooper M, Estey E, Kantarjian H. Phase I study of farnesyl transferase inhibitor (FTI), bms-214662, in patients with refractory or relapsed acute leukemias. Blood 98:594a, 2001.
295.	Faderl S, Garcia-Manero G, Thomas D, Cortes J, O’Brien S, Giles F, Koller C, Beran M, Verstovsek S, Kwari M, Gandhi V, Plunkett W, Kantarjian H. Phase I study of tezacitabine (FMdC) in patients with relapsed and refractory hematologic malignancies. Blood 98:595a, 2001.
296.	Giles F, Garcia-Manero G, O’Brien S, Estey E, Kantarjian H. Phase II study of Mylotarg plus Troxatyl in patients with refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). Blood 98:212b, 2001.
297.	Giles F, Cortes J, Garcia-Manero G, Faderl S, Thomas D, Waddelow T, Talpaz M, Kantarjian H, Estrov Z. Phase II study of pegylated intron in patients essential thrombocythemia (ET). Blood 98:629a, 2001.
298.	Kurzrock R, Cortes J, Ryback ME, Thibault A, Faderl S, Estey E, Garcia-Manero G, Giles F, Thomas D, O’Brien S, Talpaz M, Kantarjian H. Phase II study of R115777, a farnesyItransferase inhibitor, in myelodysplastic syndrome. Blood 98:848a, 2001.
299.	Giles F, Feldman E, Cortes J, Faderl S, Larson R, Mamus S, Thomas D, Garcia-Manero G, O’Brien S, Beran M, Talpaz M, Kantarjian H. Phase II study of troxatyl in patients with chronic myeloid leukemia in blastic phase (CML-BP). Blood 98:258b, 2001.
300.	Thomas D, Cortes J, O’Brien S, Garcia-Manero G, Kurzrock R, Giles F, Faderl S, Thibault A, Rybak ME, Kantarjian H. R115777, a farnesyl transferase inhibitor (FTI), has significant anti-leukemia activity in patients with chronic myeloid leukemia (CML). Blood 98:727a, 2001.
301.	Kantarjian H, Cortes J, Garcia-Manero G, Thomas D, Yazji S, Bivins C, Jolivet J, Giles F. Randomized phase I/II study of troxacitabine combined with topotecan, ara-C or idarubicin in patients with leukemia. Proceedings of the American Society of Clinical Oncology 20:224b, 2001.
302.	Kantarjian H, Cortes J, O’Brien S, Giles F, Albitar M, Rios MB, Shan J, Faderl S, Garcia-Manero G, Issa JP, Thomas D, Capdeville R, Talpaz M. Results if imatinib mesylate (STI571), a bcr-able tyrosine kinase inhibitor, in Philadelphia chromosome-positive chronic myelogenous leukemia in blastic phase (ph + CML-BP). Blood 98:260b, 2001.
303.	Kantarjian H, Cortes J, O’Brien S, Faderl S, Thomas D, Giles F, Garcia-Manero G, Albitar M, Andreeff M, Kornblau SM, Rios MB, Shan J, Beran M, Koller C, Resta D, Capdeville R, Estey E, Keating M, Freireich E, Talpaz M. Results if imatinib mesylate (STI571) in Philadelphia chromosome positive chronic myelogenous leukemia in chronic phase (ph + CML-CP) post interferon alpha (IFN) failure. Blood 98:260b, 2001.
304.	Kantarjian HM, O’Brien S, Cortes J, Giralt S, Rios MB, Shan J, Giles F, Thomas D, Faderl S, de Lima M, Arlinghaus R, Garcia-Manero G, Issa JP, Resta D, Capdeville R, Talpaz M. Results of imatinib mesylate (STI571) therapy in patients (pts) with chronic myelogenous leukemia (CML) in relapse after allogeneic stem cell transplantation (allo SCT). Blood 98:137a, 2001.
305.	Thomas D, Cortes J, Giles F, Faderl S, O’Brien S, Garcia-Manero G, Keating M, Cabanillas F, Kantarjian H. Rituximab and hyper-CVAD for adult burkitt’s (BL) or burkitt’s-like (BLL) leukemia or lymphoma. Blood 98:804a, 2001.
306.	Chen XQ, Ahuja N, Shen LL, Mannari R, Garcia-Manero G, Issa J-P. THBS2 promoter Hypermethylation and silencing in cancer. Proceedings of the American Association of Cancer Research 42:poster 2560, 2001.
307.	Thomas D, Cortes J, Giles F, O’Brien S, Faderl S, Koller C, Beran M, Issa JP, Garcia-Manero G, Estey E, Pierce S, Andreeff M, Kornblau S, Keating M, Kantarjian H. The modified hyper-CVAD regimen in newly diagnosed adult acute lymphoblastic leukemia. Blood 98:590a, 2001.
308.	Kantarjian H, O’Brien S, Cortes J, Faderl S, Giles F, Thomas D, Garcia-Manero G, Albitar M, Rios MB, Shan J, Issa JP, Resta D, Capdeville R, Keating MJ, Freireich EJ, Talpaz M. Treatment of accelerated phase of Philadelphia chromosome-positive chronic myelogenous leukemia (ph + CML AP) with imatinib mesylate (STI571). Blood 98:141a, 2001.
309.	Cortes J, Talpaz M, O’Brien S, Garcia-Manero G, Thomas D, Faderl S, Capdeville R, Kantarjian H. Treatment of chronic myeloid leukemia (CML) with STI571 in patients age > 60 years. Blood 98:256b, 2001.
310.	Garcia-Manero G, Talpaz M, Giles F, Cortes J, O’Brien S, Faderl S, Thomas D, Rios MB, Kantarjian H. Treatment of Philadelphia chromosome positive chronic phase myelogenous leukemia (ph + CML) with pegylated interferon alpha 2b (peg-ifn/sch54031) and low-dose cytosine arabinoside (ara-C). Blood 98:258b, 2001.
311.	Thomas DA, O’Brien S, Faderl S, Fayad L, Garcia-Manero G, Wierda W, Verstovsek S, Kornblau S, Pierce S, Kantarjian H, Keating M. Treatment of splenic lymphoma with villous lymphocytes (SLVL) and marginal zone lymphomas (MZL) with single agent rituximab. Blood 98:134a, 2001.
312.	Giles F, Faderl S, Thomas D, Cortes J, Jeha S, Garcia-Manero G, Douer D, Levine A, Estey E, Beran M, O’Brien S, Koller C, Andreeff M, Kantarjian H. Troxatyl plus topotecan, ara-C, or idarubicin in patients with refractory acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), or blastic-phase chronic myeloid leukemia (CML-BP): a randomized phase I/II study. Blood 98:594a, 2001.
313.	Garcia-Manero G, O’Brien S, Cortes J, Faderl S, Giles F, Albitar M, Lerner S, Kantarjian H, Keating M. Update of results of the combination of fludarabine, cyclophosphamide and rituximab for previously treated patients with chronic lymphocytic leukemia (CLL). Blood 98:633a, 2001.
314.	Faderl S, Kantarjian H, O’Brien S, Cortes J, Thomas D, Giles F, Freireich E, Koller C, Estey E, Beran M, Garcia-Manero G, Williams M. A broad exploratory trial of campath-1h in the treatment of acute leukemias. Blood 96:324a, 2000.
315.	Garcia-Manero G, O’Brien S, Cortes J, Giles F, Faderl S, Lerner S, Albitar M, Kantarjian H, Keating M. Combination fludarabine, cyclophosphamide, rituximab for previously treated patients with chronic lymphocytic leukemia (CLL). Blood 96:757a, 2000.
316.	Garcia-Manero G, Daniel J, Pierce S, Kornblau S, Kantarjian H, Issa J. CpG island methylation profile in acute lymphocytic leukemia (ALL). Blood 96:102a, 2000.
317.	Flomenberg N, Grosso D, Beardell F, Brunner J, Cohn J, Ferber A, Filicko J, Friedman A, Garcia-Manero G, Martinez J, Rose L, Tice D, Wagner J, Capizzi R. High complete remission rate and normal organ cytoprotection using dose escalation of idarubicin with amifostine in high risk patients with AML. Blood 96:211b, 2000.
318.	Flomenberg N, Garcia-Manero G, Grosso D, Beardell F, Brunner J, Cohn J, Flicko J, Friedman A, Martinez J, Rose L, Tice D, Capizzi R. High CR rate & normal organ cytoprotection using dose escalation of idarubicin with amifostine in high risk patients with AML. Proceedings of the American Society of Clinical Oncology 19:12a, 2000.
319.	Giles F, Cortes J, Thomas D, DeJager R, Garcia-Manero G, Jeha S, Kantarjian H. Phase I study of exatecan mesylate (DX-8951f), a novel topoisomerase I (topo 1) inhibitor. Blood 96:121a, 2000.
320.	Faderl S, Thomas D, Cortes J, Giles F, Garcia-Manero G, O’Brien S, Koller C, Keating M, Cabanillas F, Sarris A, Grigsby V, Plunkett W, Kantarjian H. Phase I study of tezacitabine, an antimetabolite deoxycytidine analog, in patients with relapsed and refractory hematologic malignancies. Blood 96:724a, 2000.
321.	Quackenbush R, Verstovsek S, Lin H, Xie S, Garcia-Manero G, Guo J, Talpaz M, Kantarjian H, Arlinghaus R. The low levels of P230 BCR-ABL expression that are typically seen in patients with neutrophilic-chronic myelogenous leukemia do not transform 32 D cells. Blood 96:351a, 2000.
322.	Flomenberg N, Garcia-Manero G, Grosso D, et al. High complete response rate and normal organ cytoprotection using dose escalation idarubicin and amisfostine in high risk patients with acute myelogenous leukemia. Blood 94:299a, 1999.
323.	Garcia-Manero G. Molecular detection of vancomycin resistant enterococci genotypes using polymerase chain reaction in patients admitted to a bone marrow transplantation unit. Blood 94:367b, 1999.
324.	Garcia-Manero G, Moscatello DK, Wong AJ. Association of a growth factor receptor and a cytokine receptor in a prostate cancer cell line. Blood 92(Supl 1):205a, 1998.
325.	Garcia-Manero G et al. Combination of ethyol (amifostine) with idarubicin and ara-c for the induction treatment of AML. Blood 92:216b, 1998.
326.	Garcia Manero G, S J Schuster, J Martinez. Myeloproliferative diseases with bone marrow fibrosis complicated by pulmonary hypertension. Blood 90:292b, 1997.
Book Chapters
1.	Atallah E, Garcia-Manero G. Epigenetic Drugs (DNA Demethylating Agents). In: Epigenetics in Biology and Medicine. Ed(s) M Estellar. CRC Press: Boca Raton, FL, 27-48, 2009.
2.	Garcia-Manero G, List A, Kantarjian H, Cortes J.E. Myelodysplastic syndromes. In: Cancer Management: A Multidisciplinary Approach, 11. Ed(s) R Pazdur, LD Wagman, KA Camphausen, WJ Hoskins. CMP Medica: Lawrence, Kansas, USA, 859-876, 2008.
3.	Garcia-Manero G Issa JP. The role of DNA hypomethylating agents in cancer treatment. In: Progress In Oncology 2004. 6, 131-158, 2004.
4.	Garcia-Manero G, Kantarjian H, Schiffer C. Adult acute lymphocytic leukemia. In: Cancer Medicine 6. BC Decker, Inc., 2003.
5.	Garcia-Manero G, Talpaz M, Faderl S, Kantarjian H. Chronic myelogenous leukemia. In: Blood: Principles and Practice of Hematology. Lippincott, Williams & Wilkins, 433, 2003.
6.	Garcia-Manero G, Kantarjian H. New approaches to the management of patients with the myelodysplastic syndrome. In: The myelodysplastic syndromes. Pathobiology and Clinical Management. Marcel Dekker, 2002.
7.	Garcia-Manero G, Martinez J. Principles of hemostasis and thrombosis. In: Management and Prevention and of Thrombosis in Primary Care, 2001.

Last updated: 10/28/2009

Present Title & Affiliation

Primary Appointment

Education & Training

Degree-Granting Education

Postgraduate Training

Board Certifications

Experience/Service

Administrative Appointments/Responsibilities

Honors and Awards

Professional Memberships

Selected Publications

Peer-Reviewed Original Research Articles

Invited Articles

Editorials

Abstracts

Book Chapters